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ATP        Adenosine triphosphate 
ADP        Adenosine diphosphate 
APC        Allophycocyanine 
B16        B16F10 melanoma cells 
BAC        Bacterial artificial chromosome 
5-BDBD  5-(3-Bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-
diazepin-2-one 
bp        Basepair(s)  
BSA        Bovine serum albumin 
Calcein-AM      Calcein acetoxymethyl ester 
CD40L       CD40 ligand (CD154) 
cDNA        Complementary DNA 
Cy5        Cyanine 5 
DAPI        4',6-diamidino-2-phenylindole 
DNA        Desoxyribonucleic acid 
EDTA        Ethylendiamine tetraacetic acid 
e.g.        Exempli gratia  
Flp        FRT recombinase 
FITC        Fluorescein isothiocyanate 
FRT        Flp recognition target  
g        Gram 
g        Standard gravity (9.80665 m/s
2) 
GAPDH      Glyceraldehyde 3-phosphate dehydrogenase 
HCl        Hydrochloric acid 
HEPES      4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
kDa        Kilodalton 
LDLR        Low-density lipoprotein receptor 
LLC1        Lewis lung carcinoma 1 cells 
min        Minute(s) 
mRNA       Messenger ribonucleic acid 
MRS2500  (1R*,2S*)-4-[2-Iodo-6-(methylamino)-9H-purin-9-yl]-2-
(phosphonooxy)bicyclo[3.1.0]hexane-1-methanol  dihydrogen 
phosphate ester tetraammonium salt 
Munc13      Mammalian uncoordinated-13 
NaCl        Natriumchloride 
NaOH       Natriumhydroxide 
OCT        Optimum cutting temperature compound 
PCR        Polymerase chain reaction 	
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PDGF       Platelet-derived growth factor 
PE        Phycoerythrin 
PF4        Platelet factor 4 (CXCL4) 
PRP        Platelet rich plasma 
P2X        Purinergic ATP receptor, G Protein-coupled 
P2Y        Purinergic ATP receptor, ion channel 
qPCR        Quantitative polymerase chain reaction 
RANTES      Regulated and normal T cell expressed and secreted (CCL5) 
rpm        Rounds per minute 
rRNA        Ribosomal ribonucleic acid 
RT        Room temperature 
s        Second(s) 
S.D.        Standard deviation 
SDS        Sodium dodecyl sulfate 
S.E.M.       Standard error of the mean 
siRNA       Small interfering ribonucleic acid 
SNAP        Soluble NSF (N-ethylmaleimide-sensitive fusion 
                           protein)-attachment protein  
SNARE      Soluble NSF attachment protein receptor 
U46619  (Z)-7-[(1S,4R,5R,6S)-5-[(E,3S)-3-hydroxyoct-1-enyl]-3-
oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic  acid,  thromboxane 
(TP) receptor agonist 
VAMP       Vesicle-associated membrane protein 
VE-cadherin      Vascular endothelial cadherin (CD144) 
VEGF        Vascular endothelial growth factor 
vWF        Von Willebrand factor 
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1  Introduction	
 ﾠ
Platelets  are  anucleate  cellular  fragments  derived  from  megakaryocytes.  Besides 
erythrocytes, they are the second largest group of blood cells, but they make up less than 
0.5% of blood volume due to their small size (2-3 µm for human platelets; 1-2 µm for mouse 
platelets). Their primary function is attributed to hemostasis. In recent years their role in 
various  pathological  conditions  is  getting  increasingly  recognized  and  anti-platelet 
interventions  may  be  a  promising  strategy  in  some  diseases.  The  functionally  relevant 
features, which enable platelets to contribute to such diverse outcomes, mainly comprise 
their ability to change their shape, to release different classes of granules and to interact 
with various other cell types.  
Platelets contain three different kinds of granules: alpha and dense granules and 
lysosomes.  
1.1  Secretory	
 ﾠMachinery	
 ﾠ
1.1.1  Alpha	
 ﾠgranules	
 ﾠ
Alpha granules are the largest (200-500 nm) and most abundant type of vesicle in platelets 
(~50-80 per human platelet) (Sixma, Slot et al. 1989; Maynard, Heijnen et al. 2007). They 
can be identified via electron microscopy by 1) the peripheral membrane of the granule, 2) 
an electron dense nucleoid that contains chemokines and proteoglycan, 3) a less electron 
dense  area  adjacent  to  the  nucleoid  that  contains  fibrinogen,  and  4)  a  peripheral 
electronluscent  zone  that  contains  von  Willebrand  factor  (vWF),  although  not  all  four 
features need to be observed to qualify as an alpha granule (White and Krumwiede 2007). 
Immunostaining  for  established  markers  like  vWF  and  fibrinogen  may  also  be  used  to 
identify alpha granules. Reported cargo of alpha granules mainly comprises proteins and 
macromolecules and includes: 
 
Protein class  Known alpha granule proteins 
Adhesion proteins & surface receptors  P-selectin  (CD62P),  integrins  (αIIbβ3, 
αVβ3),  CD36,  CD9,  GLUT-3,    fibrinogen, 
fibronectin,  vitronectin,  thrombospondin, 
vWF (von Willebrand factor) 
Growth factors  VEGF,  PDGF-B,  TGF-β  ,  EGF,  IGF-1, 
bFGF, angiopoietin-1 and -2 
Chemokines & cytokines  PF4, RANTES, SDF-1α, MCP-1, MCP-3, IL-
1β, IL-8, MIP-1α, β-thromboglobulin, GRO-
α, 12-HETE, NAP-2, ENA-78, CTAP-3,  
Fibrinolytic agents  PAI-1,  TAFI,  2-antiplasmin  α2-
Macroglobulin, plasminogen 	
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Coagulation pathway  coagulation  factors:  V,  XI,  XIII;  kininogen, 
multimerin 
Immunologic molecules  Β 1H globulin, factor D, C1 inhibitor, IgG 
Table 1:   Well-established  alpha  granule  molecules  in  literature.  Glut-3,  glucose 
transporter  type  3;  PDGF-B,  platelet-derived  growth  factor  B;  TGF-β, 
transforming growth factor beta; EGF, epidermal growth factor; IGF-1, insulin-like 
growth  factor  1;  bFGF,  basic  fibroblast  growth  factor;  SDF-1α,  stromal  cell-
derived factor 1 alpha; MCP, monocyte chemoattractant protein; IL, interleukin; 
MIP-1α,  macrophage  inflammatory  protein  1  alpha;  GRO-α,  growth-regulated 
oncogene aplha; 12-HETE, 12-hydroxyeicosatetraenoic acid; NAP-2, neutrophil-
activating protein 2; ENA-78, epithelial neutrophil-activating protein 78; CTAP-3, 
connective tissue-activating protein 3; PAI-1, plasminogen activator inhibitor 1; 
TAFI, thrombin-activatable fibrinolysis inhibitor (Rendu and Brohard-Bohn 2001; 
Maynard, Heijnen et al. 2007). 
The major part of alpha granule content is acquired during budding in the megakaryocyte 
but proteins like fibrinogen are taken up via endocytosis in the circulation. There are several 
recent reports which suggest regulated differential sorting and exocytosis of alpha granule 
proteins,  especially  pro-  and  anti-angiogenic  factors  like  VEGF  and  endostatin (Italiano, 
Richardson et al. 2008). Seghal et al. found non-overlapping localizations of fibrinogen and 
vWF in platelets (Sehgal and Storrie 2007). The molecular mechanisms involved still need 
to be elucidated. Substructural organization within the alpha granule often found includes 
dense nucleoid compartments, more translucent zones and tubular vWF structures in the 
periphery. P-Selectin was found to be associated with alpha and dense granule membranes 
in  immunogold  labeling  (Stenberg,  McEver  et  al.  1985;  Israels,  Gerrard  et  al.  1992; 
Youssefian, Masse et al. 1997).  Alpha granule organization and components are highly 
variable and may differ between species. 
Alpha  granule  release  is  slower  than  dense  granule  release  (minutes  instead  of 
seconds) and may be differentially regulated by the kind of stimulus present (Italiano and 
Battinelli 2009). Alpha granules can fuse with each other upon platelet activation and are 
thought to be exocytosed mainly via the OCS (White 1999; White 1999; Gader, Ghumlas et 
al. 2008). Upon activation of platelets, a centralization of alpha granules is often observed, 
which precedes fusion with the OCS (White 1999; White and Krumwiede 2007). The major 
structural features of platelets, centralization of alpha granules upon stimulation and release 
of alpha granules are illustrated in figure 1 (White and Krumwiede 2007). 	
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Figure 1:   Transmission  electron  microscopic  images  of  fixed  human  platelets.  (A) 
Discoid platelet section in the equatorial plane revealing alpha granules (Gr), a 
few  mitochondria  (Mi),  occasional  dense  bodies  (DB)  and  glycogen  (GLY) 
randomly  dispersed  in  the  cytoplasm.  The  discoid  shape  is  maintained  by  a 
circumferential  coil  of  microtubules  (T)  (Magnification  x  27,000).  (B)  After 
exposure to thrombin, the platelet developed lamellapodia. Organelles have been 
transported  to  the  center  of  the  cell  by  the  ring  of  microtubules  (T)  and 
microfilaments (Magnification x 50,000). (C) Platelet exposed to thrombin, fixed 
and  stained  with  tannic  acid.  Together  with  osmic  acid,  tannic  acid  produces 
osmium black and stains fibrinogen in alpha granules (Gr), which have fused with 
each  other  and  the  channels  of  the  open  canalicular  system  (OCS)  during 
secretion (Magnification x 37,000). (From: White and Krumwiede 2007). 
1.1.2  Dense	
 ﾠgranules	
 ﾠ
Platelets  contain  approximately  6-10  electron-dense  structures,  which  appear  inherently 
opaque  and  have  a  characteristic  bull  eye-like  shape  in  electron  microscopic  imaging. 
Some of these dense granules, also called dense bodies or δ-granules, show a whip-like 
tail (White and Krumwiede 2007; Gader, Ghumlas et al. 2008). Dense granules contain 
small molecules like ADP, ATP, GDP, GTP, Ca
2+, serotonin, histamine and polyphosphates 
(Ruiz, Lea et al. 2004; Maynard, Heijnen et al. 2007; White and Krumwiede 2007; Muller, 
Mutch et al. 2009). They are released within seconds upon stimulation (Ge, Woo et al. 	
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2011) and their secretion is mainly mediated by F-actin, not microtubules (Ge, White et al. 
2012).  It  was  proposed  that  dense  granules  both  fuse  with  the  OCS  and  the  outer 
membrane (Ge, White et al. 2009). 
1.1.3  Lysosomes	
 ﾠ
Lysosomes  are  mainly  considered  as  separated  acidic  degradative  units  rather  than 
releasable granules. Several hematopoietic cells like macrophages (Tapper and Sundler 
1990),  cytotoxic  T  lymphocytes  (Griffiths  1997)  and  platelets  (Silverstein  and  Febbraio 
1992) have so called secretory lysosomes. Lysosomes mainly store acid hydrolases able to 
degrade  glycoproteins,  glycolipids  and  glyco-aminoglycans  like  ADAM17  and  ADAM10 
which have been shown to cleave GPVI (Silverstein and Febbraio 1992). Cathepsins and 
hexosaminidase found in platelet lysosomes may play a role in clot remodeling or in further 
platelet activation (Ren, Ye et al. 2008). Although lysosomal release has been shown in 
vitro and hexosaminidase release at sites of local platelet activation has been observed in 
humans  (Ciferri,  Emiliani  et  al.  2000)  physiological  relevance  remains  controversial 
(Polasek  1989).  Lysosomal  release  in  vitro  is  only  partial  even  at  high  agonist 
concentrations  and  needs  high  and  maintained  levels  of  strong  platelet  agonists  (Ren, 
Wimmer et al. 2010).  
1.2  Platelet	
 ﾠactivation	
 ﾠ
Platelet  activation,  shape  change  and  release  of  granule  contents  are  the  mechanisms 
which  govern  platelet  function  in  hemostasis,  but  also  thrombotic  events  and  other 
pathophysiological processes. A set of platelet surface receptors and platelet agonists are 
able to activate platelets. The context of platelet activation determines which molecules act 
on  their  respective  platelet  receptors  and  signaling  cascades.  Ultimately,  the  diverging 
pathways  all  lead  to  elevated  intracellular  calcium  levels,  followed  by  shape  change 
(pseudopod  formation),  secretion  of  platelet  granules  and  aggregation  (crosslinking  with 
nearby activated platelets). It is well established that rise in intracellular calcium results in 
exocytosis  of  platelet  dense  and  alpha  granules  but  the  mechanisms  are  not  yet  fully 
elucidated (Ren, Ye, et al. 2008).   
1.2.1  Main	
 ﾠplatelet	
 ﾠreceptors	
 ﾠinvolved	
 ﾠin	
 ﾠplatelet	
 ﾠactivity	
 ﾠ
Under hemostatic conditions, platelets do not adhere to the vessel wall as endothelial cells 
lining the vessel lumen synthesize platelet inhibitors and protect the underlying extracellular 
matrix  from  being  exposed.  Endothelial  cells  produce  prostaglandin  I2  (PGI2)  from 
arachidonic acid (Moncada, Gryglewski et al. 1976; Weksler, Marcus et al. 1977), which 
binds to the platelet IP receptor and stimulates adenylyl cyclase, leading to cAMP formation 
and inhibition of platelet activation (Stegner and Nieswandt 2011). In addition, endothelial 
cells synthesize NO which inhibits a rise in intracellular Calcium levels mainly through cyclic 
GMP (cGMP) and the cGMP-dependent protein kinase type I (PKG I) (Dangel, Mergia et al. 	
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2010).  Once  endothelial  cells  get  activated,  they  expose  P-Selectin  and  multimeric 
structures  of  von  Willebrand  factor  (vWF)  on  their  surface  which  enables  platelets, 
leukocytes and platelet-leukocyte aggregates to “roll” on endothelium, slow down and form 
tight interactions with the vessel wall through various surface receptors. On platelets, the 
initial interaction is mainly mediated by glycoprotein receptor GPIbα, which binds to vWF 
(Munnix, Cosemans, et al. 2009).  Under high shear stress, as observed in small vessels, 
the GPIbα-binding domain of vWF (A1) unfolds and this unfolding is thermodynamically 
coupled to binding to GPIbα (Auton, Zhu et al. 2010). GPIb is associated with GPV and 
GPIX  (GPIb-V-IX  complex).  If  the  endothelial  barrier  is  disrupted  and  the  extracellular 
matrix  gets  exposed,  platelets  encounter  molecules  such  as  collagen,  vWF,  fibrinogen, 
fibronectin,  vitronectin  and  laminin,  which  immediately  bind  to  their  respective  platelet 
receptors. Collagen from the ECM activates and binds platelets mainly through GPVI and 
its  co-receptor  FcγII  with  a  supporting  role  for  integrin  α2β1  in  the  formation  of  stable 
thrombi (Munnix, Cosemans, et al. 2009). Binding of GPVI and GPIbα by their respective 
ligands activates platelets and leads to an intracellular rise in calcium levels which in turn 
causes  release  of  secondary  mediators  and  recruitment  of  other  platelets.  Release  of 
dense granule ADP and ATP as well as formation of thromboxane A2 and thrombin are the 
main  mediators  amplifying  activation  via  autocrine  and  paracrine  feedback  loops.  Upon 
platelet activation, thromboxane A2 is generated through liberation of arachidonic acid from 
the  plasma  membrane,  metabolization  to  prostaglandin  H2  and  transformation  to 
thromboxane A2 by thromboxane synthase (McNicol and Israels 2003). Thromboxane A2 is 
released and binds to TP receptor subtypes α or β on platelets to potentiate activation. 
Thrombin generation by the coagulation cascade is facilitated on the surface of activated 
platelets  through  exposure  of  phosphatidylserine  which  enhances  coagulation  factor 
binding and activation (Sims and Wiedmer 2001). Human platelets express mainly PAR1 
and PAR4 Thrombin receptors on their surface whereas mouse platelets exhibit PAR3 and 
PAR4. In humans, PAR1 seems  to  be  the  central  receptor  for  thrombin  signaling  while 
PAR4 mediates a slower, more prolonged activation (Covic, Gresser et al. 2000). In mice, 
PAR3 is the primary mediator of thrombin action and PAR4 may serve as “co-activator” 
(Bender, Hofmann et al. 2010). 
Agonist  stimulation  of  platelets  and  the  resulting  PLC  activation  is  followed  by 
formation of IP3 and DAG, which leads to a rise in intracellular calcium levels and in the 
end, triggers the switch of a “low-affinity state” of integrin αIIbβ3 to a “high-affinity state”. 
This  influences  the  efficiency  of  integrin  αIIbβ3  to  bind  to  its  ligand  fibrinogen,  which 
enhances  platelet  aggregation  and  further  “outside-in”  signaling  of  integrin  αIIbβ3  to 
stabilize aggregates. Therefore, activation of integrin αIIbβ3 is termed the “final common 
pathway”  of  platelet  activation  (Nieswandt,  Varga-Szabo  et  al.  2009;  Stegner  and 
Nieswandt 2011). Stable thrombi are formed by crosslinking activated platelets with each 
other through adhesive plasma proteins like fibrinogen and vWF. The C-type lectin receptor 
CLEC-2 recently discovered as platelet surface receptor (Suzuki-Inoue, Fuller et al. 2006) 	
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binds to the tumor-associated ligand podoplanin, HIV-1 and the snake venom rhodocytin in 
addition  to  its  role  in  hemostasis  and  thrombosis.  Blocking  CLEC-2  on  platelets  with  a 
specific antibody inhibits their ability to form stable aggregates under flow in vitro and leads 
to an enhanced bleeding time and a marked defect in thrombus formation in vivo (May, 
Hagedorn et al. 2009). The known platelet activating pathways are summarized in figure 2. 
Prostaglandin E2, epinephrine and serotonin can potentiate platelet activation mechanisms 
described  above  but  are  not  sufficient  to  trigger  major  platelet  responses  on  their  own 
(Stegner and Nieswandt 2011). 
 
 
Figure 2:   “Platelet  receptors  and  important  signaling  molecules  leading  to  platelet 
activation.  Soluble  agonists  stimulate  G  protein-coupled  receptors,  triggering 
pathways involving the corresponding G proteins. Cross-linking of GPVI or CLEC-
2  results  in  activation  of  phospholipase  (PL)  Cγ2.  TF  tissue  factor,  TxA2 
thromboxane A2, TP TxA2 receptor, PAR protease-activated receptor, RhoGEF 
Rho-specific  guanine  nucleotide  exchange  factor,  PI3K  phosphoinositide-3-
kinase,  AC  adenylyl  cyclase,  PIP2  phosphatidylinositol-4,5-bisphosphate,  PIP3 
phosphatidylinositol-3,4,5-trisphosphate,  IP3  inositol-1,4,5-trisphosphate,  DAG 
diacylglycerol.” (Excerpt from: Stegner and Nieswandt 2011). 	
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Figure 3 displays the most important signaling cascades and interactions of platelets upon 
exposure of extracellular matrix (Stegner and Nieswandt 2011). 
 
Figure 3:  “Model  for  platelet  adhesion  to  the  subendothelial  matrix  at  sites  of 
vascular  injury  and  subsequent  thrombus  formation.  The  initial  contact 
(tethering) to the ECM is mediated predominantly by GPIb–vWF interactions. In a 
second step, GPVI–collagen interactions initiate cellular activation followed by the 
shift of integrins to a high-affinity state and the release of second-wave agonists, 
most importantly ADP, ATP, and thromboxane  A2  (TxA2).  In  parallel,  exposed 
tissue factor locally triggers the formation of thrombin, which in addition to GPVI, 
mediates cellular activation. Finally, firm adhesion of platelets to collagen through 
activated α2β1 (directly) and αIIbβ3 (indirectly via vWF or other ligands) results in 
sustained  GPVI  signaling,  enhanced  release  of  soluble  agonists  and 
procoagulant activity. Released ADP, ATP, and TxA2 amplify integrin activation 
on  adherent  platelets  and  mediate  thrombus  growth  by  activating  additional 
platelets. The forming thrombus is stabilized by signaling through CLEC-2, whose 
ligand/counter-receptor remains to be identified, and other receptors.” (Excerpt 
from: Stegner and Nieswandt 2011). 
Apart from the main platelet receptors discussed above there are a couple of others, which 
have minor or supportive roles or are relevant in other contexts. Describing their function is 
beyond the scope of this introduction, for review see e.g. Munnix, Cosemans, et al. 2009; 
Coller 2011; Stegner and Nieswandt 2011. Table 2 gives an overview of the human platelet 
receptors known so far (Coller 2011; Stegner and Nieswandt 2011). 
Receptor class  Receptors present on human platelets 
Integrins  αIIbβ3, αVβ3, α2β1, α5β1, α6β1 
Leucine-rich repeat receptors  GPIbα, GPIbβ, GPV, GPIX 
Immunoglobulin repeat receptors  PECAM-1, GPVI, FcγRIIA, CLEC-2 
Selectins  P-selectin 
Tetraspanins  CD9, CD151, TSSC6, CD63, Tspan9 	
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G protein-coupled seven 
transmembrane receptors 
PAR-1,  PAR-4,  P2Y1,  P2Y12,  thromboxane–
prostanoid  receptors  TPα  and  TPβ, 
prostaglandin  receptors  IP1  and  EP3,  α2A-
adrenergic  receptor,  arginine  vasopressin 
receptor  V1A,  serotonin  receptor  5-HT2A, 
adenosine receptors A2A and A2B 
Table 2:   Known  receptors  on  human  platelets  (Coller  2011;  Stegner  and  Nieswandt 
2011). 
1.3  Platelet	
 ﾠexocytosis	
 ﾠ
1.3.1  SNARE	
 ﾠproteins	
 ﾠ
Regulated exocytosis is a very conserved process. It has been intensely studied especially 
in  the  context  of  neuronal  signal  transduction.  The  key  proteins  and  signaling  events 
discovered  in  neurotransmitter  release  were  found  in  all  secreting  hematopoietic  cells 
studied so far (Logan, Odemuyiwa et al. 2003). At the center of the exocytotic process, 
members  of  three  classes  of  SNARE  proteins  bound  either  to  the  vesicle  membrane 
(VAMPs)  or  the  outer  cell  membrane  (SNAP-23/-25  and  syntaxins)  align  close  to  the 
plasma  membrane,  overcome  the  rejection  of  the  two  lipid  bilayers  and  mediate  fusion 
between the two. VAMPs and syntaxins contain one coiled-coil domain and SNAP-23/-25 
two, all of them are close to the membrane anchor domains of the three protein classes. 
The coiled-coil domains are called “SNARE motifs” and they can form a very stable four-
helix bundle, which brings the opposing membranes in close proximity. In the resting state, 
another regulatory domain consisting of three parallel α-helices (Habc domain) folds onto 
the SNARE motif of syntaxin. The Sec-1/Munc18-1 (SM) protein Munc18-1 is believed to 
bind to this inactive syntaxin conformation and keep it unavailable for contact with the other 
two  SNAREs.  Usually,  elevated  calcium  levels  trigger  release  of  Munc18-1,  opening  of  
syntaxin and SNARE complex formation. Small GTPases from the Rab3 family are also 
involved in alignment of the three SNAREs. After fusion and release of vesicle content, NSF 
attachment proteins (SNAPs, no relation to SNAP-23/-25) and N-ethylmaleimide senstitive 
factor (NSF) bind to the SNARE core complex and disassemble it through the ATPase 
activity of NSF. The components of the exocytotic machinery are recycled and Munc18-1 
binds again to inactive syntaxin (Chen and Scheller 2001; Jahn, Lang et al. 2003; Sollner 
2003; Hong 2005; Rizo and Rosenmund 2008). Figure 4 illustrates the exocytotic process 
in the single steps described above (Chen and Scheller 2001). 	
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Figure 4:   SNARE-mediated exocytosis and recycling. (A) VAMP is bound to the vesicle 
membrane and has one coiled-coil “SNARE motif” reaching out into the cytosol. 
SNAP-25 (or SNAP-23) and syntaxin are bound to the outer cell membrane an 
have one and two cytosolic coiled-coil domains, respectively. Munc18-1 (n-Sec1) 
keeps the two syntaxin coiled-coil domains in an “inactive” state folded onto each 
other.  (B)  The  signals  triggering  exocytosis  (mostly  elevation  of  intracellular 
calcium levels) lead to release of Munc18-1 (n-Sec1) and that together with the 
small GTPase Rab leads to alignment of the SNARE motifs of the three SNARE 
proteins (“nucleation”) and (C) calcium-supported “zippering” from the N-terminal 
ends of the SNARE motifs to the C-terminal ends. (D) The two membranes fuse 
with  each  other  and  the  vesicle  content  is  released.  (E)  NSF  and  SNAP  are 
recruited to the SNARE complex and (F) through the ATPase activity of NSF, the 
SNARE complex is disassembled and recycled. (From: Chen and Scheller 2001). 
According to literature, human and mouse platelets contain the following isoforms of the 
three SNARE protein families: SNAP-23, syntaxin-2, -4, and -7, and VAMP-2, -3, VAMP-
7/TI-VAMP, and VAMP-8 with the later being the most abundant (Ren, Ye et al. 2008). 
SNAP-23 is involved in all exocytotic events in platelets. Syntaxin-2 and -4 are the main 
syntaxin isoforms contributing to platelet secretion (Flaumenhaft, Rozenvayn et al. 2007), 
with syntaxin-2 being important for dense granule release (Chen, Bernstein et al. 2000) but 
functionally  overlapping  with  syntaxin-4  in  alpha  granule  and  lysosomal  release  (Chen, 
Lemons et al. 2000; Ren, Ye et al. 2008). VAMP-3 and VAMP-8 have been shown to play a 
role in platelet secretion (Flaumenhaft, Croce et al. 1999; Feng, Crane et al. 2002; Polgar, 
Chung  et  al.  2002)  but  VAMP-3  knockout  mice  have  normal  granule  release  (Schraw, 
Rutledge et al. 2003), indicating that VAMP-8 can compensate for a loss of VAMP-3. 
It  is  well  established  that the  light  chains  of  botulinum toxins and tetanus toxin can be 
efficiently applied to interfere with granule secretion in various cell lines in vitro (Schiavo, 	
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Matteoli  et  al.  2000),  a  finding,  which  was  also  confirmed  for  isolated,  permeabilized 
platelets (Ren, Barber et al. 2007). Upon entering the hosts’ body, Clostridium toxins are 
taken up by nerve endings and lead to shut-down of neuromusculur signal transmission by 
cleaving specific members of the SNARE protein families and impeding transmitter release. 
The light chain encodes the zinc metalloproteinase capable of cleaving respective SNARE 
proteins,  thus  making  them  unavailable  or  even  act  in  a  dominant-negative  manner  for 
SNARE complex formation. Table 3 shows the Clostridium toxins and their target SNARE 
proteins.  
Toxin  Target SNARE protein(s) 
TeNT  VAMP-1, -2, -3 
BoNT-A  SNAP-25 (not SNAP-23) 
BoNT-B  VAMP-1, -2 
BoNT-C  Syntaxin-1, -2, -3, SNAP-25 (not SNAP-23) 
BoNT-D  VAMP-1, -2 
BoNT-E  SNAP-23, -25 
BoNT-F  VAMP-1, -2 
BoNT-G  VAMP-1, -2 
Table 3:   Clostridium  toxins  and  their  respective  SNARE  protein  targets.  TeNT, 
tetanus toxin; BoNT-A to -G, botulinum toxin A to G. (Humeau, Doussau et al. 
2000; Schiavo, G., M. Matteoli, et al. 2000; Dolly and Aoki 2006).  
1.3.2  Munc13	
 ﾠproteins	
 ﾠ
Several proteins have been identified, which can influence regulated exocytosis via acting 
directly  or  indirectly  on  SNARE  proteins.  One  of  these  proteins  is  the  Munc13  protein 
family,  which  is  exclusively  present  in  the  “active  zone”,  the  area  close  to  the  plasma 
membrane  where  readily  releasable  vesicles  are  transported  and  fusion  takes  place. 
Munc13 is required in the “docking” and “priming”  step of SNARE-mediated exocytosis, 
meaning  the  process  of  bringing  the  two  membranes  in  close  proximity,  disassembling 
syntaxin and Munc18-1 and alignment of the three SNARE proteins. The mechanisms by 
which Munc13 achieves its effect are still not clear, it is suggested that activated Munc13 
might lower the energy barrier for fusion or play a role in release of Munc18-1 from syntaxin 
(Hong  2005;  Basu,  Betz  et  al.  2007).  Anyway,  deletion  of  Munc13  usually  has  severe 
consequences, e.g. deletion in neurons (Rosenmund, Sigler et al. 2002), chromaffin cells 
(Ashery, Varoqueaux et al. 2000), cytotoxic T cells (Feldmann, Callebaut et al. 2003) and 
neutrophils  (Brzezinska,  Johnson  et  al.  2008)  results  in  strong  reduction  of  regulated 
exocytosis of the respective granule cargo. It has been demonstrated that Munc13-4, the 
ubiquitous isoform present in platelets (Ren, Ye et al. 2008) controls dense granule release 
in platelets together with Rab27a and b (Shirakawa, Higashi et al. 2004).  The Munc13 
proteins  comprise  four  family  members,  Munc13-1  to  Munc13-4.  While  Munc13-1  to 
Munc13-3 are brain-specific, there are two ubiquitous isoforms, ubMunc13-2, a Munc13-2 	
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variant, and Munc13-4 which is the more prevalent and functionally important isoform in 
most  secretory  cell  types  studied  so  far  (Feldmann,  Callebaut  et  al.  2003;  Brzezinska, 
Johnson  et  al.  2008;  Ren,  Ye  et  al.  2008).  The  diagram  below  shows  the  structure  of 
Munc13  proteins  (figure  5).  Munc  homology  domains  (MHD)  serve  as  bindind  sites  to 
SNAP-23 and -25 (Abdullah, Bundy et al. 2003; Basu, Betz et al. 2007), C1 domain can 
bind diacylglycerol (DAG) and C2 domains are calcium sensing domains.  
 
Figure 5:  Schematic  representations  of  the  Munc13  isoforms  and  most  of  their 
functional domains. MHD: Munc homology domain; C1: Diacylglycerol (DAG) 
binding domain; C2: Calcium sensing domain; ubMunc13-2: ubiquitous Munc13-2 
variant; bMunc13-2: brain-specific Munc13-2 variant. (From: Abdullah, Bundy et 
al. 2003). 
The  Bruce  Beutler  laboratory  established  a  mouse  line  with  a  functional  null-mutant  of 
Munc13-4 (Munc13-4
Jinx). The Jinx mutation was first identified in a screen of the mouse 
cytomegalovirus  (MCMV)  resistome  which  comprised  3500  G(3)  germline  mutant  mice 
(Crozat, Georgel et al. 2006). The NK cell phenotype related to the MCMV resistance was 
described by Crozat et al. in 2007 (Crozat,  Hoebe  et  al.  2007).  They  mapped  the Jinx 
mutation  to  an  intron  in  the  C-terminus  of  Munc13-4  causing  a  frame  shift  and  thus  a 
premature stop codon (figure 6 A). They observed no expression of wild-type Munc13-4 
mRNA in Jinx mice (figure 6 B).  
 
Figure 6:  Location of Jinx mutation in the genomic sequence of the Jinx mutation in the 
Munc13-4 gene (Unc13d
Jinx) (A), which causes a premature stop codon in the C-
terminal  Munc  homology  domain  (MHD).  Effect  of  the  Jinx  mutation  at  the 
mRNA level  (B). KpnI cuts the WT cDNA twice with a 3,467-bp amplification 
fragment leading to 1,922-, 1,221-, and 324-bp bands. In the Jinx mutant, the 53-	
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bp insertion contains an additional KpnI site, giving 1,922-, 596-, 678-, and 324-
bp bands. In the mutant cDNA pool, no WT transcript was detectable. C2, Ca2+-
binding domain; MHD, MUNC homology domain; DUF, DUF1041 domain. (From: 
Crozat, Hoebe et al). 
1.4  Platelets	
 ﾠand	
 ﾠatherosclerosis	
 ﾠ
1.4.1  Platelet	
 ﾠFactor	
 ﾠ4	
 ﾠ	
 ﾠ
Macrophages  play  an  important  role  in  atherogenesis.  They  differentiate  from  blood 
monocytes,  migrate  to  the  subendothelial  space  and  further  develop  into  lipid-enriched 
foam cells. A critical factor in monocyte differentiation is M-CSF and ApoE-deficient knock-
out mice show a reduction in atherosclerotic plaque formation. However, in recent years, 
evidence  is  accumulating  that  Platelet  Factor  4  (PF4;  CXCL4)  secreted  by  activated 
platelets and deposited at sites of vascular damage can lead to a specific pro-atherogenic 
macrophage  differentiation  profile  which  is  characterized  by  a  loss  of  the  hemoglobin-
haptoglobin (Hb-Hp) scavenger receptor CD163 and the consequential inability to express 
the atheroprotective enzyme heme oxygenase-1 in response to Hb-Hp complexes. Thus, 
hemoglobin clearance after plaque rupture is impaired and knockout of the PF4 gene in 
ApoE-deficient mice leads to a reduction in atherogenesis (Gleissner, Shaked et al. 2010). 
A recent review even suggests to call the characteristic macrophage differentiation upon 
stimulation with PF4 “M4” because it is clearly distinct from the established macrophage 
phenotypes (Gleissner 2012) (figure 7).  
 
Figure 7:  Schematic  overview  of  heterogenic  macrophage  populations  in 
atherosclerotic  plaques.  Different  growth  factors,  chemokines  or  lipoproteins 
may  induce  differential  development  in  monocytes  entering  the  plaque 
micromilieu. “Dotted arrows indicate monocyte-macrophage differentiation, while 
solid  arrows  signify  macrophage  polarization.  Arrows  are labeled  with the  key 
drivers of differentiation or polarization. Colors and distances indicate similarities 	
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and differences between the different macrophage types. M-DC, dendritic cells; 
M-ox,  foam  cells  induced  by  oxidized  low  density  lipoprotein  (oxLDL);  M-HA, 
hemorrhage-associated  macrophages;  CXCL4,  platelet  factor  4;  GM-GSC, 
granulocyte-macrophage  colony-stimulating  factor;  Hb/Hp,  hemoglobin-
haptoglobin  complexes;  IFN-γ,  interferon-gamma;  IL,  interleukin;  LPS, 
lipopolysaccharide.” (Excerpt from: Gleissner 2012). 
PF4, together with another alpha granule protein, RANTES (CCL5), was also shown to 
enhance T cell effector differentiation (Gerdes, Zhu et al. 2011). 
1.4.2  Other	
 ﾠpro-ﾭ‐inflammatory	
 ﾠmediators	
 ﾠreleased	
 ﾠfrom	
 ﾠplatelets	
 ﾠ
Platelet CD40 ligand (CD40L) is another molecule released from activated platelets, which 
has been implicated in atherogenesis. CD40L-deficient platelets show impaired aggregation 
and thrombus stability. In ApoE-deficient, atherosclerosis-prone mice, injection of CD40L-
deficient  platelets  but  not  wild-type  platelets  decreased  plaque  formation  (Lievens, 
Zernecke et al. 2010). Several molecules released from platelet dense granules have been 
implicated in inflammation and atherogenesis. Dense-granule-derived polyphosphates have 
been shown to upregulate bradykinin production, which in turn stimulates the generation of 
the pro-inflammatory cytokines IL1β and TNFα (Muller, Mutch et al. 2009). The protein 14-
3-3ζ was identified in dense granules from human platelets with a proteomics approach and 
shown  to  be  present  in  atherosclerotic  plaques  from  patients’  samples  with  aneurysms 
(Hernandez-Ruiz,  Valverde  et  al.  2007).  Serotonin  has  mitogenic  effects  on  endothelial 
cells (Pakala, Willerson et al. 1994) and smooth muscle cells (Hodivala-Dilke, McHugh et 
al. 1999) in vitro and could contribute to the proliferation of these cell types characteristic for 
atherosclerotic plaque formation in vivo. 
1.5  Platelets	
 ﾠand	
 ﾠCancer	
 ﾠ
1.5.1  Historical	
 ﾠoverview	
 ﾠ
Armand Trousseau was the first to describe a relation between cancer and platelets as 
early  as  1865  (Armand  Trousseau,  Phlegmasia  alba  dolens,  in:  Clinique  Medicale  de 
l’Hotel-Dieu de Paris, Vol 3, 2
nd Edition, Ballière, Paris, 1865, pp 654-712). He noted that 
patients  with  thromboembolism  had  an  increased  risk  to  host  an  occult  tumor  and  vice 
versa,  patients  with  a  diagnosed  tumor  were  more  likely  to  develop  thrombotic  events. 
Since then, evidence has gathered showing a prominent role of platelets also in the leading 
cause  of  cancer-related  deaths  today,  the  formation  of  distant  metastases.  Gasic  et  al. 
reported  in  1968  that  pharmacologic  reduction  of  platelets  in  the  circulation  leads  to  a 
reduction of experimental pulmonary metastasis and that this decrease can be restored by 
infusion of platelets (Gasic, Gasic et al. 1968). Development of depleting antibodies for 
platelets  allowed  verifying  the  observations  made  by  Gasic  in  an  experimental  setting 
where  platelets  were  virtually  absent  (Pearlstein,  Ambrogio  et  al.  1984).  Crissman  and 	
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colleagues demonstrated for the first time that platelets are associated with tumor cells 
shortly after vascular arrest (Crissman, Hatfield et al. 1988), a finding, which was later also 
reported by other groups (Im, Fu et al. 2004). In the 1990s, it was first shown that platelets 
bind to tumor cells and protect them against lysis from natural killer (NK) cells (Nieswandt, 
Hafner et al. 1999). The strong reduction in metastasis in platelet-depleted mice could be 
repeated with genetic depletion of platelets (Camerer, Qazi et al. 2004). As early as 1973, it 
was shown that the ability of tumor cells to activate platelets correlates with their metastatic 
potential (Gasic, Gasic et al. 1973; Pearlstein, Salk et al. 1980) and in 2012, confirmation 
for a major role of platelet activation in the clinical context was provided by a large post-hoc 
analysis  of  cardiovascular  outcome  trials  (Rothwell,  Wilson  et  al.  2012).  Rothwell  and 
colleagues found a 15% reduction in cancer-related deaths with intake of daily low-dose 
aspirin, which inhibits platelet activation, starting 5 years after initiation of therapy.  
1.5.2  Platelet	
 ﾠeffects	
 ﾠon	
 ﾠprimary	
 ﾠtumors	
 ﾠ
Platelets  store  a  multitude  of  pro-angiogenic  factors  in  alpha  granules  such  as  VEGF, 
PDGF, bFGF (FGF2), EGF, IGF and angiopoietin, and several anti-angiogenic factors such 
as angiostatin, thrombospondin-1, endostatin, TGFβ and S1P (Jain, Harris et al. 2010; Gay 
and Felding-Habermann 2011). All of these molecules have been shown to influence tumor 
angiogenesis (Gay and Felding-Habermann 2011; Claesson-Welsh 2012). Several reports 
have found differential release of pro- and anti-angiogenic stimuli from platelets in response 
to certain stimuli (Ma, Perini et al. 2005; Italiano, Richardson et al. 2008; Bambace, Levis et 
al.  2010;  Peterson,  Zurakowski  et  al.  2010;  Chatterjee,  Huang  et  al.  2011;  Nylander, 
Osman et al. 2012), which implies that release of these mediators can be tightly controlled 
as  is  required  in  tumor  microenvironment  (Spano  and  Zollo  2012).  Platelet  depletion 
reportedly leads to hemorrhage in primary tumors (Ho-Tin-Noe, Goerge et al. 2008) and the 
authors conclude that constant release from platelet granules prevents excessive leakage 
from newly formed tumor vessels since infusion of resting platelets restored vessel integrity 
whereas infusion of degranulated platelets did not. 
1.5.3  Platelet	
 ﾠeffects	
 ﾠon	
 ﾠtumor	
 ﾠmetastasis	
 ﾠ	
 ﾠ
Tumor  metastasis  is  the  leading  cause  of  cancer  death  and  is  a  complex  and  still 
incompletely  understood  process.  Tumor  cells  of  the  primary  tumor  need  to  acquire  an 
invasive  phenotype,  enter  the  circulation  and  withstand  shear  forces  and  immune  cell 
attacks before they extravasate in the target organ and grow in the organ parenchyma 
(Sahai  2007;  Joyce  and  Pollard  2009;  Nguyen,  Bos  et  al.  2009;  Chaffer  and  Weinberg 
2011). 	
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Figure 8:   Overview of the main events involved in formation of metastases from a 
primary tumor. Tumor cells need to acquire an invasive phenotype (A), invade 
the circulation (B), travel to the target organ (C), extravasate (D), survive (E) and 
proliferate (F) in the organ parenchyma. (From: Chaffer and Weinberg 2011). 
As mentioned above, the contribution of platelets to tumor metastasis is well established 
(Gasic, Gasic et al. 1968; Pearlstein, Ambrogio et al. 1984; Camerer, Qazi et al. 2004). The 
effects of almost complete absence of platelets due to anti-platelet antibodies or genetic 
depletion on the number of experimental metastasis are dramatic: a reduction of more than 
94% compared to controls was reported (Pearlstein, Ambrogio et al. 1984; Camerer, Qazi 
et al. 2004; Coupland, Chong et al. 2012). To achieve such a pronounced reduction in 
metastasis, it is sufficient to deplete platelets at the time of tumor cell injection (Coupland, 
Chong et al. 2012), indicating that platelets play an important role during vascular arrest 
and extravasation of tumor cells. Several mechanisms have been proposed how platelets 
mediate these effects. Platelets were shown to bind to tumor cells and protect them from 
NK cell lysis in vitro (Nieswandt, Hafner et al. 1999) and in vivo (Palumbo, Talmage et al. 
2005; Placke, Kopp et al. 2011). Circulating tumor cells of patients display co-expression of 
platelet  markers  (Placke,  Orgel  et  al.  2012).  NK  cells  are  the  primary  immune  cells 
efficiently  clearing  tumor  cells  from  the  circulation  (Gorelik,  Wiltrout  et  al.  1982;  Hanna 
1985).  It has been suggested that platelets form a cloak around circulating tumor cells, 
thereby shielding them against recognition from NK cells (Nieswandt, Hafner et al. 1999) 
and that releasate from platelets modulates NK cell function, partially by downregulating the 
NK cell activating receptor NKG2D on NK cells (Placke, Kopp et al. 2010; Placke, Kopp et 
al. 2011). However, a recent study found no correlation between platelet-mediated and NK 
cell-mediated effects on tumor cell metastasis (Coupland, Chong et al. 2012). 
Several  platelet  surface  receptors  have  been  implicated  in  tumor  metastasis.  P-
selectin-deficient mice exhibit at strong reduction in experimental metastasis (Kim, Borsig et 	
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al. 1998) and some of the anti-metastatic effects of heparins or related compounds have 
been ascribed to their inhibitory action on P-selectin (Kim, Borsig et al. 1998; Varki and 
Varki 2002; Li, Luo et al. 2010; Gong, Mi et al. 2012). However, it is difficult to discriminate 
between contributions of endothelial versus platelet P-selectin and the importance of P-
selectin in metastasis depends on the target organ (Coupland, Chong et al. 2012; Matsui, 
Amano et al. 2012). 
A role for the important platelet surface receptor integrin αIIbβ3 in tumor cell induced 
platelet  aggregation  (TCIPA)  was  first  described  in  1987  (Bastida,  Almirall  et  al.  1987; 
Grossi, Fitzgerald et al. 1987; Nierodzik, Klepfish et al. 1995). Integrin αIIbβ3 was shown to 
bind to integrin ανβ3 on tumor cells expressing this receptor and this interaction lead to 
increased adhesion of melanoma cells to endothelial cells in vitro (Lonsdorf, Kramer et al. 
2012).  Blockade  of  integrin  αIIbβ3  with  specific  antibodies  reduced  the  formation  of 
metastasis in several tumor cell lines (Karpatkin, Pearlstein et al. 1988; Erpenbeck and 
Schon 2010). 
Contradictory results have been obtained for an involvement of GPIbα in platelet-
tumor  cell  interactions,  depending  on  tumor  cell  line  studied  and  experimental  settings 
(Erpenbeck  and  Schon  2010).  Mice  constitutively  lacking  GPIbα  showed  a  reduction  in 
metastasis (Bergmeier, Rackebrandt et al. 2000), whereas injection of blocking antibodies 
against GPIbα evoked a dramatic increase in experimental metastasis (Jain, Zuka et al. 
2007). Lack of GPIbα leads to defects in platelet and megakaryocyte biogenesis similar to 
Bernard  Soulier  syndrome  and  resulting  effects  thus  exceed  the  impact  of  anti-GPIbα 
antibodies, which could in part explain these differing observations (Erpenbeck and Schon 
2010). 
Blockade  of  the  major  platelet  collagen  receptor,  GPVI,  does  not  influence 
experimental metastasis (Erpenbeck and Schon 2010).  
Figure  9  shows  effects  of  platelet  depletion  (A),  anti-GPIbα  antibody  (B),  anti-
integrin αIIbβ3 antibody (C), anti-GPVI antibody (D) and global deletion of P-selectin on 
B16 melanoma metastasis in the lung (Erpenbeck and Schon 2010). 	
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Figure 9:  “Examples  for  modulation  of  pulmonary  melanoma  metastasis  through 
targeted interference with platelet receptors. In all experiments (performed by 
L.E. in the laboratory of M.P.S.), C57/BL6 mice were intravenously injected with 
2.5 x 10
5 B16F10 melanoma cells, and pulmonary metastasis was evaluated after 
10 to 14 days. (A) Antibody-mediated depletion of platelets prevents metastasis 
formation. (B) Inhibition of platelet GPIbα by function-blocking, monovalent Fab 
fragments results in a marked increase of pulmonary melanoma metastases. (C) 
Inhibition of αIIbβ3 by specific Fab fragments decreases the number of metastatic 
melanoma nodules in the lung. (D) Antibody-mediated blockade of GPVI does not 
significantly influence pulmonary melanoma metastasis. (E) P-selectin deficiency 
causes  marked  reduction  of  pulmonary  melanoma  metastasis.”  (Excerpt  from: 
Erpenbeck and Schon 2010). 
The recently discovered platelet receptor CLEC-2 (Suzuki-Inoue, Fuller et al. 2006) has 
been implicated in interactions with tumor cells expressing podoplanin (Aggrus) on their 
surface (Suzuki-Inoue 2011) as was found for e.g. B16 melanoma cells (Lowe, Navarro-
Nunez et al. 2012). Podoplanin is known to cause platelet aggregation (Lowe, Navarro-
Nunez et al. 2012) and there is data suggesting that presence of podoplanin on tumor cells 
is connected with metastasis and poor clinical outcome (Mishima, Kato et al. 2006; Yuan, 
Temam et al. 2006).  
Thrombin  is  one  of  the  most  important  and  potent  agonists  in  normal  platelet 
function. Tissue factor exposure on cells together with coagulation factors leads to thrombin 
generation in the circulation. It has been shown that a number of tumor cells expose tissue 
factor on their surface and metastatic potential and tumor angiogenesis correlate with tissue 
factor expression for colorectal and melanoma cell lines (Voigtlander, Rand et al. 2002). In 
addition, some tumor cells themselves express thrombin receptors on their surface and this 
also correlates with their metastatic potential (Zigler, M., T. Kamiya et al. 2011). Thrombin-	
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stimulated tumor cells can bind more efficiently to platelets and endothelial cells and form 
more pulmonary metastases in a mouse model (Erpenbeck and Schon 2010).  
Figure  10  summarizes  possible  interactions  of  circulating  tumor  cells  with  platelets  and 
other cell types (Gay and Felding-Habermann 2011).  
 
Figure 10:  Tumor cell and platelet interactions in the circulation. (A) Upon entering the 
circulation,  tumor  cells  activate  platelets,  stimulate  platelet  secretion  and  bind 
platelets  to  their  surface.  Interactions  with  other  platelets  and  potentially 
leukocytes are enabled through cross-linking with fibrinogen and vWF. (B) Tissue 
factor  exposure  on  tumor  cells  together  with  factor  (F)  VIIa  leads  to  thrombin 
generation, which further activates platelets and can also stimulate PAR receptor-
expressing  tumor  cells.  (C)  Platelet-covered  tumor  cells  are  protected  against 
lysis  by  NK  cells  during  transit.  (D)  In  the  microcirculation,  platelets  bound  to 
tumor cells may brigde interactions with endothelial cells and facilitate vascular 
arrest. (From: Gay and Felding-Habermann 2011).	
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2  Aims	
 ﾠof	
 ﾠthis	
 ﾠstudy	
 ﾠ
Platelets  contain  a  large  number  of  secretable  mediators  able  to  influence  various 
pathophysiological processes. Mostly indirect evidence is accumulating that platelets play a 
role in detrimental diseases like atherosclerosis and cancer. We sought to  
(I)  generate and  
(II)  describe genetically modified mouse lines with defective platelet secretion but 
otherwise unaltered morphology and function and  
(III)  to study the effects of specific defects in platelet granule secretion in murine 
models of atherosclerosis and tumor progression. 
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3  Materials	
 ﾠ
3.1  Laboratory	
 ﾠequipment	
 ﾠ
Agarose gel electrophoresis equipment  Bio Rad, GE 
Analytical balance  Satorius, GE 
Apact 4 S Plus aggregometer   Diasys Greiner, GE 
Bio Photometer Eppendorf  Eppendorf, GE 
Biofuge pico Heraceus  Heraceus, GE 
Coombs and chambers for electrophoresis  Workshop University Heidelberg, 
GE 
Cryotome  Leica, GE 
DynaMag cell separation magnet  Invitrogen, USA 
Eppendorf centrifuge 5417  Eppendorf, GE 
Eppendorf centrifuge 5810R  Eppendorf, GE 
FACSCalibur flow cytometer  BD Biosciences, GE 
FACSCanto flow cytometer  BD Biosciences, GE 
Flexstation  Molecular Devices, USA 
Flow chamber system  Workshop University Heidelberg, 
GE 
Fluorometer/ Luminometer  Thermo Fisher Scientific, USA 
Gel Doc 2000 system  BioRad, GE 
Gene Quant pro Photometer   Amersham Bioscience/Biochrom, 
UK 
GenePulser  Bio Rad, GE 
Gradient Cycler PTC 200 DNA Engine  Bio Rad, GE 
Innova 4300 incubator shaker  New Brunswick Scientific, USA 
Leica DFC 280 camera  Leica, GE 
Leica DMLS2 microscope  Leica, GE 
Leica SP5 confocal microscope  Leica, GE 
Lightcycler 480 qPCR cycler   Roche, GE 
Magnetic Mini-Stirrer  HANNA, GE 
Magnetic mixer  Variomag, GE 
Microtome  Leica, GE 
Microwave heater  Panasonic, GE 
NanoDrop ND1000 Spectrophotometer   Biozym, GE 
Neubauer counting chamber  Karl Hecht, GE 
Olympus IX81 microscope  Olympus, JP 
Owen WTB-Binder incubator plates  Binder, GE 	
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pH 211 Microprocessor pH meter  HANNA, GE 
Photospectrometer  Thermo Fisher Scientific, USA 
Refrigerators, 4 °C, -20 °C, -80°C  Liebherr Premium, GE 
Thermomixer compact Eppendorf  Eppendorf, GE 
Two-syringe infusion pump KDS200  KD Scientific, USA 
Vortex  A. Hartenstein, GE 
Water bath  Eppendorf, GE 
Western blot equipment  Bio Rad, GE 
Zeiss Axio Observer.Z1   Zeiss, GE 
Table 4:  Laboratory equipment used in this study. 
3.2  Software	
 ﾠ	
 ﾠ
CellQuestPro  BD Bioscience, GE 
Blast  NIH, USA 
End Note X1  Thomson Reuters  
FACSDiva  BD Bioscience, GE 
GraphPadPrism 5  GraphPad Software, USA 
Image J  NIH, USA 
Microsoft Office 2007  Microsoft, USA 
ND-1000 V3.1.0   Nanodrop, USA 
Adobe Design Suite CS6  Adobe  Systems  Incorporated, 
USA 
Quantity One  BioRad, GE 
Vector NTI 10 advance  Invitrogen, GE 
Table 5:  Software used in this study. 
3.3  Laboratory	
 ﾠsupplies	
 ﾠ
Accucount flurescent particles  Spherotech, USA 
Acryl-cuvettes   Sarstedt Nümbrecht, GE 
Agar-plates  Brand, GE 
Amaxa nucelofector cell electroporator  Lonza, CH 
Apact 4 S Plus cuvettes  Diasys Greiner, GE 
Bacteria culturing tube, 5 ml   Brand, GE 
Beakers  Brand, GE 
Capillares 10 µl  Kabe, GE 
Cell culture dishes  Greiner Bio One, GE 
Cell culture pipettes  BD Bioscience, GE 
Cell culture plates  Greiner Bio One, GE 
Cell sieve 70 µm  BD Falcon, GE 	
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Cryosection slides  Thermo Fisher Scientific, USA 
Dynabeads cell separation beads  Invitrogen, USA 
Nunc Maxisorp ELISA plates  Nunc, Thermo Scientific, USA 
Eppendorf tubes 0.5 ml, 1.5 ml and 2 ml   Eppendorf, GE 
FACS tubes  BD Bioscience, GE 
Falcon tubes 15, 50 ml  BD Bioscience, GE 
Filter paper  Neolab, GE 
Gel casting platform  Bio Rad, GE 
Gel combs  Bio Rad, GE 
Genepulser cell electroporator  Bio Rad, GE 
Gilson pipettes  Gilson, USA 
Glass bottles, Kolben  Brand, GE 
Glass cylinders  Brand, GE 
Microscop coverslip  Hartenstein, GE 
Microscope slides  Hartenstein, GE 
Needle 27G, 24G  BD Bioscience, GE 
Pasteur pipette  Greiner BioOne, GE 
PCR wells  Roche, GE 
Pipette tips (10 µl, 200 µl, 1000 µl)  Brand, GE 
Plastic pipette 5 ml  Greiner BioOne, GE 
Scalpel   Dahle, Rödental, GE 
Surgical tools  Megro/Ratiomed, GE 
Syringe 1 ml  BD Bioscience, GE 
Syringe filter, 0.22 µm  Roth, GE 
Transwell plate 8 µm pore size  Corning, USA 
Table 6:  Laboratory supplies used in this study. 
3.4  Chemicals	
 ﾠ
Agar  AppliChem, GE 
Agarose  Invitrogen, GE 
Ampicillin sodium salt  AppliChem, GE 
ADP  Sigma, GE 
Apyrase grade VII  Sigma, GE 
ATP  Sigma, GE 
ATPγS (adenosine 5’-O-(3-thio)triphosphate)  Jena Bioscience, GE 
5-BDBD  (5-(3-Bromophenyl)-1,3-dihydro-2H-
benzofuro[3,2-e]-1,4-diazepin-2-one) 
Tocris, USA 
Bromo phenol blue  Sigma, GE 
BSA (bovine serum albumin)  Sigma, GE 	
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BSA essentially fatty acid free  Sigma, GE 
Calcein AM (Calcein acetoxymethyl ester)  Sigma, GE 
Calcium chloride dehydrate (CaCl2 x 3H2O)  AppliChem, GE 
Carbon dioxide (CO2)  ZBT, GE 
Chloramphenicol  Sigma, GE 
Chloroform  Sigma, GE 
CRP (collagen-related peptide)  Gift from Bernhard Nieswandt 
DAPI (4’,6-diamidino-2-phenylindole)  Sigma, GE 
dATP  Promega, GE 
dCTP   Promega, GE 
dGTP  Promega, GE 
Di-sodium hydrogenphosphat-2-hydrate   Riedel-de Haën, GE 
DNA loading dye 6x   Fermentas, GE 
dTTP   Promega, GE 
EDTA (ethylendiamine tetraacetic acid)  Roth, GE 
Ethanol absolute   ZBT, GE 
Ethidium bromide  Merck, GE 
Ferric chloride (FeCl3)  Sigma, GE 
Fiblillar type I collagen  Nycomed, GE 
FITC-dextran 70 kDa  Sigma, GE 
FITC-dextran 70 kDa, lysine-fixable  Invitrogen, USA 
Fluo-4  AM  (2-{[2-(2-{5-[bis(carboxymethyl)amino]-2-
methylphenoxy}ethoxy)-4-(2,7-difluoro-6-hydroxy-3-
oxo-3H-xanthen-9-
yl)phenyl](carboxymethyl)amino}acetic  acid 
acetoxymethyl ester) 
Molecular Probes, USA 
Flurbiprofen  ((±)-2-fluoro-α-methyl-[1,1’-biphenyl]-4-
acetic acid) 
Cayman Chemical, USA 
Glucose D(+)  Merck, GE 
Glutaraldehyde solution 25%  Merck, GE 
Glycerol 99%  Merck, GE 
Glycine  AppliChem, GE 
Heparin-sodium  B.Braun Melsungen, GE 
HEPES  (4-(2-hydroxyethyl)-piperazin-1-
ethansulfonicacid) 
AppliChem, GE 
High Range Latter  Fermentas, GE Hydrogen 
Hydrogen chloride (HCl)  AppliChem, GE 
Hydrogen peroxide  Sigma, GE 
Isoflurane  Abbot Laboratories, USA 	
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Isopropanol 99% (2-propanol)  Roth, GE 
Ketamine  ((RS)-2-(2-Chlorophenyl)-2-
(methylamino)cyclohexanone) 
Kepro, NL 
L-arabinose  Sigma, GE 
Ligation buffer  New England BioLabs, GE 
Magnesium chloride hexahydrate   Merck, GE 
Mineral oil  Sigma, GE 
MRS2500  (1R*,2S*)-4-[2-Iodo-6-(methylamino)-9H-
purin-9-yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1-
methanol dihydrogen phosphate ester tetraammonium 
salt) 
Tocris, USA 
Nonidet P-40 (Ethylphenyl-polyethylene glycol)  AppliChem, GE 
Oil Red O (1-([4-(Xylylazo)xylyl]azo)-2-naphthol, 1-[2,5-
dimethyl-4-(2,5-dimethylphenylazo)phenylazo]-2-
naphthol) 
Sigma, GE 
OPD (1,2-phenylenediamine dihydrochloride) tablet  Dako, DK 
Para-formaldehyde  Sigma, GE 
Phenol  Roth, GE 
Phenol/ chloroform  Roth, GE 
Potassium chloride   AppliChem, GE 
Rhodocytin   Gift from Bernhard Nieswandt 
SDS (sodium dodecyl sulfate)  AppliChem, GE 
Sepharose CL4b  Sigma, GE 
Smart Ladder marker 200-10 000bp   Eurogentec, GE 
Sodium chloride   AppliChem, GE 
Sodium hydroxide   Roth, GE 
Sodium hydrogencarbonate-monohydrate  Sigma, GE 
Sodium-di-hydrogenphosphate-monohydrate  Neolab, GE 
Spermidin 100 mM  Sigma, GE 
Sucrose   Sigma, GE 
Tamoxifen  Sigma, GE 
Tetracycline  Sigma, GE 
Thrombin from bovine plasma  Sigma, GE 
Tris (Trishydroxymethylaminomethan)  AppliChem, GE 
Trisodium-salt-dihydrate  Sigma, GE 
Trypton  AppliChem, GE 
Trypton  Roth, GE 
U46619  Cayman Chemical, USA 
UTP  Sigma, GE 	
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Xylazine  (N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-
thiazin-2-amine) 
Kepro, NL 
Yeast extract  AppliChem, GE 
Table 7:  Chemicals used in this study. 
3.5  Antibodies	
 ﾠ	
 ﾠ
Antigen   Company 
Asialo GM1, mouse  Wako, JP 
β-actin, mouse  Acris Antibodies, GE 
CD3ε, mouse  BD Pharmingen, GE 
CD9, mouse  Emfret, GE 
CD41, mouse  BD Pharmingen, GE 
CLEC-2, mouse  Gift from Bernhard Nieswandt, GE 
GPIbα, mouse  Emfret, GE 
GPV, mouse  Emfret, GE 
GPVI, mouse  Emfret, GE 
GPIX, mouse  Emfret, GE 
Integrin αIIb, mouse  Emfret, GE 
Integrin αIIbβ3, mouse  Emfret, GE 
Integrin αIIbβ3 active conformation, mouse  Emfret, GE 
Integrin β1, mouse  Emfret, GE 
Ly6G, mouse  BD Pharmingen, GE 
Ly6G, mouse  Biolegend, USA 
Munc13-4, mouse  Santa Cruz, USA 
Myc peptide  Novus, USA 
NK1.1, mouse  BD Pharmingen, GE 
PF4, mouse  R&D Systems, USA 
P-selectin, mouse  BD Pharmingen, GE 
SNAP-23, mouse  Synaptic Systems, GE 
SNAP-25, mouse  Synaptic Systems, GE 
Syntaxin-1A, mouse  Synaptic Systems, GE 
Syntaxin-1B, mouse  Synaptic Systems, GE 
Syntaxin-2, mouse  Synaptic Systems, GE 
Syntaxin-3, mouse  Synaptic Systems, GE 
Syntaxin-4, mouse  Synaptic Systems, GE 
Syntaxin-5, mouse  Synaptic Systems, GE 
Syntaxin-5, mouse  Synaptic Systems, GE 
Syntaxin-6, mouse  Synaptic Systems, GE 
Syntaxin-7, mouse  Synaptic Systems, GE 	
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VAMP-1, mouse  Synaptic Systems, GE 
VAMP-2, mouse  Synaptic Systems, GE 
VAMP-3, mouse  Synaptic Systems, GE 
VAMP-4, mouse  Synaptic Systems, GE 
VAMP-5, mouse  Synaptic Systems, GE 
VAMP-6, mouse  Synaptic Systems, GE 
VAMP-7 (TI-VAMP), mouse  Novus, USA 
VE-cadherin (CD144), mouse  BD Pharmingen, GE 
vWF, human  Dako, DK 
vWF-HRP, human  Dako, DK 
Table 8:  Antibodies used in this study. 
3.6  Enzymes	
 ﾠ
Antarctic phosphatase  New England Biolabs, USA 
CIP (Calf intestinal alkaline phosphatase)  New England Biolabs, USA 
Dispase  Sigma, GE 
Proteinase K  AppliChem, GE 
Restriction enzymes  New England Biolabs, USA 
RNaseA  New England Biolabs, USA 
Taq polymerase  Promega, USA 
T4 DNA ligase  New England Biolabs, USA 
VentR DNA polymerase  New England Biolabs, USA 
vWF-HRP, human  Dako, DK 
Table 9:  Enzymes used in this study. 
3.7  Buffers	
 ﾠand	
 ﾠsolutions	
 ﾠ
Self-made  buffers  and  solutions  were  prepared  in  fresh  double-distilled  and  deionised 
water.  Buffers  and  solutions  used  during  cloning  were  autoclaved.  Concentrations  are 
indicated as final concentrations. 
PBS (phosphate buffered saline)  8.0 g/l NaCl, 0.2 g/l KCl, 1.44 g/l Na2HPO4, 0.24 g/l 
KH2PO4, pH 7,4 
10x digestion buffer1/2/3  New England Biolabs, USA 
10x Taq-buffer  200 mM Tris-HCL (pH 8.4), 500 mM KCl 
Mini/Maxi-preparation-buffers: B1-B3   
B1:  50 mM Tris, 10 mM EDTA, 100 ug/mL RnaseA, pH 
8.0 with HCl 
B2:  0.2 M NaOH, 1% SDS 
B3:  3 M potassium-acetat, pH 5.5 with 100% acetic acid  
Eosin solution  Sigma, GE 	
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Haematoxylin solution  Sigma, GE 
Injection buffer  10 mM Tris-HCL pH 7.5, 0.1 mM EDTA, 100 mM-
NaCl 
Kaiser’s glycerol gelatine  Merck Millipore, GE 
Loading buffer (6x)  0.25 % bromo phenol blue, 0.25% xylene cyanol, 
30 % glycerol 
OCT  (Optimum  cutting  temperature 
compound) 
Thermo Fisher Scientific, USA 
Red blood cell lysis buffer  Sigma, GE 
Sterile saline (0.9 % NaCl) solution  B.Braun Melsungen, GE 
TAE-buffer  40 mM Tris acetate, 1 mM EDTA, pH 8.0 
Tail-buffer  0.1 M EDTA, 0.5 % SDS, 50 mM Tris pH 8, 0.5 mg / 
ml Proteinase K 
TE-buffer  10 mM Tris-HCL, 1 mM EDTA, pH 7.5 
Thermo Polymerase buffer  New England Biolabs, USA 
Table 10:  Buffers and solutions used in this study. 
3.8  Cell	
 ﾠculture	
 ﾠmedia	
 ﾠ&	
 ﾠsolutions	
 ﾠ
All self-made culture media were autoclaved before using. 
BSA (bovine serum albumin), sterile  Invitrogen, USA 
DMEM medium  Invitrogen, USA 
DMEM/F12 medium  Invitrogen, USA 
EGM2 medium  Lonza, CH 
EC growth supplement with heparin  Promocell, USA 
FBS (fetal bovine serum )  Invitrogen, USA 
Glutamine, sterile  Invitrogen, USA 
HBSS (Hank’s balanced salt solution)  Invitrogen, USA 
LB-medium  5  g/l  yeast  extract,  10  g/l  trypton,  7  g/l  NaCl, 
dissolved in ddH2O 
LB-medium for plates  5 g/l yeast extract, 10 g/l trypton, 7 g/l NaCl, 10 g 
agar per liter LB-medium, dissolved in ddH2O 
Non-essential amino acids, sterile  Invitrogen, USA 
PBS, sterile  Invitrogen, USA 
Penicillin/ streptomycin, sterile  Invitrogen, USA 
RPMI medium  Invitrogen, USA 
SOB-Mg medium  20 g/l trypton, 5 g/l yeast extract, 10 mM NaCl, 10 
mM KCl, dissolved in ddH2O 
Trypsin EDTA  Invitrogen, USA 
Table 11:  Cell culture media and solutions used in this study. 	
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3.9  Kits	
 ﾠ
Amaxa cell line nuclofector kit V  Lonza, CH 
Celltrace  CFSE  (Carboxyfluorescein  diacetate 
succinimidyl ester) labeling kit 
Invitrogen, USA  
Counter-Selection-BAC modification kit     Gene Bridges, GE 
Enliten ATP kit  Promega, USA 
High pure PCR product purification kit  Roche, GE 
Lightcycler 480 probes master  Roche, GE 
Mini RNA isolation kit  Qiagen, GE 
PF4 ELISA kit  Raybiotech, USA 
RNase-free DNase set  Qiagen, GE 
Transcriptor high fidelity cDNA synthesis kit  Roche, GE 
Universal probe library set, human  Roche, GE 
Universal probe library set, mouse  Roche, GE 
Table 12:  Kits used in this study. 
3.10  Vectors	
 ﾠ&	
 ﾠBAC	
 ﾠ
706-Flp  Gene Bridges, GE  
pBigT  Addgene, USA 
pBS(II)KS(+) (pBluescript II KS(+))  Agilent Technologies, USA 
phCre2_ERT2    Gift from Günter Schütz 
RP24-98A BACs  BAC/PAC  Resources,    Oakland, 
USA 
Table 13:  Vectors and BAC used in this study. 
3.11  Bacterial	
 ﾠstrain	
 ﾠ
DH10B:  Genotype:  F-  mcrA.  (mrr-hsdRMS-mcrBC)  φ80lacZ.M15 
.lacX74recA1  endA1  araD139.  (ara,  leu)7697  galU  galK  ë- 
rpsL nupG 
Invitrogen, USA 
3.12  Cell	
 ﾠlines	
 ﾠ
B16F10   ATCC, USA 
CF-PAC1  ATCC, USA 
HUVEC  Lonza, CH 
LLC1   ATCC, USA 
MS1 (Mile Sven 1)  Gift from Boris Strilić 
SH-SY5Y  ATCC, USA 	
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Table 14:  Cell lines used in this study. 
3.13  Mouse	
 ﾠstrains	
 ﾠ	
 ﾠ
C57Bl/6J (referred to as “wild-type mice“)  Jackson Laboratory, USA 
LDLR KO (B6.129S7-Ldlrtm1Her/J)  Jackson Laboratory, USA 
P2Y2 KO (B6.129P2-P2ry2tm1Bhk/J)  Jackson Laboratory, USA 
Munc13-4 mutant (Unc13d
Jinx)  Scripps Research Institute, USA 
Table 15:  Mouse strains used in this study. 
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4  Methods	
 ﾠ
4.1  Cloning	
 ﾠ
4.1.1  Cloning	
 ﾠof	
 ﾠPF4-ﾭ‐BAC-ﾭ‐toxin	
 ﾠconstructs	
 ﾠ
Materials: BAC vector RP24-98A4 containing PF4 gene was from BAC/PAC Resources, 
Oakland,  CA;  primers  were  from  Invitrogen;  cloning  enzymes  were  from  New  England 
Biolabs;  pBluescript  II  KS(+)  phagemid  vector  was  from  Agilent  Technologies;  pBigT 
plasmid carrying the BGH-pA was from Addgene; phCre2_ERT2 plasmid containing the 
FRT-flanked  ampicillin  resistance  gene  was  a  kind  gift  from  Günter  Schütz,  DKFZ, 
Heidelberg; Counter-Selection BAC Modification Kit for E/T cloning was from Gene Bridges; 
706-Flp plasmid containing the flippase recombinase gene was from Gene Bridges  
The cloning process was similar for the three toxin light chains used in this study (tetanus 
toxin (TeNT), botulinum toxin C and E (BoNT-C, BoNT-E)). The sequence used for the 
PF4-TeNT construct corresponds to the original Clostridium tetani sequence of the toxin 
light  chain  containing  the  zinc  metalloproteinase  capable  of  cleaving  certain  SNARE 
proteins but not binding to cell surface receptors and internalization. For both BoNT-E and 
BoNT-C light chain sequences, Entelechon designed and produced sequences optimized 
for  expression  in  Mus  musculus.  To  engineer  the  5’  homology  arms  for  E/T  cloning, 
approximately  100-150  basepairs  (bp)  upstream  and  downstream  sequence  of  the  PF4 
gene  on  BAC  vector  RP24-98A4  was  amplified  by  PCR  and  a  restriction  site  was 
introduced via the 5’ primer while the 3’ primer carried 8 bases overlapping with the first 
bases of the respective toxin light chains. Then, 300-800 bp of the 5’ end of the toxin light 
chains were amplified by PCR until a unique restriction site in the toxin and construct was 
reached at the 3’ end. The 5’ primer carried eight nucleotides overlapping with the 3’ end of 
the  5’  homology  arm.  Via  overlap  PCR  with  the  modified  5’  homology  arms  and  the 
modified 5’ partial sequence of the respective toxin light chain PCR products as templates 
and the 5’ primer of the 5’ homology arm and the 3’ primer of the partial toxin sequence as 
primers, the 5’ homology arm and the partial toxin sequence were joined and cloned into 
the  pBluescript  II  KS(+)  (pBSIIKS(+))  phagemid  vector  which  was  used  as  a  cloning 
backbone. The remaining parts of the toxin light chains were cloned into the PBSIIKS+ 
vector via the unique restriction sites. The BGH-polyA (BGH-pA) tail was excised from the 
pBigT  plasmid  and  introduced  immediately  3’  of  the  toxin.  The  Ampicillin-resistance 
cassette was excised from the phCre2_ERT2 plasmid including the FRT-sites flanking the 
gene and placed behind the 3’ end of the BGH-pA. In analogy to the 5’ homology arm, the 
3’  homology  arm  was  produced  by  amplifying  approximately  150  bp  of  the  genomic 
sequence immediately 3’ of the PF4 stop codon with the RP24-98A4 BAC as template. Via 
the primers, restriction sites were introduced into the PCR products on both ends and these 
restriction  sites  were  used  to  clone  the  3’  homology  arms  behind  the  3’  end  of  the 
ampicillin-resistance cassette. To replace the PF4 gene in the RP24-98A4 BAC construct 	
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with  the  final  construct  assembled  in  the  pBSIIKS(+)  cloning  vector,  E/T  cloning  was 
employed. This method is based on recombination of DNA strands carrying homologous 
sequences mediated by the λ phage-derived proteins Redα and Redβ. Redα is a 5’ to 3’ 
exonuclease, which produces 3’ single strand DNA overhangs. Redβ binds to 3’ overhangs 
and promotes annealing to homologous DNA. The Counter-Selection BAC Modification E/T 
cloning  kit  from  Gene  Bridges  was  used  for  homologous  recombination  of  the  toxin 
constructs  into  the  RP24-98A4  BAC  vector  and  selection  of  recombined  clones  was 
achieved  by  testing  for  ampicillin  resistance.  In  a  final  step,  the  ampicillin  resistance 
cassette was removed employing the 34 bp FRT sites flanking the cassette, which are 
recognized by the Saccharomyces cerevisiae-derived enzyme flippase encoded in the 706-
Flp plasmid used here. The sequence between the FRT sites is excised by the flippase 
leaving just an eight bp core of each FRT site in the construct. The final BAC construct 
containing the toxin light chain and the BGH-pA instead of the PF4 gene was verified by 
PCR with primers binding upstream of the 5’ homology arm and in the toxin light chain 
sequence  and  a  second  pair  binding  inside  the  BGH-pA  and  downstream  of  the  3’ 
homology arm to test for correct location. In addition, the construct was sequenced starting 
upstream and downstream of the inserted sequence. Restriction digests of the modified 
RP24-98A4  BAC  DNA  with  three  different  restriction  enzymes  was  performed  yielding 
specific cleavage patterns of the complete genomic sequence carried by RP24-98A4 BAC. 
This assures integrity of the complete sequence and would detect multiple insertions of the 
toxin constructs in unwanted places. The purified BAC construct was linearized and injected 
into  mouse  oocytes.  Injection  into  mouse  pronuclei  was  performed  at  the  Interfakultäre 
Biomedizinische Forschungseinrichtung (IBF) of the University of Heidelberg. 
4.1.2  Cloning	
 ﾠof	
 ﾠPF4-ﾭ‐BAC-ﾭ‐SNAP-ﾭ‐23	
 ﾠconstructs	
 ﾠ
Materials: BAC vector RP24-98A4 containing PF4 gene was from BAC/PAC Resources, 
Oakland,  CA;  primers  were  from  Invitrogen;  cloning  enzymes  were  from  New  England 
Biolabs;  pBluescript  II  KS(+)  phagemid  vector  was  from  Agilent  Technologies;  pBigT 
plasmid carrying the BGH-pA was from Addgene; phCre2_ERT2 plasmid containing the 
FRT-flanked  ampicillin  resistance  gene  was  a  kind  gift  from  Günter  Schütz,  DKFZ, 
Heidelberg; Counter-Selection BAC Modification Kit for E/T cloning was from Gene Bridges; 
706-Flp plasmid containing the flippase recombinase gene was from Gene Bridges  
Two genetically modified dominant-negative transgenic constructs of the SNAP-23 gene 
were designed for this study. The first mutant lacked the last eight amino acids (24 bp) of 
the  original  SNAP-23  Mus  musculus  sequence  and  was  termed  SNAP-23  ∆8.  This 
truncated  variant  was  generated  by  mRNA  isolation  from  mouse  platelets,  subsequent 
cDNA  production  and  amplification  of  the  desired  sequence  via  PCR  with  primers 
introducing  a  short  (eight  bp)  overlapping  sequence  with  the  5’  homology  arm  and  a 
restriction site on the 3’ end. The second construct contained three mutations and was 
termed SNAP-23 Ala as three polar amino acids were replaced by the unipolar alanine. The 	
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first was asparagine to alanine (N to A) at position 53 in the protein sequence (Accession ID 
BAA20345), the second glutamic acid to alanine at position 150 (E to A) and the third 
glutamine  (Q  to  A)  to  alanine  at  position  157.  For  higher  expression,  the  first  intron  of 
murine  IgCµ  heavy  chain  and  the  third  intron  of  IgCε  heavy  chain  were  inserted  after 
position 99 and position 422 in the cDNA sequence (Accession ID AF007169), where intron 
3-4  and  intron  6-7  are  located  in  the  genomic  SNAP-23  sequence  (accession  ID 
MGI109356).  The  further  cloning  procedure  was  analogous  to  the  PF4-toxin  cloning 
process described above except that a triple myc tag was inserted immediately upstream of 
the SNAP-23 start codon in both SNAP-23 mutants to enable detection of expression of the 
transgene. In the final BAC constructs, the PF4 gene in BAC RP24-98A4 was thus replaced 
by a triple myc tag, the SNAP-23 ∆8 mutant or the SNAP-23 Ala mutant, respectively, and a 
BGH-pA tail. The purified BAC constructs were linearized and injected into mouse oocytes. 
Injection  into  mouse  pronuclei  was  performed  at  the  Interfakultäre  Biomedizinische 
Forschungseinrichtung (IBF) of the University of Heidelberg. 
4.2  Platelet-ﾭ‐specific	
 ﾠmethods	
 ﾠ
4.2.1  Platelet	
 ﾠpreparation	
 ﾠ
Materials: All chemicals were from Sigma 
Blood  was  collected  from  2-4  mice  or  healthy  volunteers  and  was  anti-coagulated  with 
citrate. Platelet-rich plasma (PRP) was prepared by centrifugation at 150 × g for 7 min. The 
PRP was centrifuged at 350 × g for 7 min, and the platelet pellet was gently resuspended in 
HEPES/Tyrode's buffer (TB; 10 mM HEPES/NaOH, pH 7.4, 5.56 mM glucose, 0.3% w/v 
BSA (essentially fatty acid free), 137 mM NaCl, 12 mM NaHCO3, 2.7 mM KCl, 0.36 mM 
NaH2PO4, 1 mM MgCl2). Platelet concentrations were determined by hemacytometer. 
4.2.2  Western	
 ﾠblotting	
 ﾠ
Materials:  Antibodies  against  mouse  Syntaxin-1A,  Syntaxin-1B,  Syntaxin-2,  Syntaxin-3, 
Syntaxin-4, Syntaxin-5, Syntaxin-6, Syntaxin-7, Syntaxin-8, SNAP-23, SNAP-25, VAMP-1, 
VAMP-2, VAMP-3, VAMP-4, VAMP-5, VAMP-8 were from Synaptic Systems; VAMP-7 (TI-
VAMP) was from Novus; anti-Munc13-4 antibody was from Santa Cruz, anti-myc antibody 
was from Novus; anti-PF4 antibody was from R&D Systems; anti-β-actin antibody was from 
Acris Antibodies 
Washed mouse platelets were centrifuged at 350 x g for 7 min, and the pellet was re-
suspended in Laemmli buffer. The samples were lysed at 90°C for 5 min and the lysate of 
5x10
6 to 1 x 10
7  (as a second essay when no signal was detected with the lysate of 5 x 10
6 
platelets at the appropriate size) platelets per lane was separated on a SDS polyacrylamide 
gel. Munc13-4 levels were detected using a mouse anti-Munc13-4 antibody. An anti-β-actin 
antibody was used as loading control. 	
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4.2.3  Flow	
 ﾠcytometry	
 ﾠ
Materials: ADP and thrombin were from Sigma; U46619 was from Cayman Chemicals; 
collagen-related  peptide  (CRP),  rhodocytin  and  the  antibody  against  CLEC-2  were 
generous gifts from Dr. Bernhard Nieswandt; antibodies against mouse GPIbα, GPV, GPVI, 
GPIX, integrin β1, integrin αIIb, integrin αIIbβ3, active integrin αIIbβ3 (JON/A) and CD9 
were  from  Emfret;  antibodies  against  mouse  CD41  and  P-selectin  were  from  BD 
Pharmingen 
For flow cytometry, washed platelets were adjusted to 1 x 10
6 platelets/ml with Tyrode’s 
buffer, and 25 µl were stimulated with the indicated agonists (if applicable) for 10 min at 
37°C. Samples were then stained with the indicated labeled antibodies for 20 min at room 
temperature  and  directly  analyzed  by  flow  cytometry  (FACSCanto;  BD  Pharmingen). 
Platelets were gated by forward/sideward scatter (FSC/SSC) characteristics and identified 
by anti-CD41 staining.  
4.2.4  Aggregometry	
 ﾠ
Materials:  fibrillar  type  I  collagen  was  from  Nycomed;  U46619  was  from  Cayman 
Chemicals; CaCl2 was from Sigma; cuvettes for Apact 4S Plus aggregometer were from 
Diasys Greiner 
Washed  platelet  suspensions  of  the  indicated  mouse  genotypes  were  adjusted  to  a 
concentration of 3 x 10
8 platelets/ml. Platelet suspensions, stock solution of CaCl2 (40 mM) 
and aggregometer (Apact 4S Plus; Diasys Greiner) were pre-warmed to 37°C. Agonists 
were diluted in Tyrode’s buffer in 20-fold higher concentrations than the final concentration. 
185 µl of platelet suspension was added to a cuvette containing a magnetic stirrer, 5 µl of 
CaCl2 stock solution was added (1 mM final concentration) and baseline of aggregometer 
was set. Measurement and stirring was started. 10 µl of agonist was added and the time 
point  noted.  Measurement  was  recorded  for  900  s.  Values  below  zero  display  platelet 
shape change after addition of agonist, values above zero mark platelet aggregation in 
percent relative to the baseline set at the beginning. Before starting a new assay, platelets 
were  tested  for  pre-activation  by  running  a  sample  without  agonist.  The  corresponding 
platelet suspension was used in further experiments if the aggregation curve stayed stable 
in the range of approximately -2% to +2% around baseline for at least 300 s. 
4.2.5  Platelet	
 ﾠcount	
 ﾠ
Materials: EDTA was from Sigma; Accucount fluorescent particles were from Spherotech; 
anti-CD41 antibody was from BD Pharmingen 
100 µl of blood per mouse was taken in EDTA (5 mM final concentration), and a defined 
concentration  of  fluorescent  particles  was  added.  Platelets  were  stained  with  a  FITC-
labeled  antibody  against  CD41  for  30  min  at  RT.  Using  flow  cytometry,  platelets  were 
counted as CD41 positive events relative to the number of fluorescent particles.  	
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4.2.6  PF4	
 ﾠrelease	
 ﾠ
Materials: Mouse PF4 ELISA kit was from Raybiotech, thrombin was from Sigma 
10 µl aliquots of supernatant from platelets (1 x 10
8/ml) treated with agonist or tumor cells 
(1 x 10
6/ml) were assayed in triplicates in a standard mouse PF4 ELISA Kit according to 
manufacturer’s instructions. Absorption at 450 nm was measured in a spectrophotometer 
(Thermo Scientific). Level of PF4 in the samples was calculated by comparison with a PF4 
standard dilution series. 
4.2.7  vWF	
 ﾠrelease	
 ﾠ
Materials: ELISA plate was from Nunc; anti-vWF antibodies and OPD tablets were from 
Dako; H2O2 and chemicals for buffer preparation were from Sigma 
50 µl aliquots of supernatant from platelets (1 x 10
8/ml) treated with agonist or tumor cells 
(1  x  10
6/ml)  were  assayed  in  triplicates  in  an  ELISA  plate  coated  with  a  human  vWF 
capturing  antibody.  The  samples  were  analyzed  with  a  secondary  HRP-labeled  vWF 
antibody  and  substrate  solution  containing  OPD  tablets  and  H2O2  according  to  Dako’s 
general ELISA procedure. Absorption at 490 nm was measured in a spectrophotometer 
(Thermo Scientific). Levels of vWF in the samples were calculated compared to a vWF 
standard dilution series. 
4.2.8  ATP	
 ﾠrelease	
 ﾠ
Materials: Enliten ATP kit was from Promega; thrombin was from Sigma; U46619 was from 
Cayman Chemical; fibrillar type I collagen was from Nycomed 
ATP  secretion  by  platelets  was  determined  using  a  luciferin/luciferase  ATP  kit.  For  this 
purpose, 10 µl aliquots of supernatant from platelets (1 x 10
8/ml) treated with agonist or 1 x 
10
6  tumor  cells/ml  were  mixed  with  100  µl  of  ATP  reagent,  and  light  emission  was 
measured using a luminometer (Thermo Scientific). Raw data were collected as relative 
light units integrated over 0.1 s and calibrated using an ATP standard. 
4.2.9  Flow	
 ﾠchamber	
 ﾠ	
 ﾠ
Materials: Heparin-natrium was from B.Braun Melsungen; fibrillar type I collagen was from 
Nycomed; BSA was from Sigma 
Heparinized blood (final concentration 5 U/ml) of wild-type and Munc13-4-deficient mice 
was mixed 1:1 with Tyrode’s buffer and was applied to a flow chamber set-up containing 
collagen-coated  coverslips.  Before  the  experiment,  coverslips  were  blocked  in  5%  BSA 
(essentially fatty acid free) for 2 hours at RT, fixed to the flow chamber and rinsed with 
Tyrode’s buffer supplemented with heparin (5 U/ml). The transparent flow chamber had a 
slit depth of 50 µm and was connected to a syringe filled with the diluted blood samples. 
Perfusion was carried out at room temperature using a pulse-free pump with a wall shear 	
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rate of 1000 s
-1. Perfusion was stopped after 5 min and chambers were rinsed with Tyrode’s 
buffer for 2 min. Coverslips were analyzed by taking 5 randomly chosen brightfield images 
per coverslip on a stereomicroscope (Zeiss Axio Observer Z.1) and measuring the plaque-
covered area with ImageJ (NIH). 
4.2.10 Adhesion	
 ﾠto	
 ﾠCollagen	
 ﾠ
Materials: Heparin-natrium was from B.Braun Melsungen; fibrillar type I collagen was from 
Nycomed; BSA was from Sigma 
The adhesion assay with collagen was performed similar to the flow chamber experiments 
with some modifications. Briefly, washed platelets (1 x 10
8/ml) of wild-type and Munc13-4-
deficient mice were applied to the flow chamber set-up instead of whole blood samples, 
transported into the flow chamber containing the collagen-coated coverslip with a low shear 
rate (100 s
-1) and let to adhere to the collagen fibers for 10 min. After that, coverslips were 
rinsed with Tyrode’s buffer for 2 min and analyzed as described above. 
4.2.11 Interaction	
 ﾠof	
 ﾠtumor	
 ﾠcells	
 ﾠwith	
 ﾠCFSE-ﾭ‐labeled	
 ﾠplatelets	
 ﾠ
Materials:  Carboxyfluorescein  diacetate  succinimidyl  ester  (CFSE)  CellTrace  was  from 
Invitrogen 
Isolated mouse platelets (1 x 10
8/ml) were stained with CFSE for 30 min and washed in 
Tyrode’s  buffer.  B16  tumor  cells  resuspended  in  TB  (1  x  10
6/ml)  were  mixed  1:1  with 
platelets and incubated for 30 min on a shaker at 37°C and 200 rpm. Platelet-tumor cell 
suspensions were analyzed in triplicates by flow cytometry (FACSCanto; BD Pharmingen). 
Mean fluorescence intensities of tumor cells were identified by for-ward/sideward scatter 
(FSC/SSC) in the FITC channel. 
4.3  Cell	
 ﾠculture	
 ﾠmethods	
 ﾠ
4.3.1  Cell	
 ﾠculture	
 ﾠ
Materials:  Medium  and  additives  were  from  Invitrogen;  B16F10,  LLC1,  SH-SY5Y,  CF-
PAC1 cell lines were from ATCC, HUVEC were from Lonza 
All  cells  were  incubated  at  37°C  and  5%  CO2.  Human  umbilical  vein  endothelial  cells 
(HUVECs) were grown in EGM2 medium and passages below passage six were used for 
all  experiments.  All  other  cell  lines  were  cultured  in  the  presence  of  10%  FBS  and 
penicillin/streptomycin each at 100 units/ml in RPMI (B16F10 melanoma cells), DMEM and 
2 mM glutamine (Lewis lung carcinoma 1 (LLC1) and Mile Sven 1 (MS1) endothelial cells), 
DMEM, 2 mM glutamine and 100 µM non-essential amino acids (SH-SY5Y neuroblastoma 
and CF-PAC1 adenocarcinoma cells). 	
 ﾠ 	
 ﾠ Methods	
 ﾠ
	
 ﾠ 43	
 ﾠ
4.3.2  Transwell	
 ﾠtransmigration	
 ﾠassay	
 ﾠ
Materials:  Transwell plates were from Corning; transfection kit was from Amaxa; siRNA 
was  from  Quiagen;  5-BDBD  and  MRS2500  were  from  Tocris;  calcein-AM  and  apyrase 
grade VII were from Sigma; flurbiprofen was from Cayman Chemical; adenosine 5’-O-(3-
thio)triphosphate (ATPγS) was from Jena Bioscience 
MS1 cells (8 x 10
3 at seeding in 50 µl) or HUVEC (6 x 10
3 at seeding in 50 µl) were cultured 
for 2 days on 96-transwell plates with polyester membranes of 8-µm pore size with medium 
changes every day. For knockdown experiments, 4 x 10
5 MS1 cells were transfected using 
Nucleofector Kit V with different sets of siRNA against the P2Y2 receptor and 1.2 x 10
4 cells 
in 50 µl were seeded to the upper compartment. Where indicated, MS1 cells were pre-
incubated with 5-BDBD (1 µM) or MRS2500 (100 nM) for 30 min. Before the experiment, 
exemplary  wells  of  each  condition  were  visually  checked  by  calcein-AM  staining  of  the 
endothelial monolayer and only plates with 100% confluency were used. For transmigration, 
the  medium  from  the  upper  compartment  was  removed  and  50  µl  of  a  1:1  mixture  of 
platelets (2 x 10
8/ml) with calcein-AM-labeled tumor cells (8 x 10
5/ml) in TB was added to 
the upper com-partment alone or with flurbiprofen (100 nM) or apyrase (20 U/ml). ATPγS 
(10  µM)  was  added  in  the  absence  of  platelets.  For  supernatant  experiments,  human 
platelets (5 x 10
7/ml) or mouse platelets (2 x 10
8/ml) were incubated for 30 min at 37°C 
alone  or  with  tumor  cells  (1.6  x  10
6/ml)  and  centrifuged  at  350  x  g  for  10  min.  The 
supernatant was mixed 1:1 with Tyrode’s buffer (for MS1 cells) or cell culture medium (for 
HUVECs) containing calcein-AM-labeled tumor cells (8 x 10
5/ml) and 50 µl were added to 
the upper compartment. In all experiments, 250 µl TB or culture medium were added to the 
lower compartment, and tumor cells were allowed to transmigrate over night. On the next 
day, the non-transmigrated tumor cells from the upper compartment were removed and 
only  the  transmigrated  tumor  cells  on  the  lower  side  of  the  filter  or  the  bottom  of  the 
transwell were imaged (Zeiss Axio Observer.Z1 and Olympus IX81) and quantified with 
ImageJ (NIH). Each experiment was performed at least 3 times with a minimum of 5 wells 
per experiment.  
4.3.3  Endothelial	
 ﾠbarrier	
 ﾠfunction	
 ﾠ
Materials:  Transwell  plates  were  from  Corning;  FITC-dextran  70  kDa  (FITC-DX)  and 
apyrase grade VII were from Sigma 
The  permeability  assay  was  performed  as  described  for  the  transwell  assay  with  some 
modifications. Briefly, MS1 cells were cultured on transwell filters and the supernatant of 
platelets alone or platelets stimulated with tumor cells was mixed 1:1 with Tyrode’s buffer 
containing 2 mg/ml 70 kDa FITC-DX of which 50 µl were added to the upper compartment 
in the absence or presence of apyrase (20 U/ml). 250 µl Tyrode’s buffer were added to the 
lower compartment. After 90 min, the amount of passed FITC-DX to the lower compartment 
was  measured  (FlexStation3,  Molecular  Devices).  For  visualization  of  changes  in  the 	
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endothelial barrier, MS1 cells were stimulated for 1 h with supernatants from tumor cells 
alone or from tumor cells after stimulation with platelets in the absence or presence of 
apyrase (20 U/ml). Cells were further processed for staining and imaging. 
4.3.4  Immunostaining	
 ﾠand	
 ﾠImaging	
 ﾠ
Materials:  Para-formaldehyde,  sucrose  and  DAPI  were  from  Sigma;  OCT  was  from  
Thermo Fisher Scientific; anti-VE-Cadherin antibody was from BD Pharmingen; Alexa Fluor 
(AF)  594-conjugated  secondary  antibody  and  AF488-conjugated  phalloidin  were  from 
Molecular Probes; Cy5-conjugated secondary antibody was from Dianova 
Cells or tissues were fixed with 4% para-formaldehyde. Tissues were further cryopreserved 
in 30% sucrose, embedded in OCT, and cryosectioned at 16 µm. Cells or sections were 
stained with rat anti-VE-Cadherin and Alexa Fluor (AF) 594- or Cy5-conjugated secondary 
antibodies. DAPI was used to stain cell nuclei, and AF488-conjugated phalloidin to stain F-
actin. Images were acquired using a Leica SP5 confocal microscope and analyzed using 
ImageJ (NIH). 
4.3.5  mRNA	
 ﾠexpression	
 ﾠanalysis	
 ﾠby	
 ﾠqPCR	
 ﾠ
Materials:  Dispase  was  from  Sigma;  PBS,  BSA,  FBS  magnetic  beads  and  magnet, 
DMEM/F12 medium, penicillin/streptomycin were from Invitrogen; anti-CD144 antibody was 
from BD Pharmingen; EC growth supplement with heparin was from PromoCell; Mini RNA 
isolation kit was from Qiagen; Transcriptor High Fidelity cDNA Synthesis kit, Master mix 
and probes for qPCR using Universal Probe Library System were from Roche 
For  isolation  of  mouse  primary  pulmonary  endothelial  cells,  lungs  were  minced  and 
digested in 50 U/ml dispase for 1 h at 37°C with shaking (350 rpm). After filtration, the cells 
were washed in PBS containing 0.5% BSA. Cells were incubated with anti-CD144 antibody-
coated magnetic beads for 1 h at room temperature, washed, and isolated with a magnet 
(Invitrogen).  Cells  were  grown  in  DMEM/F12  supplemented  with  10%  FBS,  penicillin/ 
streptomycin, and EC growth supplement with heparin on fibronectin-coated wells. Cells 
were  harvested,  and  RNA  was  isolated  with  a  standard  RNA  isolation  kit  according  to 
manufacturer’s instructions. RNA was transcribed using a kit and quantitative PCR was 
performed employing the Universal Probe Library System on a Lightcycler 480 instrument 
(Roche). Primers were designed with the online tool provided by Roche. For each gene, at 
least the two top result primers were tested and the pair with the higher efficiency and 
reproducibility was used for quantification. Relative expression levels for mouse and human 
genes were obtained by normalizing with 18S rRNA and H3F3A or 18S rRNA and GAPDH 
values, respectively. Sequences for forward (Fw) and Reverse (Rev) primers of mouse and 
human receptors are depicted from 5’ to 3’ end. Primers for mouse P2Y receptors are 
displayed in table 16. 
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Gene name  Primer 
orientation 
Sequence  Probe 
number 
P2Y1  Fw  CTGTGTGGACCCCATTCTTT  19 
  Rev  TCGGGACAGTCTCCTTCTGA  19 
P2Y2  Fw  TGGTACTGGCCGTCTTCG  4 
  Rev  AG-TAGAGGGTGCGCGTGA  4 
P2Y4  Fw  CGGCGACTGTATCGACCT  17 
  Rev  GAGAGAACGGAGCCGAGAA  17 
P2Y6  Fw  GCAGTCTTTGCTGCCACA  42 
  Rev  GTGGGCTCAGGTCGTAGC  42 
P2Y12  Fw  TGCTGTACACCGTCCTGTTC  107 
  Rev  AAATCCTCATTGCCAAGCTG  107 
P2Y13  Fw  ATGTGTGAGATGGGGAAAGG  18 
  Rev  CTGACTACTGTGGTGGTCTTCG  18 
P2Y14  Fw  TCTTAGAAGACACCCAGTCTTTCC  69 
  Rev  AAATAGATACGAGTGTTGCTTGGA  69 
Table 16:  Primer sequences for mouse P2Y receptors from 5’ to 3’ end used for qPCR 
and  designed  with  the  Assay  Design  Center  online  tool  provided  by  Roche 
(http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000, 
November 1
st, 2012) 
Primer sequences for mouse P2X primers are shown in table 17. 
 
Gene name  Primer 
orientation 
Sequence  Probe 
number 
P2X1  Fw  TGTAAGCCCCTGTCCCATC  19 
  Rev  TCCTGCAGAGGACATGTGG  19 
P2X2  Fw  GCTCCAGCTCTGCTCTGACT  77 
  Rev  TTTGTCCCATATGCTGGTCA  77 
P2X3  Fw  TTTCATCAACCTCCCCTCTG  100 
  Rev  GACAGTACCCCATCACCCATA  100 
P2X4  Fw  AGAGGAATATCCTCCCCAACAT  10 
  Rev  GCGCATTATAAATGCACGAC  10 
P2X5  Fw  CACAGTCATCAACATTGGTTCC  45 
  Rev  AGGTAGATAAGTACCAGGTCACAGAAG  45 
P2X6  Fw  AGCTGCGGCTAAAGTTGC  18 
  Rev  GGCTGCAGAAGCCATGTT  18 
P2X7  Fw  CAGTCACTGGAGGAACTGGAA  17 
  Rev  CCAAAGGAAACACACCGATT  17 	
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Table 17:  Primer sequences for mouse P2X receptors from 5’ to 3’ end used for qPCR 
and  designed  with  the  Assay  Design  Center  online  tool  provided  by  Roche 
(http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000, 
November 1
st, 2012). 
 Primers for mouse housekeeping genes are shown in table 18. 
 
Gene name  Primer 
orientation 
Sequence  Probe 
number 
18S rRNA  Fw  GCAATTATTCCCCATGAACG  48 
  Rev  GGGACTTAATCAACGCAAGC  48 
H3F3A  Fw  AGGCAAGTGAGGCCTACCA  56 
  Rev  TAAGCACGTTCTCCGCGTAT  56 
Table 18:  Primer sequences for mouse housekeeping genes from 5’ to 3’ end used for 
qPCR and designed with the Assay Design Center online tool provided by Roche 
(http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000, 
November 1
st, 2012). 
Primers for human P2Y receptors are displayed in table 19. 
 
Gene name  Primer 
orientation 
Sequence  Probe 
number 
P2Y1  Fw  ATGTTCTGTGTCCCCTTGGT  26 
  Rev  AAATCAAAGCTCTCACAATTAATCC  26 
P2Y2  Fw  TAACCTGCCAC-GACACCTC  41 
  Rev  CTGAGCTGTAGGCCACGAA  41 
P2Y4  Fw  CATCACCCGCACCATTTACT  64 
  Rev  TTCAGTACTCGGCAGTCAGC  64 
P2Y6  Fw  CTGCCCACAGCCATCTTC  42 
  Rev  GCTGAGGTCATAGCAGACAGTG  42 
P2Y11  Fw  GTTGGTGGCCAGTGGTGT  17 
  Rev  CCGCATGATGTGGTAGGG  17 
P2Y12  Fw  CATGATTCTGACTTTTCCATTCA  48 
  Rev  TGACACACAAAAGTTCTCAGTGG  48 
P2Y13  Fw  TTTCTTGACCGGCATCC  21 
  Rev  AGCTGGGGATGTGAACAAAC  21 
P2Y14  Fw  CTTGCGGTATATGAAAGAATTCAC  82 
  Rev  AAGAAATAAATAATAGGGTCCAAG 
CA 
82 
Table 19:  Primer sequences for human P2Y receptors from 5’ to 3’ end used for qPCR 
and  designed  with  the  Assay  Design  Center  online  tool  provided  by  Roche 	
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(http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000, 
November 1
st, 2012). 
 Primer sequences for human P2X primers are shown in table 20. 
 
Gene name  Primer 
orientation 
Sequence  Probe 
number 
P2X1  Fw  TCCCCAGGAAGTCTCCTACC  13 
  Rev  CCCTGAGCTTCTGGCAAAC  13 
P2X2  Fw  CAAGGTGATCGTGGTGAGG  15 
  Rev  CGATGAATACGTACCACACGAA  15 
P2X3  Fw  CTTGCACGAGAAGGCTTACC  76 
  Rev  CTTGGTTACCACCGAGGACT  76 
P2X4  Fw  TGGGACCCAGACCGACTA  66 
  Rev  GGCGTGTCGTACTCGAACA  66 
P2X5  Fw  GTCAGAAGGGGAACGGATCT  17 
  Rev  AATTCACGTGCTCCTGTGG  17 
P2X6  Fw  TCCCTGCTGGTTGAGAAGAG  23 
  Rev  GCCTCATCCTTGCTTTCG  23 
P2X7  Fw  ATGTCAAGGGCCAAGAAGTC  64 
  Rev  AGGAATCGGGGGTGTGTC  64 
Table 20:  Primer sequences for mouse P2X receptors from 5’ to 3’ end used for qPCR 
and  designed  with  the  Assay  Design  Center  online  tool  provided  by  Roche 
(http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000, 
November 1
st, 2012). 
Primers for human housekeeping genes are shown in table 21. 
 
Gene name  Primer 
orientation 
Sequence  Probe 
number 
18S rRNA  Fw  GCAATTATTCCCCATGAACG  48 
  Rev  GGGACTTAATCAACGCAAGC  48 
GAPDH  Fw  GCATCCTGGGCTACACTGA  82 
  Rev  CCAGCGTCAAAGGTGGAG  82 
Table 21:  Primer sequences for human housekeeping genes from 5’ to 3’ end used for 
qPCR and designed with the Assay Design Center online tool provided by Roche 
(http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000, 
November 1
st, 2012). 	
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4.3.6  Calcium	
 ﾠmobilization	
 ﾠassay	
 ﾠ
Materials: Fluo-4 AM was from Molecular Probes; Hanks balanced salt solution (HBSS) 
was from Invitrogen, UTP was from Sigma 
Changes in intracellular Ca
2+ concentration were measured with the calcium sensitive dye 
Fluo-4. Briefly, upon knockdown, MS1 cells were incubated with 4 µM Fluo-4 at 37°C for 30 
min in Hanks balanced salt solution (HBSS) containing 1 mM CaCl2 and then washed 2 
times with HBSS. Samples were analyzed for 20 sec to establish a base line and then 
stimulated with 10 µM UTP. Changes in fluorescence emission were measured using a 
plate reader (FlexStation3, Molecular Devices). 
4.4  In	
 ﾠvivo	
 ﾠexperiments	
 ﾠ
4.4.1  Genetic	
 ﾠmouse	
 ﾠmodels	
 ﾠ
Control  C57BL/6J  animals,  LDL  receptor-deficient  mice  (B6.129S7-Ldlrtm1Her/J)  and 
P2Y2-deficient  mice  (B6.129P2-P2ry2tm1Bhk/J)  were  obtained  from  The  Jackson 
Laboratory (Bar Harbor, ME). The Munc13-4 mutant mouse line (Unc13d
Jinx) was kindly 
provided by Bruce Beutler (Department of Genetics, The Scripps Research Institute, La 
Jolla, USA). All experimental animal procedures were approved by the Regierungspräsidien 
Darmstadt and Karlsruhe. 
4.4.2  Tail	
 ﾠbleeding	
 ﾠtime	
 ﾠ
Materials: Isoflurane was from Abbott Laboratories; NaCl was from Sigma 
Age-matched  wild-type  and  Munc13-4  mice  were  kept  under  isoflurane  anesthesia 
throughout the experiment. 15 ml falcon tubes were filled with sterile 0.9% NaCl solution 
and pre-warmed to 37°C. a sterile scalpel was used to cut 2 mm off the end of the tail and 
the tail was immediately immersed into the saline-filled falcon tube. Blood flow and time 
after tail cut were monitored and bleeding was counted as terminated if blood flow stopped 
longer than 30 s. To avoid critical loss of blood, the experiment was terminated after 20 min 
if blood flow had not stopped until that time. 
4.4.3  FeCl3	
 ﾠthrombosis	
 ﾠmodel	
 ﾠ
Materials: Xylazine and ketamine were from Kepro; 0.9% sterile NaCl solution was from 
B.Braun Melsungen, FeCl3 was from Sigma 
21  days  old  wild-type  and  Munc13-4  mice  were  anesthetized  with  xylazine  (6  mg/kg 
bodyweight)  and  ketamine  (100  mg/kg  bodyweight).  The  heatable  stage  of  an  inverse 
microscope (Zeiss Axio Observer.Z1) and 0.9% sterile saline solution were pre-heated to 
37°C. Through a lateral abdominal incision, the small intestine was carefully pulled out with 
saline-soaked cotton buds. A jejunal artery was arranged on the microscopic stage in a way 
that blood flow could be monitored. A filter paper with a width of 1 mm was soaked in 10% 	
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FeCl3 solution and applied on a fat-free part of the artery for 30 s. After removal of the filter 
paper,  the  time  to  complete  occlusion  of  the  vessel  was  measured.  A  vessel  was 
considered  completely  occluded  if  no  fluid  movement  was  observed  for  1  min.  The 
experiment was terminated by killing the animal after 60 min if the artery was not occluded 
until that time. Only one artery was used per animal. 
4.4.4  Atherosclerosis	
 ﾠmodel	
 ﾠ
Materials: High fat (21%), high cholesterol (1.5%) diet was from Sniff Spezialdiäten GmbH; 
para-formaldehyde, sucrose, EDTA, isopropanol and Oil Red O were from Sigma; xylazine 
and ketamine were from Kepro; Kaiser’s glycerol gelatine was from Merck Millipore 
12 weeks old male LDL receptor knockout mice were lethally irradiated with 9.5 Gray and 
transplanted with 5 x 10
6 bone marrow cells each derived from the femur and ossa cruris of 
age-matched  male  wild-type  and  Munc13-4-deficient  mice.  Control  mice  receiving  only 
irradiation and no bone marrow transplantation died within 10 days after irradiation. Mice 
were let to recover on normal chow for four weeks. After this time, mice were fed a high fat 
(21%), high cholesterol (1.5%) diet for 16 weeks with weekly monitoring of bodyweight. 
Mice  were  anesthetized  with  xylazine  (6  mg/kg  bodyweight)  and  ketamine  (100  mg/kg 
bodyweight) and perfused with PBS and 4% para-formaldehyde. The aorta was excised 
from ascending aorta to bifurcation and immersed overnight in a solution containing 4% 
para-formaldehyde, 5% sucrose and 20 mM EDTA in PBS. The next day, fat and adventitia 
were carefully removed from the vessel and the aortas were opened with one longitudinal 
cut through the whole aortic segment. Aortas were rinsed with 60% isopropanol for 2 min 
and stained for 15 min in a 0.3 % Oil Red O (w/v) solution in 60% isopropanol. Afterwards, 
aortas  were  rinsed  with  60%  isopropanol  for  10  min.  Isopropanol  was  removed  and 
replaced by PBS and aortas were mounted with Kaiser’s glycerol gelatin. Oil Red O-stained 
lipid-containing plaque areas were measured as percent relative to total aortic area with 
ImageJ (NIH). 
4.4.5  Tumor	
 ﾠmodels	
 ﾠ
Materials:  B16F10  and  LLC1  cell  lines  were  from  ATCC;  PBS  was  from  Invitrogen; 
isoflurane  was  from  Abbott  Laboratories,  para-formaldehyde,  haematoxylin  and  eosin 
solutions were from Sigma 
B16F10 melanoma cells or LLC1 cells were harvested and resuspended in PBS. Mice (at 8-
10 weeks of age) were anesthetized with isoflurane and 1 x 10
6 B16 or LLC1 cells in 100 µl 
PBS were were injected subcutaneously to their flanks. Mice with B16 primary tumor were 
sacrificed 19 days and mice with LLC1 tumor 21 days after injection of tumor cells, and 
primary tumors as well as lung metastases were analyzed. Alternatively, 125 µl of a tumor 
cell  (5  x  10
4  cells)  suspension  was  injected  to  the  lateral  tail  vein  of  mice,  and  lung 
metastases  were  analyzed  12  days  later.  Animals  were  perfused  with  PBS  and  para-	
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formaldehyde.  Primary  tumors  were  removed  and  weighed.  For  analysis  of  pulmonary 
metastases, the lungs were removed and fixed in para-formaldehyde. Lungs were then cut 
in 5 µm sections and one section every 200 µm throughout the whole lung was screened 
histologically, the number of metastases was counted and assigned to the respective size 
category: small (diameter: <0.1 mm), medium (diameter: 0.1-1.0 mm) or large (diameter: 
>1.0 mm).  
4.4.6  Analysis	
 ﾠof	
 ﾠendothelial	
 ﾠbarrier	
 ﾠfunction	
 ﾠin	
 ﾠvivo	
 ﾠ
Materials: B16F10 cell line was from ATCC; sterile saline was from B.Braun Melsungen; 
isoflurane was from Abbott Laboratories; fixable FITC-dextran 70 kDa and PBS were from 
Invitrogen;  para-formaldehyde,  haematoxylin  and  eosin  solution  and  sucrose  were  from 
Sigma 
Mice  were  anesthetized  using  isoflurane  and  100  µl  of  fixable  FITC-dextran  with  a 
molecular weight of 70 kDa) in 0.9% saline was injected retroorbitally at a concentration of 
15 mg/kg. One min later, 1 x 10
5 B16 tumor cells in 125 µl PBS were injected via the lateral 
tail vein. After 3 hours, animals were sacrificed, and lungs were carefully excised. Lungs 
were fixed in para-formaldehyde, cryo-preserved in 30% sucrose and further processed for 
immunostaining and imaging. 
4.4.7  NK	
 ﾠcell	
 ﾠdepletion	
 ﾠ
Materials:  anti-asialo  GM1  depleting  antibody  was  from  Wako;  sterile  saline  was  from 
B.Braun Melsungen; B16F10 cell line was from ATCC; EDTA and red blood cell lysis buffer 
were from Sigma; antibodies against mouse NK1.1 and CD3ε were from BD Pharmingen 
NK  cells  were  depleted  with  an  anti-asialo  GM1  depleting  antibody.  25  µl  of  antibody 
solution diluted 1:4 in 0.9% saline per animal was injected i.v.. One day after initial injection 
of antibody, 5 x 10
4 B16 tumor cells in PBS were injected in the tail vein of mice. Injection of 
antibody was repeated every 3.5 days throughout the experiment. Animals were sacrificed 
on day 12 after tumor cell injection, and the number of lung metastases was determined as 
described above. NK cell levels were determined via flow cytometry before the first injection 
of antibody (=basal) and on day 7 and 12 after injection of tumor cells. For this purpose, 50 
µl of blood per mouse was taken in EDTA (5 mM final concentration), red blood cells were 
lysed and NK cells were stained with an APC-labeled antibody against NK1.1 and a FITC-
labeled antibody against CD3ε for 30 min at RT. NK cells were identified as NK1.1 and 
CD3ε positive events and expressed as percent of granulocyte population (identified in a 
fixed gate in forward/sideward scatter).  
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4.4.8  Neutrophil	
 ﾠdepletion	
 ﾠ
Materials:  anti-Ly6G  depleting  antibody  was  from  Biolegend;  sterile  saline  was  from 
B.Braun Melsungen; B16F10 cell line was from ATCC; EDTA and red blood cell lysis buffer 
were from Sigma; FITC-labeled anti-Ly6G antibody was from BD Pharmingen 
Neutrophils were depleted with an anti-Ly6G depleting antibody. 25 µg of antibody solution 
diluted 1:4 in 0.9% saline per animal was injected i.v.. Three hours after initial injection of 
antibody, 5 x 10
4 B16 tumor cells in PBS were injected in the tail vein of mice. Injection of 
antibody was repeated every 3 days throughout the experiment. Animals were sacrificed on 
day 8 after tumor cell injection, and the number of lung metastases was determined as 
described  above.  Neutrophil  levels  were  determined  via  flow  cytometry  before  the  first 
injection  of  antibody  (basal)  and  on  day  5  and  8  after  injection  of  tumor  cells.  For  this 
purpose, 50 µl of blood per mouse was taken in EDTA (5 mM final concentration), red blood 
cells were lysed and Neutrophils were stained with a FITC-labeled antibody against Ly6G 
for  30  min  at  RT.  Neutrophils  were  expressed  as  percent  of  granulocyte  population 
(identified in a fixed gate in forward/sideward scatter).  
4.5  Statistical	
 ﾠanalysis	
 ﾠ
If  not  stated  otherwise,  one  representative  of  at  least  3  independently  performed 
experiments is shown. All raw data was analyzed with Student’s t-test. Depicted are mean 
values ± S.D. or ± S.E.M. as indicated in the figure legends. Statistical significance was 
defined as *, P<0.05; **, P<0.01; ***, P<0.001; n.s., not significant.   
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5  Results	
 ﾠ
5.1  Generation	
 ﾠof	
 ﾠmouse	
 ﾠlines	
 ﾠwith	
 ﾠa	
 ﾠspecific	
 ﾠplatelet	
 ﾠ
secretion	
 ﾠdefect	
 ﾠ
5.1.1  Establishing	
 ﾠa	
 ﾠmouse	
 ﾠline	
 ﾠwith	
 ﾠspecific	
 ﾠplatelet	
 ﾠgranule	
 ﾠ	
 ﾠ	
 ﾠ
secretion	
 ﾠdefect	
 ﾠvia	
 ﾠheterologous	
 ﾠtoxin	
 ﾠexpression	
 ﾠ
In order to study the role of platelet secretion in various pathological contexts, we sought to 
establish and describe a mouse line with defined platelet secretion abnormalities but with 
intact general platelet morphology and function. In a first approach, we generated mouse 
lines  with  heterologous  expression  of  Clostridium  toxins,  specifically  Botulinum  toxin  C 
(BoNT-C) and E (BoNT-E) and Tetanus toxin (TeNT) under the promoter of platelet factor 4 
(PF4). The toxins were chosen with respect to their ability to render those proteins of the 
SNARE  superfamily  non-functional,  which  are  expressed  in  platelets  and  known  to 
contribute to granule release. BoNT-C cleaves syntaxin-1, -2 and -3 and SNAP-25, but not 
SNAP-23.  BoNT-E  cleaves  SNAP-23  and  SNAP-25.  TeNT  cleaves  VAMP-1,  -2  and  -3 
(Humeau, Doussau et al. 2000; Schiavo, G., M. Matteoli, et al. 2000; Dolly and Aoki 2006). 
PF4 expression is restricted to platelets and the promoter is activated  in late stages of 
thrombopoiesis, shortly before fragmentation from megakaryocytes. It is also one of the 
most abundant proteins in platelets, which lead us to assume that expression of the toxins 
under control of the PF4 promoter can reach sufficient levels to affect granule exocytosis.  
BoNT-ﾭ‐C	
 ﾠ	
 ﾠ
Botulinum toxin C (BoNT-C) cleaves members of the syntaxin protein family and recognizes 
an  Arginine-Alanine  (RA)-motif  towards  the  C-terminal  end  of  the  protein  (Humeau, 
Doussau et al. 2000). It is still not well described which other amino acids around this motif 
or influencing secondary and tertiary structure of the protein are required for cleavage by 
Botulinum toxin C. Based on the known RA-motif and similarity of amino acids surrounding 
this motif, we predicted members of the mouse syntaxin family which can be potentially 
cleaved by Botulinum toxin C as limited experimental data is available (Table 22). We also 
determined  the  protein  levels  of  the  syntaxin  protein  for  which  a  specific  antibody  was 
available. 
Protein name 
Sequence Accesion 
ID 
Cleavage by BoNT-
C expected 
Expressed in 
mouse platelets 
Syntaxin-1A  NP_058081  Yes  No 
Syntaxin-1B  NP_077725  Yes  No 
Syntaxin-2  NP_031967  Yes  Yes 
Syntaxin-3  NM_152220  Yes  No 
Syntaxin-4  NM_009294  No  Yes 	
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Syntaxin-5  NM_019829  No  Yes 
Syntaxin-6  NM_021433  No  Yes 
Syntaxin-7  NM_016797  ?  No 
Syntaxin-8  NM_018768  No  Yes 
Syntaxin-11  XM_920202  Yes  Not determined 
Syntaxin-12  NM_133887  No  Yes 
Syntaxin-16  NM_172675  Yes  Yes 
Syntaxin-17  NM_026343  Yes  Not determined 
Syntaxin-18  NM_026959  No  Not determined 
Syntaxin-19  NM_026588  No  Not determined 
Table 22:  Expected cleavage of syntaxin proteins by BoNT-C derived from sequence 
similarity to   known cut protein and protein expression in mouse platelets as 
determined by Western blot. Some SNARE proteins are very conserved and no 
specific  antibody  is  commercially  available  so  the  expression  by  Western  blot 
could not be determined. 
According to literature (Flaumenhaft, Rozenvayn et al. 2007), syntaxin-2 and -4 are the 
main isoforms involved in platelet secretion. Syntaxin-2 is cleaved by BoNT-C, but syntaxin-
4 is not. For generation of transgenic mice, a BAC-construct based on BAC RP24-98A4, 
which covers approximately 100’000 base pairs upstream and downstream of the mouse 
PF4 gene, was generated. The PF4 gene was replaced by RedE/T-mediated homologous 
recombination  with  a  construct  previously  assembled  in  the  pBluescript  II  KS(+) 
(pBSIIKS(+)) cloning vector. This construct contained  the sequence of the clostridial BoNT-
C light chain optimized for murine codon usage (Entelechon), followed by a BGH-pA tail 
and a stop codon. A schematic overview of the final BAC construct is given in figure 11. 
 
 Figure 11:  Schematic overview over the BAC constructs.  The BAC vector consists of 
approximately 100’000 upstream (PF4 promotor) and downstream (not shown) 
regulatory sequence of the PF4 gene. Approximately 150 base pairs adjacent to 
the  PF4  start  and  stop  codon  were  included  in  the  cloning  vector  to  mediate 
homologous recombination to the BAC vector (5’HA, 3’HA). The toxin light chain 
sequence replaced the PF4 gene and was followed by a polyA tail and a stop 
codon (not shown). 	
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The final BAC construct was sequenced in a region extending approximately 100-200 base 
pairs upstream and downstream of the inserted toxin and the integrity of the whole BAC 
sequence  was  screened  by  digestion  with  four  different  restriction  enzymes  to  avoid 
multiple insertions of the toxin. The cleavage band pattern shown in figure 12 corresponds 
to the expected bands from in silico predictions. 
 
Figure 12:  Restriction digest of the final PF4-BAC construct in which the PF4 gene 
was replaced with the BoNT-C construct. PF4-BAC wild-type (WT) and PF4-
BoNT-C-BAC (BoNT-C) DNA was cut with BamHI, KpnI, PacI and XhoI. The wild-
type  and  genetically  modified  band  patterns  matched  the  in  silico  predictions. 
Bands larger than approximately 25,000 kDa could not be resolved. 
In addition, sequencing was performed with primers binding upstream of the 5’ homology 
and in the construct as well as from inside the construct further downstream than the 3’ 
homology arm. This construct was purified and perinuclear injection into mouse oocytes 
produced 61 pups of which 5 mice showed integration of the transgene in tail DNA PCR. To 
test  for  cleavage  of  syntaxin-2  in  platelets,  we  used  a  specific  antibody  against  the  N-
terminal region of syntaxin-2, which was able to recognize the full-length protein and the 
cleaved  version  (Synaptic  Systems).  The  Western  blot  below  (figure  13)  shows  lysed 
platelets isolated from each of the five transgene-positive founder mice blotted for syntaxin-
2. The cleaved product of syntaxin-2 is expected to weigh approximately 4 kDa less than 
the full-length protein. 
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Figure 13:   Western blot for cleavage of syntaxin-2 of platelets isolated from the five PCR-
positive  founder  mice  (F1-F5)  obtained  from  the  PF4-BoNT-C  line  and  two 
littermate  control  mice  (WT).  The  anti-syntaxin-2  antibody  used  (Synaptic 
Systems)  was  able  to  detect  the  cleaved  product.  β-actin  served  as  loading 
control. 
Only two of the five founders showed the BoNT-C cleavage product. The amount of cleaved 
product relative to full-length syntaxin-2 was approximately 15% for founder 3 and 60% for 
founder 5. Founder 5 was mated for further experiments and the cleavage rate of syntaxin-
2 could be confirmed for its offspring (data not shown). 
BoNT-ﾭ‐E	
 ﾠ
BoNT-E  cleaves  members  of  the  SNAP  protein  family.  It  is  known  which  amino  acids 
surrounding the cleavage site are needed for recognition by the toxin light chain (Chen and 
Barbieri  2006;  Chen  and  Barbieri  2007).  For  SNAP-23,  which  has  been  shown  to  be 
involved in platelet exocytosis (Flaumenhaft, Croce et al. 1999; Lemons, Chen et al. 2000), 
and SNAP-25, there is experimental evidence of cleavage of murine SNAP-23 by BoNT-E 
(Vaidyanathan, Yoshino et al. 1999). SNAP-29 and SNAP-91, which are not expressed in 
mouse platelets are also members of the SNAP family but their physiological function is 
less  well  defined  and  is  probably  more  related  to  intracellular  transport  and  fusion 
mechanisms. Nevertheless, based on the known recognition motif for BoNT-E, their protein 
sequences show considerable variation in the respective region and cleavage by BoNT-E is 
unlikely.  The  BAC  construct  used  for  generation  of  transgenic  mice  was  similar  to  the 
construct used for BoNT-C. The same BAC carrying the PF4 gene (RP24-98A4) was used 
and  a  version  of  the  BoNT-E  light  chain  optimized  for  expression  in  mice  (Entelechon) 
followed by a BGH-pA tail and a stop codon replacing the PF4 gene was inserted. To verify 
the final BAC sequence, the same tests as mentioned for the PF4-BoNT-C construct were 
applied (sequencing, PCR and restriction digest) and results confirmed identity with the in 
silico sequence (data not shown). Following injection into mouse oocytes, 57 pups were 
born, of which four showed integration of the transgene. A specific antibody against SNAP-
23 (Synaptic Systems) was used to determine cleavage of this protein in the platelets of 
founder animals by BoNT-E (figure 14).  	
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Figure 14:   Western blot for cleavage of SNAP-23 of platelets isolated from the four PCR-
positive  founder  mice  (F1-F4)  obtained  from  the  PF4-BoNT-E  line  and  two 
littermate  control  mice  (WT).  Membranes  were  probed  with  anti-SNAP-23 
antibody (Synaptic Systems), β-actin served as loading control. 
The  anti-SNAP-23  antibody  was  not  able  to  detect  the  cleaved  product  because  a  C-
terminal peptide was used for immunization, as this is the only part of the protein distinct 
from SNAP-25. Thus, SNAP-23 cleavage by BoNT-E could only be estimated by comparing 
the amounts of SNAP-23 in relation to β-actin. Founder 1 is the only animal which has a low 
signal for SNAP-23 in platelets, but total amount of platelets was also less as measured 
with the anti-β-actin antibody. From this result, it was inconclusive if any of the founders for 
this  mouse  line  had  significant  cleavage  of  SNAP-23.  To  avoid  stress  for  the  founder 
animal, founder 1 was mated and only the next generation of mice was tested again for 
reduction in SNAP-23 levels. 
 
Figure 15:   Western blot of platelets isolated from two mice of the F1 generation from 
founder 1 in the PF4-BoNT-E line (F1#1, F1#2) and a littermate control (WT). 
Membranes  were  probed  with  anti-SNAP-23  antibody  and  β-actin  served  as 
loading control. 
Offspring #1 shows a marked reduction of approximately 40% in SNAP-23 while its sibling 
#2 shows only a minor reduction if any (figure 15).  
TeNT	
 ﾠ
Tetanus  toxin  recognizes  a  specific  motif  in  VAMP  proteins  described  in  literature  for 
VAMP-1 (Schiavo, Matteoli et al. 2000). Based on sequence similarity, we predicted that 
VAMP-2 and -3 are also cleaved by TeNT whereas VAMP-4, -5 and -8 are unlikely to be 
cleaved  (Table  23).  This  would  mean,  that    one  VAMP  isoform  known  to  contribute  to 
platelet secretion is cleaved (VAMP-3), while the other one is not (VAMP-8) (Ren, Ye et al. 
2008). Specific antibodies were used to determine expression in mouse platelets. 
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Protein name  Sequence Accesion ID 
Cleavage by TeNT 
expected 
Expressed in 
mouse platelets 
VAMP-1  NP_033522  Yes  No 
VAMP-2  NP_033523  Yes  Yes 
VAMP-3  NP_033524  Yes  Yes 
VAMP-4  NP_058076  No  No 
VAMP-5  NP_058568  No  No 
VAMP-7 (TI-VAMP)  NP_035645  No  ? 
VAMP-8  AAC23665  No  Yes 
Table 23:   Expected  cleavage  of  syntaxin  proteins  by  TeNT  derived  from  sequence 
similarity to   known cut protein and protein expression in mouse platelets as 
determined by Western blot. For VAMP-7 it could not be determined whether the 
signal detected roughly at the expected size was specific. 
The anti-VAMP-7 antibody did not detect a band of the expected size although expression 
in platelets was claimed (Ren, Barber et al. 2007). However, VAMP-7 was not shown to be 
involved  in  platelet  secretion  and  is  also  known  for  its  role  in  endosomal  trafficking 
(Chaineau, Danglot et al. 2009). The PF4-TeNT construct was assembled as described for 
the other toxins except that the original Clostridial toxin light chain sequence was used 
instead  of  a  modified  version.  The  antibody  against  VAMP-3  used  to  screen  the  five 
transgene-positive mice of the PF4-TeNT  oocyte injection was raised  against  a  peptide 
comprising the N-terminal part of the protein with 10 amino acids overlapping into the C-
terminal end that is cleaved by TeNT. It is thus unclear if this antibody is able to detect the 
cleaved version of VAMP-3 or not. Western blot of platelet lysates from the three founder 
mice is shown below (figure 16). 
 
Figure 16:   Western blot for cleavage of VAMP-3 of platelets isolated from the three PCR-
positive founder mice (F1-F3) obtained from the PF4-TeNT line and two littermate 
control mice (WT). Membranes were probed with anti-VAMP-3 antibody (Synaptic 
Systems), β-actin served as loading control.  
From  these  results,  it  is  inconclusive  whether  VAMP-3  levels  were  decreased  in  the 
transgenic mice. All three founders were mated for further analysis. Western blots of the F1 
generation indicated a small if any reduction in the amount of VAMP-3 in platelets (data not 
shown).  
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Functional	
 ﾠanalysis	
 ﾠof	
 ﾠthe	
 ﾠPF4-ﾭ‐toxin	
 ﾠmouse	
 ﾠlines	
 ﾠ	
 ﾠ	
 ﾠ
The  cleavage  rates  of  the  toxins  for  the  respective  SNARE  proteins  in  the  transgenic 
founder animals was not as high as expected with 60% of syntaxin-2 cleaved for PF4-
BoNT-C,  around  40%  of  SNAP-23  cleaved  for  PF4-BoNT-E  and  uncertain  cleavage  of 
VAMP-3  by  PF4-TeNT  constructs.  In  the  mouse  line  with  the  best  cleavage  rate,  PF4-
BoNT-C, syntaxin-4 might be able to compensate for a reduction in syntaxin-2. SNAP-23 is 
the only SNAP protein described previously in platelet release (Flaumenhaft, Croce et al. 
1999; Lemons, Chen et al. 2000) and thus the PF4-BoNT-E transgenic mice were more 
likely to show functional consequences of the reduction in SNAP-23 in alpha and dense 
granule  release  than  the  other  two  mouse  lines.  We  used  P-selectin  exposure  on  the 
surface of thrombin-activated and secreting platelets determined by a labeled antibody in 
flow  cytometry  to  measure  release  of  secretory  granules.  No  difference  in  P-selectin 
exposure was observed in offspring from the founder mice of the toxin transgenic lines and 
littermate controls. Figure 17 shows representative results from transgenic mice of the PF4-
BoNT-E line. 
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Figure  17:  P-Selectin  exposure  on  platelet  surfaces  in  transgenic  toxin  mice  was 
determined  with  a  FITC-labeled  anti-P-selectin  antibody  (emfret)  in  flow 
cytometry.  Platelets  from  wild-type  (WT)  and  PF4-BoNT-E  transgenic  (PF4-
BoNT-E) mice were isolated, left untreated (unstim.) or stimulated with collagen 
(Nycomed) for 15 min and identified with a PE-labeled anti-CD41 antibody (BD) 
(number  of  events  counted).  A  gate  was  set  (M1)  to  visualize  increase  in  P-
selectin exposure upon stimulation. 
The steepness and end point of light transmission curves in aggregometry is influenced by 
both alpha and dense granule secretion, especially in response to low doses of collagen 
because only a limited number of platelets is activated via direct contact to the large and 
heavy collagen fibrils. Thus, for fast and efficient platelet aggregation, secondary mediators 
are important. No difference in light transmission exceeding accidental variation between 
toxin  transgenes  and  controls  was  observed  upon  stimulation  with  various  agonist 
concentrations, represented by data from mice of the PF4-BoNT-E line stimulated with 0.3  
µg/ml collagen (Figure 18).  
 
Figure 18:  Light  transmission  curves  of  platelet  suspensions  (3x10
8/ml)  before  and 
after addition (arrow) of 0.3 µg/ml collagen. The x-axis shows the time from 
start of measurement to 900 s, the y-axis shows percentage of aggregation. The 
arrow  indicates  application  of  agonist  and  the  curves  show  light  transmission 
curves of platelets isolated from several wild-type (WT), and two PF4-BoNT-E 
transgene positive animals (PF4-BoNT-E #1, #2). 
Re-injection of the PF4-BoNT-C and PF4-BoNT-E constructs in mouse oocytes produced 
10 and 6 transgenic animals but only weaker cleavage (10-40 %) of syntaxin-2 and no 
obvious cleavage for SNAP-23, respectively (data not shown). Breeding homozygous mice 
and crossing the mouse lines to combine the transgenes also did not lead to a phenotype in 
in vitro platelet release assays (data not shown), so the project was discontinued. 	
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5.1.2  Establishing	
 ﾠa	
 ﾠmouse	
 ﾠline	
 ﾠwith	
 ﾠspecific	
 ﾠplatelet	
 ﾠgranule	
 ﾠ
secretion	
 ﾠdefect	
 ﾠvia	
 ﾠexpression	
 ﾠof	
 ﾠdominant-ﾭ‐negative	
 ﾠSNAP-ﾭ‐
23	
 ﾠmutants	
 ﾠ
SNAP-23  is  the  central  single  protein  in  the  formation  of  the  exocytotic  SNARE  core 
complex  which  is  expressed  in  platelets  and  necessary  for  platelet  exocytosis 
(Flaumenhaft, Croce et al. 1999; Chen, Bernstein et al. 2000; Chen, Lemons et al. 2000; 
Lemons, Chen et al. 2000). Hence, loss of SNAP-23 cannot be compensated for by other 
proteins and should strongly affect platelet granule release. Our next approach to interfere 
with platelet release thus focused on creating dominant-negative SNAP-23 variants which 
would again be expressed in mice under the control of the promoter of the platelet-specific, 
highly abundant protein PF4. 
SNAP-ﾭ‐23	
 ﾠdelta	
 ﾠ8	
 ﾠmutant	
 ﾠ
The  C-terminal  end  of  SNAP-23  mediates  binding  to  VAMP  and  thus  engagement  in 
exocytotic core complex formation. If the last exon of SNAP-23 is deleted, exocytosis is 
severely disturbed in mast cells (Vaidyanathan, Puri et al. 2001) and regulated exocytosis 
in rat pancreatic acinar cells is inhibited by C-terminal truncation of SNAP-23 (Huang, Sheu 
et al. 2001). In platelets, studies with permeabilized platelets (Chen, Bernstein et al. 2000; 
Chen,  Lemons  et  al.  2000;  Lemons,  Chen  et  al.  2000)  and  culture-derived  platelets 
(Gillitzer, Peluso et al. 2008) have shown that presence of a C-terminally truncated SNAP-
23  can  strongly  reduce  platelet  alpha  and  dense  granule  secretion.  Based  on  these 
findings, we designed a construct, which lacked the last 8 amino acids of SNAP-23 (SNAP-
23  ∆8).  SNAP-23  RNA  was  isolated  from  mouse  platelets,  transcribed  into  cDNA  and 
amplified with primers covering SNAP-23 from start codon to 24 base pairs before the stop 
codon.  The  rest  of  the  BAC-construct  was  designed  as  described  for  the  toxin  vectors 
except for a triple myc tag which was inserted immediately upstream of the SNAP-23 ATG 
(figure 19) to monitor construct expression in vivo. 
 
Figure  19:  Schematic  overview  over  the  BAC  constructs.  The  BAC  vector  consists  of 
approximately 100’000 upstream (PF4 promoter) and downstream (not shown) 
regulatory sequence of the PF4 gene. Approximately 150 base pairs adjacent to 
the  PF4  start  and  stop  codon  were  included  in  the  cloning  vector  to  mediate 
homologous recombination to the BAC vector (5’HA, 3’HA). A triple myc tag and 
the SNAP-23 ∆8 mutant replaced the PF4 gene and were followed by a polyA tail 
and a stop codon (not shown). 	
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Nine transgenic animals were obtained after blastocyst injection. The calculated mass for 
the SNAP-23 peptide sequence (accession ID BAA2c345) is 23.2 kDa, but the anti-SNAP-
23 antibody detected a signal at approximately 26 kDa. The transgenic PF4-SNAP-23 ∆8 
mutant has a mass of 22.58 kDa, so it is unlikely that the two proteins can be distinguished 
in a normal Western blot. No extra band below 26 kDa was detected in the Western blot 
probed for SNAP-23 (Figure 20). No specific band was detected in a second blot incubated 
with an anti-myc antibody (data not shown), which suggests that the myc-tagged transgenic 
SNAP-23 ∆8 was not expressed in these animals.  
 
 
Figure 20:   Western blot of platelets isolated from the nine PCR-positive founder mice 
(F1-F9) obtained from the PF4-SNAP-23 ∆8 line and four littermate control mice 
(WT).  Anti-SNAP-23  antibody  was  applied  to  check  for  expression  of  mutant 
SNAP-23. 
Nevertheless,  the  founder  animals  were  mated  and  the  offspring  was  analyzed  in  the 
functional assays described for the toxin transgenes but platelet function was not perturbed 
(data not shown). 
SNAP-ﾭ‐23	
 ﾠAla	
 ﾠmutant	
 ﾠ
We  designed  a  second  SNAP-23  mutant  based  on  the  observation  by  Sorensen  et  al. 
(Sorensen, Matti et al. 2002) that three amino acids in SNAP-25 are particularly important 
for SNAP-mediated exocytosis. When these three sites are mutated to the unpolar amino 
acid alanine, the binding of divalent cations is perturbed and exocytosis in chromaffin cells 
is strongly reduced. SNAP-23 and -25 are very conserved and the corresponding regions 
and mutated amino acids identical or almost identical in both proteins (Figure 21). 
 
SNAP-25   12   
EEMQRRADQLADESLESTRRMLQLVEESKDAGIRTLVMLDEQGEQLERIEEGMDQINKDM   
SNAP-23    7    
-EEVQLRAHQVTDESLESTRRI-LGLAI-ESQDAGIKTI-TMLDEQGEQLNRIEEGMDQINKDM   
 
SNAP-25   72    
KEAEKNLTDLGKFCGLCVCPCNKLK----SSDAYKKAWG----------NQDGVVASQPARVVDER-   
SNAP-23   67   
REAEKTLTELNKCCGLCICPCNRTKNFESGKNYKATWGDGGDNSPSNVVSKQPSRITNGQ   
 
SNAP-25  125  
--EQM----AISGGFIRRVTNDARENEMDENLEQVSGIIGNLRHMALDMGNEIDTQNRQIDRI   
SNAP-23  127   
PQQTTGAASGGYIKRITNDAREDEMEENLTQVGSILGNLKNMALDMGNEIDAQNQQIQKI   	
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SNAP-25  182    
MEKADSNKTRIDEANQRATKMLGS   
SNAP-23  187    
TEKADTNKNRIDIANTRAKKLIDS   
 
Figure 21:  Murine  sequences  of  SNAP-25  (Accession  ID:  NP_035558)  and  SNAP-23 
(Accession ID: BAA20345) aligned (BLAST, NCBI). Mutated amino acids in the 
SNAP-23 Ala mutant are highlighted in red. Original amino acids were replaced 
by the unpolar amino acid alanine. 
We  thus  hypothesized  that  mutation  of  these  three  amino  acids  would  affect  SNAP-23 
function  similarly  to  SNAP-25.  A  high  expression  level  was  essential  for  this  dominant 
negative approach to work so we sought to optimize the construct in this respect. Lacy-
Hulbert et al. report 30-fold enhanced expression of their construct when they introduced 
short intron sequences derived from the first intron of murine IgCµ heavy chain and the 
third intron of IgCε heavy chain at two original splice sites in GFP and bacteriophage P1-
derived cre recombinase cDNA sequences (Lacy-Hulbert, Thomas et al. 2001). We also 
inserted the first intron of murine IgCµ heavy chain and the third intron of IgCε heavy chain, 
both of which are rather short, at two sites in SNAP-23 cDNA sequence which contained 
introns prior to processing. A schematic overview of the construct is displayed in figure 22. 
 
Figure 22:  Schematic  representation  of  the  PF4-SNAP-23  Ala  construct.  The  BAC 
vector for PF4-SNAP-23 Ala consists of approximately 100’000 upstream (PF4 
promoter) and downstream (not shown) regulatory sequence of the PF4 gene. 
Approximately 150 base pairs adjacent to the PF4 start and stop codon were 
included in the cloning vector to mediate homologous recombination to the BAC 
vector (5’HA, 3’HA). A triple myc tag and the SNAP-23 Ala mutant replaced the 
PF4 gene and were followed by a polyA tail and a stop codon (not shown). Yellow 
parts in SNAP-23 represent the first intron of IgCµ heavy chain (5’) and the third 
intron of IgCε (3’). Arrows indicate site and identity of mutated amino acids. 
The  SNAP-23  Ala  sequence  containing  the  three  mutations  and  the  two  introns  were 
synthetized (Entelechon) and cloned into the final construct. Thirteen PCR-positive founder 
animals were obtained after blastocyst injection of PF4-SNAP-23 Ala. In the platelets of 
three of the positive founders, a band at around 32 kDa was detected in Western blot when 
probed with anti-myc antibody after long exposure (>20 min), suggesting expression of the 
construct in platelets (figure). However, in a second Western blot stained for SNAP-23, only 	
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the band of endogenous SNAP-23 running at approximately 26 kDa was observed even 
after long exposure of the film (figure 23). 
 
Figure 23:  Western blot of platelets isolated from the PF4-SNAP23 Ala PCR-positive 
founder  mice.  Shown  are  the  three  mice  that  displayed  a  signal  in  anti-myc 
staining (upper panel; F1-F3). In the lower panel, platelet lysates of the same 
mice were probed with anti-SNAP-23 antibody. Two littermate control mice (WT) 
were processed in parallel. 
These  findings  indicate  that  the  PF4-SNAP-23  Ala  construct  was  indeed  expressed  in 
platelets but expression levels compared to endogenous SNAP-23 levels were very low. 
Accordingly, no difference in P-selectin exposure and aggregometry between mutants and 
wild-type controls were observed (data not shown). Using transgenic SNAP-23 mutants to 
interfere with platelet secretion was thus abandoned. 
5.2  Analysis	
 ﾠof	
 ﾠthe	
 ﾠJinx	
 ﾠmouse	
 ﾠline,	
 ﾠa	
 ﾠgenetically	
 ﾠ
modified	
 ﾠnull-ﾭ‐mutant	
 ﾠof	
 ﾠthe	
 ﾠMunc13-ﾭ‐4	
 ﾠgene	
 ﾠ
5.2.1  Basal	
 ﾠanalysis	
 ﾠ
The Munc13 protein family is involved in the priming and docking step of SNARE-mediated 
exocytosis. It has been demonstrated that Munc13-4, the isoform present in platelets (Ren, 
Ye et al. 2008), controls dense granule release in platelets together with Rab27a and b 
(Shirakawa, Higashi et al. 2004). The Bruce Beutler laboratory generated a mouse line with 
a functional null-mutant of Munc13-4 (Munc13-4
Jinx). Given the major role of Munc13 in 
regulated  exocytosis,  we  hypothesized  that  Munc13-4  deficiency  should  cause  a  major 
platelet secretion defect. We first determined Munc13-4 protein levels in Jinx platelets and 
found  no  detectable  production  of  Munc13-4  protein  (figure  24  A).  Therefore,  the  Jinx 
mouse line will be termed “Munc13-4 KO” or Munc13-4-deficient” for clarity from here on. 
Western blot analysis of platelet lysates from isolated wild-type and Munc13-4 KO platelets 
probed with an antibody against the alpha granule protein PF4 showed no difference in PF4 
protein levels between both genotypes (figure 24 B). Platelet numbers determined with flow 
cytometry in whole blood were not changed in Munc13-4 KO mice compared to wild-type 
animals  (figure  24  C).  Transmission  electron  microscopy  revealed  intact  platelet 
morphology  and  normal  granule  numbers  in  Munc13-4  KO  platelets  (figure  24  D;  Ren, 
Wimmer et al. 2010). 	
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Figure 24:  Basic analysis of the phenotype of Munc-13-4-deficient platelets. (A) Platelet 
extracts from wild-type (WT) and Munc-13-4-deficient mice (KO) were analyzed 
by Western blotting using an anti-Munc13-4 antibody (n = 3). Pan-actin staining 
served as loading control. (B) Platelet extracts from wild-type (WT) and Munc-13-
4-deficient  mice  (KO)  were  analyzed  by  Western  blotting  using  an  anti-PF4 
antibody  (n  =  3).  Pan-actin  staining  served  as  loading  control.  (C)  Platelet 
numbers of wild-type (WT) and Munc-13-4-deficient mice (KO) were determined 
by  flow  cytometry  as  described  in  methods  (n  =  3).  (D)  Wild-type  (WT)  and 
Munc13-4  KO  (Munc13-4  KO)  platelet  morphology  was  visualized  with 
transmission  electron  microscopy  (magnification  x  10,000).  Shown  are  mean 
values ± S.D.; n.s., not significant. 
We next investigated whether basal surface expression of important platelet receptors is 
altered in Munc13-4 KO platelets. Therefore, we stained isolated Munc13-4 and wild-type 
platelets with antibodies against GPIb, GPV, GPVI, GPIX, integrin α2, integrin β1, integrin 
αIIbβ3,  CD9  and  CLEC-2  and  measured  their  relative  fluorescence  intensities  in  flow 
cytometry  (figure  25).  There  was  no  difference  between  wild-type  and  Munc13-4  KO 
platelets  in  the  expression  level  of  the  surface  receptors  tested  except  for  a  small  but 
significant reduction in CD9 and CLEC-2 levels in Munc13-4 KO platelets. 	
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Figure 25:  Basal  surface  receptor  expression  on  Munc13-4  KO  platelets.  Washed 
platelets from wild-type (WT) and Munc-13-4-deficient mice (KO) were stained 
with labeled antibodies against the indicated and staining was quantified by flow 
cytometry (n = 3). Shown are mean values ± S.D.; **, P<0.01. 
Integrin αIIbβ3 activation leads to a calcium-dependent conformational change that can be 
monitored  with  a  specific  antibody  (JON/A,  Emfret)  recognizing  an  epitope  that  is  only 
exposed  in  the  activated  conformation.  Wild-type  and  Munc13-4  KO  platelets  were 
stimulated with increasing concentrations of thrombin (figure 26 A) or a panel of different 
platelet agonists (figure 26 B) and the relative fluorescence intensity of bound anti-integrin 
αIIbβ3  antibody  was  determined  by  flow  cytometry.  Several  agonists  lead  to  a  slight 
decrease of active integrin αIIbβ3 in Munc13-4 KO platelets compared to wild-type platelets 
(0.1  U/ml  thrombin,  U46619+ADP,  CRP)  but  only  the  small  reduction  in  JON/A 
fluorescence intensity evoked by the snake venom rhodocytin was significant (figure 26 B). 	
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Figure 26:  Activation of surface integrin αIIbβ3 in Munc13-4 KO platelets. (A,B) Washed 
platelets from wild-type (WT) and Munc-13-4-deficient mice (KO) were activated 
with thrombin (A) or the indicated agonists (B) for 15 min, subsequentially stained 
with a labeled antibody against the active conformation of integrin αIIbβ3 (JON/A) 
and  quantified  by  flow  cytometry  (n  =  3).  U46619, thromboxane A2  analogue; 
CRP, collagen-related peptide. Shown are mean values ± S.D.; *, P<0.05; n.s., 
not significant. 
Platelet alpha granules contain multiple proteins and there are an increasing number of 
publications  reporting  regulated  release  of  specific  proteins  (Sehgal  and  Storrie  2007; 
Italiano, Richardson et al. 2008; Battinelli, Markens et al. 2011). We therefore chose two 
different proteins as representative markers for alpha granule release: PF4 and vWF. We 
assessed PF4 (figure 27 A) and vWF (figure 27 B) levels of supernatants from wild-type 
and Munc13-4 KO platelets after thrombin stimulation with specific ELISA assays. There 
was  no  difference  in  the  secretion  of  both  alpha  granule  proteins  at  sub-maximal  and 
maximal platelet stimulation (figure 27 A and B).  	
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Figure 27:   Munc13-4 KO platelets exhibit normal alpha granule protein release. (A,B) 
Effect  of  increasing  concentrations  of  thrombin  on  release  of  platelet  factor  4 
(PF4) (A) or von Willebrand factor (vWF) (B) from wild-type (WT) or Munc13-4-
deficient platelets (KO) (n = 3-5) measured in ELISA assays. Shown are mean 
values ± S.D.; n.s., not significant. 
Platelet alpha granule membranes contain P-selectin (Stenberg, McEver et al. 1985) but P-
selectin was also shown to be associated with dense granule membranes (Israels, Gerrard 
et al. 1992; Youssefian, Masse et al. 1997). Upon activation and granule secretion, granule 
membranes get integrated into the outer platelet membrane and P-selectin is exposed and 
serves as a binding receptor for various cell types (Zarbock, Polanowska-Grabowska et al. 
2007; van Gils, Zwaginga et al. 2009). P-selectin exposure on the surface of wild-type and 
Munc-13-4 deficient platelets was determined via flow cytometry in response to increasing 
thrombin concentrations (figure 28 A) or a panel of other platelet agonists (figure 28 B). 
There was a trend toward lower P-selectin exposure in Munc13-4 KO platelets compared to 
wild-type platelets but a significant reduction in P-selectin signal was only observed for the 
two highest thrombin concentrations (figure 28 A), the combination of U46619 and ADP and 
rhodocytin (figure 28 B).  	
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Figure 28:   Exposure of P-selectin on platelet outer membranes. (A,B) Washed platelets 
from  wild-type  (WT)  and  Munc-13-4-deficient  mice  (KO)  were  activated  with 
thrombin (A) or the indicated agonists (B) for 15 min, subsequentially stained with 
a  labeled  anti-P-selectin  antibody  and  quantified  by  flow  cytometry  (n  =  3). 
U46619, thromboxane A2 analogue; CRP, collagen-related peptide. Shown are 
mean values ± S.D.; *, P<0.05; n.s., not significant. 
We  measured  ATP  secretion  as  a  parameter  to  investigate  dense  granule  secretion  in 
Munc13-4-deficient platelets. Virtually no ATP secretion was detected in platelets isolated 
from mice lacking Munc13-4 in response to increasing doses of thrombin (figure 29 A), the 
thromboxane A2 analogue U46619 (figure 29 B) and collagen (figure 29 C). 	
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Figure 29:  Impaired dense granule secretion in Munc-13-4-deficient mice. (A,B,C) Effect 
of thrombin (A), the thromboxane A2-analogue U46619 (B) or fibrillar collagen (C) 
on release of ATP from wild-type platelets (WT) or Munc13-4-deficient platelets 
(KO)  (n  =  3-5).  Shown  are  mean  values  ±  S.D.;  *,  P<0.05;  **,  P<0.001;  ***, 
P<0.001. 
Adhesion to collagen under static conditions requires binding of platelet receptor GVI and 
may be supported by binding to integrin α2β1 (Nieswandt, Pleines et al. 2011).  We  let 
washed platelets of wild-type and Munc13-4-deficient mice adhere to coverslips previously 
coated  with  fibrillar  collagen,  washed  the  coverslips  and  analyzed  the  area  covered  by 
platelets (figure 30 A). Quantification (figure 30 B) reveals no difference in static adhesion 
to collagen between both genotypes. 	
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Figure 30:   Munc13-4 KO platelets show normal adhesion to collagen. (A,B) Collagen-
coated  coverslips  incubated  with  platelet  suspensions  of  wild-type  (WT)  and 
Munc-13-4-deficient  mice  (KO).  Coverslips  were  washed  and  representative 
brightfield images are shown (A). Bar length: 20 µm. Five randomly chosen areas 
per genotype (n = 3) were quantified (B). Shown are mean values ± S.D.; n.s., 
not significant.  
Platelet aggregation is an important tool in analysis of platelet function and is influenced by 
both alpha and dense granule secretion. The impact of secondary mediators in aggregation 
responses depends on the platelet agonist and the concentration applied to the platelet 
suspensions. Strong agonists like thrombin are less suitable to assess secretion defects 
because through stirring and diffusion, they reach every platelet very fast and lead to an 
immediate  formation  of  pseudopodia  (filopodia)  and  aggregation,  in  high  concentrations 
even without measurable  shape change. No substantial difference between aggregation 
curves  of  Munc13-4-deficient  platelets  and  wild-type  platelets  was  observed  after 
stimulation with thrombin (data not shown). In contrast to thrombin, collagen type I fibers 
only  activate  the  platelets  in  their  immediate  vicinity  by  binding  to  GPVI  and  platelet 
aggregation is supported by activation of neighboring cells via secondary mediators like 
ADP and thromboxane A2. Figure displays representative light transmission curves of wild-
type platelets and Munc13-4 KO platelets stimulated with 30 µg/ml (figure 31 A), 10 µg/ml 
(figure 31 B), 3 µg/ml (figure 31 C) and 0.3 µg/ml collagen (figure 31 D). A right-shift of 
Munc13-4  platelet  aggregation  compared  to  wild-type  curves  is  observed  in  all 	
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concentrations tested, showing a delayed onset of shape change and aggregation which is 
expected for a defect in dense granule secretion. Once aggregation is initiated, platelet 
secretion  plays  only  a  minor  role  in  reaching  plateau  aggregation  levels  but  the  strong 
defect  in  dense  granule  secretion  still  leads  to  a  marked  decrease  in  plateau-phase 
aggregation in Munc13-4 KO platelets compared to wild-type platelets (figure 31 A-D).  
 
Figure 31:  Aggregation of Munc13-4 KO platelets is impaired in response to collagen. 
(A-D)  Representative  light  transmission  curves  from  at  least  3  independent 
experiments of washed platelet suspensions (3x10
8/ml) from wild-type (WT) or 
Munc13-4-deficient  (Munc13-4  KO)  mice  were  measured  in  an  aggregometer. 
The x-axis shows the time from start of measurement to 900 s, the y-axis shows 
percentage of aggregation. The arrow indicates application of collagen at a final 
concentration of 30 µg/ml (A), 10 µg/ml (B), 3 µg/ml (C) or 0.3 µg/ml (D).  
Even when isolated Munc13-4 KO platelets were stimulated with intermediate to low doses 
of  the  thromboxane  A2  analogue  U46619,  the  delay  in  onset  of  aggregation  and  the 
decrease  in  plateau  aggregation  level  reached  were  obvious  compared  to  wild-type 
platelets (figure 32 A-C). 	
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Figure 32:  Aggregation of Munc13-4 KO platelets is impaired in response to U46619. 
(A-C)  Representative  light  transmission  curves  from  at  least  3  independent 
experiments of washed platelet suspensions (3x10
8/ml) from wild-type (WT) or 
Munc13-4-deficient  (Munc13-4  KO)  mice  were  measured  in  an  aggregometer. 
The x-axis shows the time from start of measurement to 900 s, the y-axis shows 
percentage of aggregation. The arrow indicates application of the thromboxane 
A2 analogue U46619 at a final concentration of 3 µM (A), 1 µM (B) or 0.1 µM (C).  
Application of whole blood samples to a flow chamber device is a more complex method to 
assess platelet function in vitro. This assay involves platelet activation, rolling and binding 
of  single  platelets,  recruitment  of  platelets  via  secondary  mediators,  formation  of 
aggregates and aggregate stability. Binding of the platelet GPIb-V-IX complex to collagen-
bound vWF initiates rolling and adhesion of platelets, then the low-affinity receptor GPVI 
can bind to collagen and activate the platelets. Aggregate stability is supported by many 
mediators,  especially  integrin  α2β1  and  αIIbβ3,  CLEC-2,  Gas6  and  CD40L  (Nieswandt, 
Pleines et al. 2011). Heparinized mouse blood is transported through a tube-like chamber 
containing a collagen-coated coverslip at a defined shear rate (1000 s
-1) and coverslips are 
analyzed  microscopically  for  bound  platelet  aggregates.  Munc13-4  KO  platelets  form 
smaller aggregates than wild-type platelets (figure 33 A) and a size distribution chart makes 
this defect even more obvious (figure 33 C). In contrast, quantification of the total area 	
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covered by platelets is approximately the same for both genotypes (figure 33 B), indicating 
again that adhesion to collagen is not perturbed in Munc13-4 platelets.  
 
Figure 33:  Munc13-4 KO platelets show impaired formation of large aggregates in flow 
chamber assays. (A-C) Collagen-coated coverslips were fixed in a flow chamber 
device which was then perfused at a defined shear rate (1000
-s) with heparinized 
blood freshly drawn from wild-type (WT) or Munc-13-4-deficient mice (KO) for 5 
min. Coverslips were washed and representative brightfield images are shown 
(A). Bar length: 20 µm. Three randomly chosen areas per mouse (n = 6) were 
quantified for total area covered with platelets per field of view (B). To visualize 
the apparent inability of Munc13-4 KO platelets to form large aggregates despite 	
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intact activation by collagen, the aggregates were split up in size categories (C). 
Shown are mean values ± S.D. where applicable (B).  
Dysfunctional  platelet  responses  often  lead  to  an  increase  in  bleeding  time.  Mice  were 
anesthetized and tails were cut by 2 mm. Immediately afterwards, tails were submerged 
into  saline  and  kept  at  37°C  until  bleeding  ceased  for  more  than  1  min  or  until  the 
experiment was stopped after 20 min. Wild-type animals had an average bleeding time of 
approximately 2 min whereas Munc13-4-deficient animals showed no sign of decrease in 
blood flow until the experiment was terminated 20 min after tail cut to avoid critical loss of 
blood (figure 34). 
 
Figure 34:  Prolonged  tail  bleeding  time  in  Munc13-4  KO  mice.  Mice were kept under 
isoflurane  anesthesia  throughout  the  experiment.  Tails  of  wild-type  (WT;  gray 
circles) and Munc13-4 KO mice (Munc13-4 KO; white triangles) were cut 2 mm, 
the tail was immediately submerged into pre-warmed (37°C) saline. Time was 
measured until bleeding stopped for more than 1 min. Experiment was terminated 
after 20 min to avoid critical loss of blood (n = 7-9). Shown are mean values ± 
S.D.; ***, P<0.001. 
Denudation of mesenteric arteries with ferric chloride is a commonly used mouse model for 
arterial thrombosis. Exposure of extracellular matrix proteins like collagen leads to platelet 
activation, secretion and finally to occlusion of the vessel by a platelet-rich plug which is 
almost devoid of red blood cells and lymphocytes. This model strongly depends on platelet 
granule secretion and there is evidence that dense granules play a major role in thrombus 
formation (King, McNamee et al. 2009). Munc13-4 KO mice showed only minor platelet 
aggregate formation and no occlusion during the follow-up time of the experiment (60 min). 
In wild-type vessels, stable plugs began to form after 2-4 min and after approximately 10 
min, no cellular transport through the occluded vessel was observed any more (figure 35 A-
D).  	
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Figure 35:  Severely  perturbed  thrombus  formation  in  Munc13-4  KO  mice  in  vivo. 
Three-weeks-old wild-type (WT; gray circles) and Munc13-4 KO mice (Munc13-4 
KO;  white  triangles)  were  anesthetized  with  ketamine/xylazine.  Through  an 
abdominal incision, the mesenteric bed was carefully pulled out and spread on a 
heated (37 °C) stage. One artery per animal was denuded with ferric chloride and 
flow  constantly  monitored  for  60  min.  Time  was  measured  until  flow  stopped 
completely for more than 1 min. (A-C) Representative brightfield images of wild-
type arteries before denudation with ferric chloride (A), partially occluded vessels 
after denudation (B) and after complete occlusion of the artery (C) (bar length: 1 
mm (A,B); 0,25 mm (C)). (D) Quantification of time to occlusion (n = 5-7). Shown 
are mean values ± S.D.; ***, P<0.001. 
Together,  these  data  show  that  Munc13-4  deficient  platelets  have  normal  morphology, 
granule numbers and contents. Dense granule secretion is abrogated while alpha granule 
secretion seems mostly unaffected. This secretion defect has major impact on platelet in 
vivo function in mice as demonstrated in tail bleeding time and thrombosis experiments.  
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Having analyzed the secretion properties of Munc13-4 mice in detail, we could now use 
these  mice  to  assess  the  progression  of  atherosclerotic  plaque  formation  compared  to 
control mice. For that purpose, we performed bone marrow transplantation of Munc13-4-
deficient and wild-type bone marrow into lethally irradiated LDL receptor knockout mice, 	
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one of the two long-established mouse models of atherosclerosis. Unlike Apolipoprotein E 
knockout mice, the other commonly used atherosclerosis model in mice, LDLR KO mice 
only develop atherosclerotic plaques after being fed with a fat- and cholesterol-rich diet. 
Mice were left on normal chow to recover from irradiation for four weeks. After that time, 
mice were fed a high-fat, high-cholesterol diet for 16 weeks and body weight was monitored 
once a week (data not shown). Mice were sacrificed and aortas were excised and carefully 
prepared  for  en  face  staining  with  Oil  Red  O,  which  stains  the  lipid  droplets  in 
atherosclerotic plaques. After staining, aortas were photographed (figure 36 A) and Oil Red 
O-stained areas were quantified (figure 36 B). There was a slight increase of plaque area in 
Munc13-4 KO mice but this difference between genotypes was not statistically significant.  
 
Figure 36:  Munc13-4  KO  mice  have  unaltered  aortic  plaque  formation  in  LDLR  KO 
atherosclerosis model. En face preparations of aortas from LDL receptor knock-
out mice, which were lethally irradiated and transplanted with bone marrow from 
either wild-type (WT) or Munc13-4 KO mice (Munc13-4 KO) and fed a high-fat, 
high-cholesterol diet for 16 weeks were stained with Oil Red O (bar length: 0.5 
cm) (A). Plaque area was quantified relative to area of whole aorta (n = 6) (B). 
Shown are mean values ± S.D.; n.s., not significant. 
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For a long time, evidence has been gathering that platelets are not only activated by tumor 
cells  and  are  thus  responsible  for  the  increased  risk  of  thrombosis  in  cancer  patients 
(Armand  Trousseau,  Phlegmasia  alba  dolens,  in:  Clinique  Medicale  de  l’Hotel-Dieu  de 
Paris, Vol 3, 2
nd Edition, Ballière, Paris, 1865, pp 654-712) but also influence tumor cells in 
the circulation and the formation of metastasis (Joyce and Pollard 2009; Erpenbeck and 
Schon 2010; Gay and Felding-Habermann 2011). In experimental settings where platelets 
were depleted by antibodies, the number of lung metastasis in mouse models was strongly 
reduced  (Erpenbeck  and  Schon  2010).  The  mechanisms  underlying  this  effect  are  still 
elusive. Since it has been shown that platelets can be directly activated by and bind to 
tumor cells (Nieswandt, Hafner et al. 1999), we hypothesized that the presence of platelets 
and possibly platelet secretion could influence properties of tumor cells. We tested this by 	
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applying platelets in a classic transmigration assay where tumor cells transmigrate through 
an  endothelial  cell  layer  in  vitro.  We  added  isolated  platelets  to  the  top  chamber  of  a 
transwell  plate  together  with  B16  mouse  melanoma  and  Lewis  lung  mouse  carcinoma 
(LLC1) cells. The tumor cells were stained with calcein prior to the experiment and tumor 
cell  transmigration  through  a  monolayer  of  Mile  Sven  I  (MS1)  microvascular  mouse 
endothelial  cells  was  assessed  15  hours  later  by  counting  the  tumor  cells  in  the  lower 
chamber.  The presence  of  platelets  significantly  increased  transmigration  of  tumor  cells 
two- to three-fold compared to tumor cells alone (figure 37 A and B).  This increase in tumor 
cell transmigration was dependent on the presence of endothelial cells, since tumor cell 
transmigration per se was not altered (figure 37 C). 
 
Figure 37:   Wild-type  platelets  enhance  B16  and  LLC1  tumor  cell  transmigration 
through  an  endothelial  layer.  (A-C)  The  indicated  murine  tumor  cells  were 
seeded  on  murine  MS1  microvascular  endothelial  cells,  and  tumor  cell 
transmigration was determined in the absence or presence of platelets (-/+ Plts) 
(A,B) or in absence and presence of endothelial cells (-/+ EC) (C) (n = 5). Shown 
are mean values ± S.E.M.; *P < 0.05; **P < 0.01; n.s., not significant. 
Platelet  supernatant  from  platelets  previously  stimulated  with  tumor  cells  alone  was 
sufficient to induce a boost in tumor cell transmigration while supernatant from unstimulated 
platelets was without effect (figure 38 A), suggesting that the tumor cell-induced platelet 
secretion stimulates tumor cell transmigration through an endothelial layer. To test whether 
soluble  mediators  of  platelet  activation  were  involved,  we  added  the  cyclooxygenase 
inhibitor  flurbiprofen  to  inhibit  formation  of  thromboxane  A2  and  the  ATP/ADP-
dephosphorylating  enzyme  apyrase  to  scavenge  these  nucleotide  platelet  agonists. 
Addition  of  flurbiprofen  did  not  influence  the  platelet-mediated  increase  in  tumor  cell 
transmigration, but apyrase completely inhibited this increase (figure 38 B). To investigate 
whether tumor cells induce platelet ATP secretion, we performed luciferase ATP assay on 
supernatants of platelets alone, B16 tumor cells alone and platelets incubated with tumor 
cells (figure 38 C). We observed a low basal ATP secretion by tumor cells. High amounts of 
ATP were released when platelets were incubated with tumor cells, and this ATP secretion 
was suppressed when apyrase was present in addition (figure 38 C).  	
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Figure 38:   Wild-type  platelet  releasates  enhance  B16  tumor  cell  transmigration, this 
effect  can  be  reversed  by  apyrase.  B16  melanoma  cells  were  seeded  on 
murine MS1 endothelial cells, and tumor cell transmigration was determined in 
the absence or presence of supernatants (supernat.) of platelets preincubated in 
the absence (- stim.) or presence of tumor cells (+ stim.) (A) (n = 5). (B) Effect of 
the  COX-inhibitor  flurbiprofen  (Flurbipr.,  100  nM)  or  the  ATP/ADP  degrading 
enzyme apyrase (Apyr., 20 U/ml) on platelet (Plts)-dependent stimulation of B16 
cell transendothelial migration (n = 5). (C) Release of ATP from platelets (Plts) 
alone, B16 tumor cells (TC) alone or a mixture of tumor cells and platelets (1:100) 
in the absence or presence of apyrase (-/+ Apyr.; 20 U/ml). Shown are mean 
values ± S.E.M. (A,B) or S.D. (C); **P<0.01; ***, P<0.001. 
We thus investigated if ATP itself influences tumor cell transmigration. Addition of the stable 
analogue  ATPγS  (figure  39  A)  or  increasing  concentrations  of  ATP  alone  (figure  39  B) 
indeed evoked a strong increase in transendothelial tumor cell transmigration, indicating 
that  ATP  secreted  from  tumor-cell-activated  platelets  interferes  directly  with  the 
transmigration of tumor cells through an endothelial layer. 	
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Figure 39:  Exogenous addition ATP or its stable analogue ATPγS stimulate tumor cell 
transmigration.  (A-C)  B16  melanoma  cells  were  seeded  on  murine  MS1 
endothelial cells, and tumor cell transmigration was determined. Effect of ATPγS 
(10 µM) (A) or increasing concentrations of ATP (B) on tumor cell transmigration 
(n = 5). (C) Effect of increasing concentrations of apyrase on the ATP-dependent 
stimulation of B16 tumor cell transmigration. Shown are mean values ± S.E.M.; 
**, P<0.01; n.s., not significant. 
This  observation  lead  us  to  investigate  whether  ATP  released  from  platelets  acts  on 
endothelial cells and thereby influences tumor cell transmigration. We used FITC-labeled 
dextran  added  to  the  upper  chamber  of  a  transwell  assay  to  monitor  changes  in 
permeability of an endothelial monolayer upon addition of supernatant from platelets alone, 
B16 tumor cells alone and platelets incubated with rumor cells in the absence or presence 
of  apyrase  (figure  40).  Only  the  supernatant  of  tumor-cell-stimulated  platelets  lead  to  a 
marked increase in endothelial permeability when FITC-dextran levels on the bottom of the 
lower  well  were  measured  and  this  effect  was  completely  inhibited  by  the  presence  of 
apyrase. 	
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Figure 40:   Supernatant  from  platelets  stimulated  with  tumor  cells  increases 
endothelial permeability, an effect, which can be abrogated by addition of 
apyrase.  MS1  endothelial  cells  were  grown  to  a  monolayer  and  buffer; 
supernatants  from  platelets  alone  (+  Plts),  B16  tumor  cells  alone  (+  TC)  or 
platelets stimulated with tumor cells in the absence or presence of apyrase (20 
U/ml; -/+ Apyr.) were added to the upper chamber together with FITC-labeled 
dextran 70,000 kDa. Diffusion of FITC-dextran through the endothelial layer to the 
lower chamber was measured after 90 min. Shown are mean values ± S.D.; **, 
P<0.01. 
Endothelial permeability is mediated by endothelial barrier function, so we visualized the 
effect of supernatants of platelets alone, tumor cells alone, platelets stimulated with tumor 
cells and platelets stimulated with tumor cells together with apyrase on MS1 endothelial cell 
morphology  by  immunocytochemistry  (figure  41).  A  marker  for  endothelial  adherens 
junctions (VE cadherin) together with staining for f-actin revealed a significant increase in 
discontinuous endothelial junctions in MS1 cells incubated with supernatant from tumor-cell 
stimulated platelets. This effect was inhibited by addition of apyrase to the platelet-tumor 
cell suspension (figure 41 A). Quantification of two independent experiments is shown in 
figure 41 B. 	
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Figure 41:   Supernatant  from  platelets  stimulated  with  tumor  cells  destabilizes 
endothelial  barriers,  an  effect,  which  can  be  abrogated  by  addition  of 
apyrase.  (A,B)  MS1  endothelial  cells  were  grown  to  a  monolayer  and  buffer, 
supernatants  from  platelets  alone  (+  Plts),  B16  tumor  cells  alone  (+  TC)  or 
platelets stimulated with tumor cells in the absence or presence of apyrase (-/+ 
Apyr.) were added for 90 min. MS1 cells were then fixed and stained for the 
adherens  junction  marker  VE-cadherin  (red)  and  f-actin  (green),  nuclei  were 
stained with DAPI (blue). Representative confocal images are shown in (A), white 
boxes are enlarged at the bottom. Discontinuous junctions were quantified in (B) 
(n = 6). Shown are mean values ± S.D.; ***, P<0.001. 
Together, these findings indicate that release of nucleotides from platelets enhances tumor 
cell transmigration trough an endothelial cell layer by modifying endothelial barriers in vitro.  
These observations translate to a human cell set-up where human tumor cells transmigrate 
trough Human umbilical vein endothelial cells (HUVECs) in the presence and absence of 
isolated human platelets. The number of transmigrated pancreatic carcinoma (CFPAC-1) 
(figure 42 A) and neuroblastoma (SH-SY5Y) (figure 42 B) cells was approximately two to 	
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three-fold  higher  when  supernatant  from  tumor  cell-stimulated  platelets  was  present 
compared to tumor cells alone. Various human tumor cell lines were able to induce ATP 
release in human platelets (figure 42 C). Permeability of monolayer of HUVEC was strongly 
increased after addition of tumor-cell-stimulated platelets and apyrase completely blocked 
this increase (figure 42 D). 
 
Figure 42:  Human  platelets  enhance  tumor  cell  transmigration  through  a  HUVEC 
monolayer  via  release  of  ATP  and  disruption  of  endothelial  barriers. 
Supernatants  of  human  platelets  preincubated  in  the  absence  (-  stim.)  or 
presence (+ stim.) of SH-SY5Y human neuroblastoma (A) or CFPAC-1 human 
pancreatic  carcinoma  cells  were  added  to  a  monolayer  of  umbilical  vein 
endothelial cells (HUVEC). Transmigration of the respective tumor cells through 
the  endothelial  cell  layer  was  determined  (n  =  5).  (C)  Release  of  ATP  from 
platelets (Plts) alone, A549 human lung carcinoma (A549; black bars), MDA-MB-
231  breast  adenocarcinoma  (MDA-MB  231;  grey  bars)  or  PC-3  prostate 
adenocarcinoma (PC-3, white bars) cells (TC) alone or a mixture of tumor cells 
and platelets (1:100) incubated for 10 min (n = 5). (D) HUVEC were grown to a 
monolayer and buffer, supernatants from platelets alone (+ Plts), SH-SY5Y tumor 
cells  alone  (+  TC)  or  platelets  stimulated  with  tumor  cells  in  the  absence  or 
presence  of  apyrase  (20  U/ml;  -/+  Apyr.)  were  added  to  the  upper  chamber 
together  with  FITC-labeled  dextran  70,000  kDa.  Diffusion  of  FITC-dextran 	
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through the endothelial layer to the lower chamber was measured after 90 min (n 
= 5). Shown are mean values± S.D. (C,D) or ± S.E.M. (A,B); *P < 0.05; **P < 
0.01; ***, P<0.001. 
There is evidence for a number of potential mechanisms how tumor cells interact directly 
with platelets, notably through platelet P-selectin and integrin αIIbβ3 (Erpenbeck and Schon 
2010; Gay and Felding-Habermann 2011). B16 tumor cells have been shown to expose 
tissue factor on their surface (Amarzguioui, Peng et al. 2006; Niers, Bruggemann et al. 
2009) and potential thrombin generation on the surface of B16 cell could activate platelets. 
We  used  hirudin  to  inhibit  thrombin  formation,  antibodies  against  most  known  platelet 
surface receptors or pre-incubation of tumor cells with anti-podoplanin antibody to inhibit 
binding  to  platelet  CLEC-2  to  study  their  impact  on  platelet-dependent  enhancement  of 
tumor cell transmigration (figure 43 A). The addition of thrombin inhibitor hirudin to tumor 
cells  prior  to  addition  to  the  transmigration  assay  and  lead  to  a  partial  but  significant 
reduction in the stimulating effect of platelets on tumor cell transmigration, but there was 
substantial  variation  between  experiments  (data  not  shown).  Blocking  of  P-selectin  on 
platelets  reduced  the  transmigration  of  tumor  cells  and  this  slight  reduction  was 
reproducible in independent experiments (data not shown) but not significant, whereas the 
reduction  of  GPIbα  was  very  variable.  None  of  the  tested  antibodies  and  inhibitors 
decreased  platelet-mediated  B16  tumor  cell  transmigration  to  basal  levels.  Addition  of 
hirudin as well as addition of the antibody against P-selectin to platelets prior to incubation 
with tumor cells also lead to lower levels of ATP secretion compared to wild-type platelets 
and B16 tumor cells alone, although this was not significant (figure 43 B).  	
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Figure 43:  Platelet-mediated enhancement of tumor cell transmigration and tumor-cell-
induced  platelet  ATP  release  are  not  influenced  by  a  panel  of  blocking 
agents.  (A)  B16  tumor  cells  were  seeded  on  murine  MS1  microvascular 
endothelial cells, and tumor cell transmigration was determined in the presence of 
platelet supernatants of unstimulated platelets (- Plts) or platelets incubated with 
the thrombin inactivator hirudin, blocking antibodies against the indicated platelet 
surface proteins or the tumor cell surface protein podoplanin and stimulated with 
B16 tumor cells (+ Plts) (n = 5). (B) Release of ATP from platelets (Plts) alone, 
B16 tumor cells (TC) alone or a mixture of tumor cells and platelets (1:100) in the 
absence or presence of the same blocking agents as in (A). Shown are mean 
values ± S.E.M. (A) or S.D. (B); ); *P < 0.05; **P < 0.01; n.s., not significant. 
The  fact  that  none  of  the  inhibitors  of  receptors  and  mediators  known  or  suspected  to 
influence platelet-tumor cell interactions (Erpenbeck and Schon 2010; Gay and Felding-
Habermann 2011) showed a strong effect in our in vitro transmigration assay indicates that 
it is either a combination of several factors or a yet unknown mechanism by which tumor 
cells elicit platelet secretion in our transmigration set-up. 	
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To further investigate whether nucleotides released from platelet dense granules mediate 
the increase in tumor cell transmigration, we employed Munc13-4 KO platelets as a suitable 
tool since extensive analysis proved that Munc13-4 KO platelets have a specific deficit in 
dense  granule  secretion  (see  above).  We  compared  the  number  of  transmigrated  B16 
(figure 44 A) and LLC1 (figure 44 B) tumor cells upon the addition of wild-type and Munc13-
4-deficient platelets to the upper chamber. Munc13-4 KO platelets in addition to both tumor 
cell lines showed the same amount of transmigrated tumor cells as tumor cells alone (figure 
44),  further  indicating  that  release  of  dense  granule  contents  from  tumor-cell-activated 
platelets is the source of increased transendothelial migration of tumor cells. 
 
Figure 44:   Platelets  with  defective  ATP  secretion  impede  platelet-mediated 
enhancement of tumor cell transmigration. (A,B) B16 (A) and LLC1 (B) tumor 
cell  transmigration  in  the  absence  (-  Plts)  or  presence  of  wild-type  (WT)  or 
Munc13-4 KO (KO) platelets through an MS1 endothelial layer (n = 5). Shown are 
mean values ± S.E.M.; *P < 0.05; **P < 0.01. 
To  exclude  that  activation  of  platelets  by  tumor  cells  uses  mechanisms  which  elicit  a 
different  secretion  pattern  in  platelets  than  the  agonists  used  above,  we  repeated  vWF 
(figure 45 A) and PF4 (figure 45 B) ELISAs and ATP luciferase assay (figure 45 C) applying 
B16  and  LLC1  tumor  cells  as  stimuli.  In  line  with  the  results  for  the  classical  platelet 
agonists, we observed similar levels of PF4 and vWF secretion in wild-type and Munc13-4-
deficient platelets whereas no ATP secretion above the levels measured for tumor cells 
alone was detected for tumor cells incubated with Munc13-4-deficient platelets. 	
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Figure 45:  Munc13-4  KO  platelets  exhibit  normal  alpha  granule  protein  release  but 
abrogated ATP release in response to tumor cells. (A,B) Effect of increasing 
concentrations  of  thrombin  on  release  of  platelet  factor  4  (PF4)  (A),  von 
Willebrand factor (vWF) (B) or ATP (C) from wild-type (WT) or Munc13-4-deficient 
platelets (KO) (n = 3-5). Shown are mean values ± S.D.; ***, P<0.001; n.s., not 
significant. 
It has been shown that platelets can adhere and stably attach to tumor cells (Nieswandt, 
Hafner et al. 1999). This property alone could possibly influence activation of platelets by 
tumor cells or survival of tumor cells in the circulation (Palumbo, Talmage et al. 2005; Gay 
and  Felding-Habermann  2011),  so  we  labeled  isolated  wild-type  and  Munc13-4  KO 
platelets  with  CFSE  and  incubated  them  with  B16  melanoma  cells.  We  used  confocal 
microscopy to visualize binding of fluorescent platelets to tumor cells (figure 46  A) and 
quantified the CFSE signal on tumor cells with flow cytometry (figure 46 B). Munc13-4-
deficient platelets equally bound to tumor cells although it appeared as if it was more single 
platelets, each in contact with the tumor cell. In wild-type platelets, two or more platelets 
could  often  be  found  attached  to  each  other  and  the  tumor  cell.  Quantification  clearly 
proved that this did not influence total amount of platelets bound to tumor cells since there 
was no difference between genotypes. 	
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Figure 46:  Munc-13-4 KO platelets show normal adhesion to tumor cells. (A,B) Washed 
wild-type (WT) and Munc13-4 KO (KO) platelets were labeled with CFSE (green) 
and incubated with B16 melanoma cells. (A) Confocal stacks were taken and 
representative images of maximum projections are displayed (bar length: 2 µm). 
(B) Quantification was performed by measuring the amount of CFSE-labeling in a 
gate set on tumor cells in flow cytometry (n = 6). Shown are mean values ± S.D.; 
n.s., not significant. 
The availability of Munc13-4 KO mice with their unique property of defective platelet dense 
granule secretion provided the means to investigate the significance of platelet nucleotide 
secretion in in vivo tumor models. Since endothelial secretion of vWF could influence tumor 
cell  adhesion  to  the  vessel  wall  (Kerk,  Strozyk  et  al.  2010),  we  determined  expression 
levels of the four Munc13 isoforms (Munc13-1, -2, -3, -4) in the MS1 mouse microvascular 
endothelial cell line (Figure 47 A) and mouse primary lung endothelial cells (figure 47 B) to 
exclude a contribution of defective endothelial secretion in Munc13-4 KO mice. Munc13-2 
was the only Munc13 isoform detected in mouse endothelial cells. 
 
Figure 47:  The  murine  microvascular  endothelial  cell  line  MS1  and  mouse  primary 
lung endothelial cells express the Munc13-2 isoform. (A,B) Two independent 
RNA preparations from MS1 (A) and isolated primary lung endothelial (B) cells 	
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were  combined  and  expression  of  the  four  known  Munc13  isoforms  was 
determined relative to 18 S rRNA (n = 3). Shown are mean values ± S.D.. 
Munc13-4 KO mice are thus a good tool to investigate the role of platelet dense granule 
release in B16 and LLC1 tumor models. We therefore employed both primary tumor models 
by injecting B16 and LLC1 tumor cells in the flank of mice and intravenous injection of both 
C57/Bl6 tumor cell lines to study metastasis formation dependent and independent of a 
primary tumor. For the flank tumor model, tumor growth was regularly monitored by caliper 
measurement. Mice were sacrificed after 21 days and lungs and primary tumors removed. 
Primary tumor weight was determined and tumors were sectioned and analyzed for gross 
angiogenesis defects by CD31 staining. B16 primary tumors from wild-type (figure 48 A) 
and Munc13-4 KO mice (figure 48 B) showed no difference in CD31 staining. Quantification 
of vessel length (Figure 48 C) and diameter (figure 48 D) was also unaltered in Munc13-4-
deficient mice compared to wild-type mice. 
   
Figure 48:  Primary  tumors  from  flank  injection  of  B16  melanoma  cells  show 
comparable  vessel  formation  in  wild-type  and  Munc13-4  KO  mice.  (A-D) 
Wild-type and Munc13-4 KO mice were injected subcutaneously with 1x10
6 B16 
melanoma cells. Mice were sacrificed after 21 days, primary tumors excised and 
30 µm cryosections were analyzed with CD31 staining to visualize the endothelial 
layer in vessels (red). Representative maximum projections of confocal stacks 
from wild-type (A) and Munc13-4 KO (B) animals are shown (bar length: 20 µm). 
Quantification  of  vessel  length  (C)  and  diameter  (D)  of  five  randomly  chosen 	
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areas per animal was done (n = 3). Shown are mean values ± S.D.; n.s., not 
significant. 
Exemplary images of LLC1 tumors derived from wild-type (figure 49 A) and Munc13-4 KO 
mice  (figure  49  B)  as  well  as  quantification  of  vessel  length  (figure  49  C)  and  vessel 
diameter (figure 49 D) revealed that also in this tumor model, the parameters assessed 
here  for  tumor  angiogenesis  are  unchanged  in  Munc13-4  KO  mice.  Hematoxylin/eosin 
(H/E)  stained  sections  from  both  primary  tumor  models  confirmed  this  finding  (data  not 
shown). 
 
Figure 49:  Primary  tumors  from  flank  injection  of  LLC1  carcinoma  cells  show 
comparable  vessel  formation  in  wild-type  and  Munc13-4  KO  mice.  (A-D) 
Wild-type and Munc13-4 KO mice were injected subcutaneously with 1x10
6 LLC1 
cells.  Mice  were  sacrificed  after  21  days;  primary  tumors  excised  and  30  µm 
cryosections were analyzed with CD31 staining to visualize the endothelial layer 
in  vessels  (red).  Representative  maximum  projections  of  confocal  stacks  from 
wild-type  (A)  and  Munc13-4  KO  (B)  animals  are  shown  (bar  length:  20  µm). 
Quantification  of  vessel  length  (C)  and  diameter  (D)  of  five  randomly  chosen 
areas per animal was done (n = 3). Shown are mean values ± S.D.; n.s., not 
significant. 
There was also no difference in B16 primary tumor growth (data not shown) and tumor 
weight (figure 50 A) between wild-type and Munc13-4 KO animals. In contrast, formation of 
metastases  in  the  lung  determined  by  H/E  stained  sections  throughout  the  lung  was 	
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strongly  reduced  in  Munc13-4  deficient  mice  (figure  50  B).  Splitting  in  size  categories 
revealed  that  metastases  of  all  sizes  were  markedly  reduced,  indicating  that  growth  of 
metastases, once established, was not affected. Likewise, tumor weight of tumors derived 
from  flank-injected  LLC1  cells  (figure  50  C)  was  unchanged  in  Munc13-4  KO  mice 
compared to wild-type mice and the number of lung metastases was also strongly reduced 
(figure 50 D) in Munc13-4-deficient animals. 
 
Figure 50:  Primary tumor weight after flank injection of B16 and LLC1 is unchanged 
but metastasis is strongly impaired in Munc13-4 KO mice compared to wild-
type  mice.  (A-D)  Wild-type  and  Munc13-4  KO  mice  were  injected 
subcutaneously with 1x10
6 B16 (A,B) or LLC1 (C,D) cells. Mice were sacrificed 
after 21 days, primary tumors excised and weighed (A,C) (n = 6-10). Lungs were 
cut and metastases counted with H/E staining. Metastases were grouped in small 
(diameter: <0.1 mm), medium-sized (diameter: 0.1-1.0 mm) or large (diameter: 
>1.0 mm) metastases (B,D) (n = 6-10). diameter (with CD31 staining to visualize 
the endothelial layer in vessels (red). Shown are mean values ± S.D.; *, P<0.05; 
**, P<0.01; n.s., not significant. 
I.v. injection of tumor cells is used to study seeding of organs independent of a primary 
tumor and effects influencing priming of tumor cells for intravasation and intravasation into 
the circulation. When we injected B16 melanoma (figure 51 A) or LLC1 carcinoma (figure 	
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51  B)  cells  into  the  tail  vein  of  mice,  we  observed  strongly  diminished  formation  of 
metastases in the lungs of Munc13-4 KO mice compared to wild-type mice after 12 days. 
 
Figure 51:  Formation  of  metastases  is  strongly  reduced  in  Munc13-4  KO  mice 
compared to wild-type mice after B16 or LLC1 i.v. injection. (A,B) B16 (A) or 
LLC1 cells (B) were injected i.v. into wild-type (WT) or Munc13-4-deficient mice 
(KO), and 12 days later, lung metastases were evaluated with H/E staining as in 
figure (n = 6-10). The images show representative lung surface metastases (A) or 
stained lung sections (B) from wild-type (WT) or Munc13-4-deficient mice (KO). 
Bar length: 100 µm. Arrowheads indicate metastases. Shown are mean values ± 
S.D.; *, P<0.05; **, P<0.01. 
These findings suggest that progression of primary tumors and tumor angiogenesis is not 
affected by the absence of platelet dense granule secretion while dense granule secretion 
has a strong impact on the occurrence of lung metastasis in the models investigated in this 
study, possibly by mechanisms which influence tumor cell extravasation as suggested by 
the  enhancement  of  tumor  cell  transmigration  in  the  presence  of  platelets  in  vitro  and 
strongly reduced metastasis after tumor cell i.v. injection in vivo. Taking into account that 
tumor cell transmigration in the absence of endothelial cells is unchanged by the addition of 
platelets and apyrase can block the platelet-mediated transendothelial migration of tumor 
cells,  we  hypothesized  that  molecules  released  from  platelet  dense  granules  upon 	
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stimulation by tumor cells, in particular nucleotides, act on endothelial receptors and modify 
endothelial junctions, thereby allowing tumor cells a more efficient passage. 
To  test  this  hypothesis,  we  first  determined  the  levels  of  P2Y  metabotropic  and  P2X 
ionotropic  receptors  on  the  pancreatic  microvascular  cell  line  used  for  the  in  vitro 
experiments, MS1 (figure 52 A and B), mouse primary lung endothelial cells (figure 52 C 
and D), and human umbilical vein endothelial cells (HUVECs) (figure 52 E and F). 
 
Figure 52:  P2Y and P2X receptor expression in the murine microvascular endothelial 
cell line MS1, mouse primary lung endothelial cells and human umbilical 
vein endothelial cells (HUVEC). (A-F) Two independent RNA preparations from 
MS1 (A,B), isolated primary lung endothelial cells (C,D) and HUVEC (E,F) were 	
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combined  and  expression  of  P2Y  (A,C,E)  and  P2X  (B,D,F)  subtypes  was 
determined relative to 18 S rRNA (n = 3). Shown are mean values ± S.D.. 
Since ATP alone was sufficient to enhance tumor cell transmigration in vitro, we focused on 
receptors with great ATP affinity (table 24). This excludes P2Y6 (UDP) and leaves P2Y1, 
P2Y2 and P2X4 as the most likely candidates mediating the ATP effects on endothelial cells.  
 
Receptor  Agonist  Organism  Mode of action  Unit  Affinity 
P2Y1  ATP 
ADP 
Human 
Human 
Partial agonist 
Full agonist 
pIC50 
pIC50 
6.1 - 7.8 
6.2 - 7.2 
P2Y2  UTP 
ATP 
Human 
Human 
Full agonist 
Full agonist 
pEC50 
pEC50 
8.1 
7.07 
P2Y4  UTP 
ATP 
Human 
Rat 
Full agonist 
Partial agonist 
pEC50 
pEC50 
6.3 
5.7 - 6.3 
P2Y6  UDP 
UTP 
ADP 
Human 
Human 
Human 
Full agonist 
Partial agonist 
Partial agonist 
pEC50 
pEC50 
pEC50 
6.5 
5.2 
4.5 
P2Y11  UTP 
ATP 
Human 
Human 
Full agonist 
Full agonist 
pEC50 
pEC50 
5.2 
4.2 - 5.6 
P2Y12  ADP 
ATP 
Human 
Human 
Full agonist 
Full agonist 
pKi 
pKi 
5.9 
5.2 
P2Y13  ADP 
ATP 
Human 
Human 
Full agonist 
Full agonist 
pIC50 
pIC50 
6.5 
5.4 
P2Y14  UDP-glucose 
UDP-glucose 
UDP-glucose 
Mouse 
Rat 
Human 
Full agonist 
Full agonist 
Full agonist 
pEC50 
pEC50 
pIC50 
7.7 
7.6 
7.1 
Table 24:  Affinities of P2Y receptor subtypes for their natural ligands. Affinities for ATP 
and ADP were highlighted with red letters. P2Y2 receptor has the highest affinity 
for  ATP,  this  is  marked  with  grey  background.  Source:  IUPHAR  database 
(www.iuphar.org), July 5
th 2012. 
To test if blockade of any of the ATP receptor found to be expressed on endothelial cells 
has  an  impact  on  platelet-induced  transmigration  of  tumor  cells  through  an  endothelial 
layer, we used specific antagonists against P2Y1 and P2X4 (figure 53 A) and knockdown of 
P2Y1, P2Y2 and P2X4 mRNAs (figure 53 B). Platelet-dependent tumor cell transmigration 
was not influenced by inhibition or knockdown of P2Y1 and P2X4, but knockdown of P2Y2 
mRNA, for which no selective antagonist is available, strongly reduced enhancement of 
tumor cell transmigration by platelets compared to control siRNA-transfected MS1 cells. 
Results are normalized to transmigration of B16 tumor cells alone through a monolayer of 
endothelial cells transfected with control siRNA. 	
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Figure 53:  Platelet-mediated  facilitation  of  tumor  cell  transmigration  involves  P2Y2 
receptors. (A) Effect of the P2X4 receptor antagonist 5-BDBD (1 µM) and of the 
P2Y1  antagonist  MRS2500  (100  nM)  on  platelet-stimulated  transendothelial 
migration of B16 cells (n = 5). (B) Endothelial cells were transfected with control 
siRNA or with siRNAs directed against the mRNAs encoding P2Y1, P2Y2 or P2X4. 
Thereafter,  transmigration  of  B16  cells  was  determined  in  the  absence  or 
presence of platelets (-/+ Plts) (n = 5). Shown are mean values ± S.E.M; *P < 
0.05; **P < 0.01; n.s., not significant. 
Knockdown efficiencies of siRNA against P2Y1 (figure 54 A), P2Y2 (figure 54 B) and P2X4 
(figure 54 C) were determined by qPCR with and normalized to 18S rRNA and H3F3A. 
Efficiencies ranged from roughly 80 % (P2X4) to approximately 90 % (P2Y1). 
 
Figure 54:  Knockdown efficiencies in MS1 cells for siRNAs against P2Y1, P2Y2 or P2X4. 
(A-C) MS1 endothelial cells were transfected with control siRNA or with siRNAs 
directed against the mRNAs encoding P2Y1 (A), P2Y2 (B) or P2X4 (C) in parallel 
to the MS1 cells used for the transmigration experiments shown in figure. After 48 
hours, when the transmigration assay was started, RNA was isolated and qPCR 
performed.  Results  are  normalized  to  18S  rRNA  and  H3F3A  levels  (n  =  4). 
Shown are mean values ± S.D.; ***P < 0.001. 
For the siRNA against P2Y2, functional effects of the knockdown were assessed in a Fluo4-
based  Calcium  assay  (figure  55  A  and  B)  showing  decrease  of  approximately  85  %  in 	
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maximum mobilization of intracellular Calcium upon addition of the specific P2Y2 agonist 
UTP. 
 
 
Figure 55:  Functional analysis of knockdown of P2Y2 mRNA in MS1 cells. (A,B) MS1 
endothelial  cells  were  transfected  with  control  siRNA  or  with  siRNA  directed 
against the mRNA encoding P2Y2 (as in figure and figure). 48 hours later, UTP 
effects (10 µM) on free intracellular [Ca2+]i in Fluo4-loaded cells (n = 5) were 
determined. Graphs of control siRNA-treated (ctrl siRNA) and transfected with 
siRNA  against  P2Y2  mRNA  (siRNA  P2Y2)  are  shown  (A)  and  area  under  the 
curve was calculated for the interval 20 - 50 s (B). Shown are mean values ± 
S.D.; ***P < 0.001. 
The  results  obtained  for  P2Y2  receptor  mRNA  knockdown  in  endothelial  cells  in 
transmigrations assays employing B16 melanoma cells could be confirmed under the same 
conditions  with  transmigrating  LLC1  carcinoma  cells  (figure  56).  The  number  of 
transmigrated LLC1 cells upon addition of platelets was reduced to the level of tumor cell 
transmigration  in  the  absence  of  platelets,  when  endothelial  cells  were  transfected  with 
siRNA against P2Y2. 
 
Figure 56:  Knockdown of P2Y2 receptor mRNA leads to reversal of platelet-enhanced 
tumor cell transmigration. Endothelial cells were transfected with control siRNA 
or  with  siRNA  directed  against  the  mRNA  encoding  P2Y2.  Thereafter, 	
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transmigration  of  LLC1  cells  was  determined  in  the  absence  or  presence  of 
platelets (-/+ Plts) (n = 5). Shown are mean values ± S.E.M***P < 0.001. 
We also determined whether P2Y receptors are expressed in the mouse tumor cell lines 
used in this study, B16 melanoma and LLC1 carcinoma, and did not find any of the seven 
known mouse P2Y receptors expressed (data not shown) on these tumor cell lines. This is 
in accordance with the unresponsiveness of both B16 and LLC1 cells to platelets in the 
transmigration  assay  without  endothelial  monolayer  (figure  37  C  and  data  not  shown) 
despite the fact that high levels of ATP and ADP released from platelets must be present 
(figure 38 C).  
Collectively,  the  in  vitro  data  suggest  that  platelets  are  activated  by  tumor  cells 
(figures 38 C, 42 C, 45 A-C), secrete large amounts of ATP (figures 38 C, 42 C, 45 C) 
which act locally on endothelial P2Y2 receptors (figures 53 B, 56), open endothelial barriers 
(figures  40,  41,  42  D)  and  lead  to  an  increase  in  transmigrated  tumor  cells.  We  next 
investigated whether similar mechanisms cause the major reduction in primary tumor and 
i.v.  metastasis  models  observed  in  Munc13-4-deficient  mice  which  lack  ATP  secretion 
(figure 51). Therefore, we injected a 70’000 kDa FITC-labeled dextran solution one minute 
before tail vein injection of 100’000 B16 melanoma cells in wild-type, Munc13-4 KO and 
P2Y2 KO mice, sacrificed the animals after 3 hours and immediately collected the lungs in 
para-formaldehyde. Immunostaining of the endothelial marker PECAM-1 (CD31) and DAPI 
for visualization of nuclei revealed spots of FITC-dextran in extraluminal sites of wild-type 
lungs injected with FITC-dextran and B16 tumor cells (figure 57 A, quantification in 57 B). 
Leakage of FITC-dextran into the parenchyma was only minimal in wild-type mice that were 
not injected with B16 tumor cells (control condition), Munc13-4 KO and P2Y2 KO lungs, 
suggesting that indeed, wild-type platelets facilitate tumor cell-dependent vascular leakage 
of the lung endothelium and either inhibition of dense granule secretion or deletion of the 
P2Y2 receptor reverses this effect.  	
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Figure 57:  Platelet-mediated  enhancement  of  tumor  cell-dependent  FITC-dextran 
vascular  leakage  in  the  lung  is  abrogated  in  mice  with  defective  ATP 
secretion  and  in  P2Y2  receptor  knockout  mice.  FITC-dextran  (70,000  kDa) 
was injected i.v. 30 s before B16 tumor cells (1x10
5) or buffer into wild-type (WT), 
Munc13-4-deficient (Munc13-4 KO) or P2Y2-deficient (P2Y2 KO) mice. 3 hours 
after injection, lungs were excised and cryosections stained for CD31 (red) or cell 
nuclei (blue). Representative images are displayed in (A), extravasation sites of 
FITC-dextran (FITC-DX; green) are indicated by arrowheads (bar length: 10 µm). 
The bar diagram (B) shows a quantification of extraluminal FITC-positive sites (n 
= 4). Shown are mean values ± S.D; ***P < 0.001. 
To test whether reduced vascular leakage in Munc13-4 KO and P2Y2 KO corresponds to 
less extravasation of tumor cells at early time points after tumor cell injection, we labeled 
B16 tumor cells with CFSE, excised the lungs 6 hours post-injection and analyzed lung 
sections.  We  found  markedly  reduced  numbers  of  extravasating  B16  tumor  cells  in 
Munc13-4 KO and P2Y2 KO lungs compared to wild-type lungs. Extravasating tumor cells 
were  identified  by  protrusions  and  cell  parts  reaching  out  of  the  lumen  (figure  58  A). 
Quantification is shown in figure 58 B. 	
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Figure 58:  Platelet-mediated  facilitation  of  tumor  cell  extravasation  and  metastasis 
involves  ATP  secretion  from  platelets  and  P2Y2  receptors.  (A,B) 
Extravasation of CFSE-labeled B16 cells in the lungs of wild-type (WT), Munc13-
4-deficient (Munc14-3 KO) or P2Y2-deficient (P2Y2 KO) mice 6 hours after i.v.-
injection.  Shown  in  (A)  are representative  images  of  lung  sections stained for 
CD31 (red) or cell nuclei (blue), B16 cells are in green (bar length: 10 µm). The 
numbers of extravasating tumor cells per 10 mm
2 lung area are quantified in (B) 
(n = 9-10). Shown are mean values ± S.D.; ***P < 0.001. 
We next determined whether less vascular permeability of FITC-dextran in P2Y2 KO mice 
and reduced numbers of extravasating tumor cells in these animals a few hours after tumor 
cell  injection  translates  to  less  metastasis  after  12  days  post-injection.    Indeed,  we 
observed strongly reduced formation of pulmonary metastases after tail vein injection of 
B16 melanoma (figure 59 A) and LLC1 carcinoma (figure 59 B) cells in P2Y2 KO mice 
compared  to  wild-type  controls.  The  level  of  reduction  in  metastasis  in  P2Y2  KO  mice 
(figure 59) corresponded to the level of reduction observed in Munc13-4 KO mice (figure 
51),  ranging  between  60-75%.  These  findings  further  support  the  concept  that  ATP 
released by platelets modifies endothelial junctions through P2Y2 receptors and facilitates 
tumor cell passage through the endothelial layer. 	
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Figure 59:  Formation of metastases involves the ATP receptor P2Y2. (A,B) B16 (A) and 
LLC1 cells (B) were injected i.v. in wild-type (WT) and P2Y2-deficient mice (KO), 
and  12  days  later,  lung  metastases  were  analyzed  histologically  (n  =  7-10). 
Shown are mean values ± S.D.; **P < 0.01; ***P < 0.001. 
NK cells lead host defense against circulating tumor cells and have been shown to strongly 
influence metastasis (Nieswandt, Hafner et al. 1999; Palumbo, Talmage et al. 2005). NK 
cell lysis of target cells involves Munc13-4, NK cells lacking Munc13-4 are largely unable to 
lyse target cells in vitro (Crozat, Hoebe et al. 2007). NK cells from Munc13-4 KO mice 
should therefore provide less protection from formation of metastases in these mice and 
rather counteract the lack of platelet dense granule secretion. We assessed the number of 
metastases in wild-type and Munc13-4 KO mice after i.v. injection of B16 melanoma cells 
under NK cell-depleted conditions. Repeated injection of anti-asialo GM1 antibody depleted 
NK  cells  by  more  than  90%  throughout  the  experiment  (figure  60  A).  The  reduction  of 
metastasis in Munc13-4-deficient animals compared to wild-type mice was not influenced 
by NK cell depletion (figure 60 B). A recent publication (Granot, Henke et al. 2011) showed 
an involvement of neutrophil P2Y2 receptor in metastasis of breast cancer cells. In addition, 
it was reported that release of tertiary granules of in vitro differentiated human neutrophils 
was slightly decreased after knock-down of Munc13-4 mRNA (Pivot-Pajot, Varoqueaux et 
al. 2008), so we tested whether depletion of neutrophils in wild-type, Munc13-4 KO and 
P2Y2 KO mice had an impact on the metastasis phenotype observed after B16 melanoma 	
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injection into the tail vein. Using an anti-Ly6G antibody, neutrophils could be depleted by 
roughly 80-90% throughout the experiment (figure 60 C) and formation of metastases in the 
lung  was  still  strongly  reduced  in  both  Munc13-4-deficient  and  P2Y2-deficient  animals 
compared to wild-types (figure 60 D). 
 
 
 
 Figure 60:  Effect of NK-cell depletion and neutrophil depletion on metastasis of B16 
tumor cells in wild-type, Munc13-4-deficient and P2Y2-deficient mice. (A) NK 
cell counts as identified by NK1.1 and CD3e staining in flow cytometry relative to 
granulocyte number before antibody injection and on day 7 and 12 after tumor 	
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cell injection (n = 4-5). (B) Number of lung metastases detected in H/E staining in 
antibody treated wild-type (WT) and Munc13-4-deficient (Munc13-4 KO) mice (n 
=  4-5).  NK  cells  were  depleted  using  repeated  injections  of  anti-asialo  GM1 
antibody.  (C)  Percentage  of  Ly6G-positive  neutrophils  relative  to  granulocyte 
number before antibody injection and on day 5 and 8 after tumor cell injection (n 
= 5). (D) Number of lung metastases detected in H/E staining in antibody treated 
wild-type (WT) Munc13-4-deficient (Munc13-4 KO) and P2Y2-deficient (P2Y2 KO) 
mice (n = 5). Neutrophils were depleted using repeated injections of anti-Ly6G 
antibody. Shown are mean values ± S.D.; **, P < 0.01; ***P < 0.001; n.s., not 
significant. 
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6  Discussion	
 ﾠ
As mentioned in the introduction, many studies in recent decades have revealed a role for 
platelets exceeding their primary function in hemostasis. Considering their ability to secrete 
two  types  of  vesicles,  alpha  and  dense  granules,  packed  with  a  multitude  of  known 
signaling molecules and intercellular mediators, to interact directly with various other cell 
types and even show distinct responses in different milieus despite their lack of a nucleus, it 
is not surprising that evidence is accumulating for a contribution of platelets to such diverse 
pathophysiological outcomes as atherosclerosis and cancer. Since these two diseases are 
the leading causes of death in industrial civilizations and there may be therapeutic potential 
for anti-platelet treatments, we sought to evaluate the role of platelet secretion in mouse 
models for atherosclerosis and cancer. So far, no genetic tool was available in mice that 
lead to a defined secretion defect in platelets while keeping morphology and other platelet 
functions intact. Thus, we first tried to generate and describe mouse lines with an isolated 
secretion defect in platelets. Subsequently, we were able to study the effect of defective 
platelet  dense  granule  secretion  in  LDLR-KO  atherosclerosis  model  and  the  two  tumor 
mouse models on C57/Bl6 background, B16F10 and LLC1. 
6.1  Establishing	
 ﾠa	
 ﾠmouse	
 ﾠline	
 ﾠwith	
 ﾠspecific	
 ﾠplatelet	
 ﾠ
granule	
 ﾠsecretion	
 ﾠdefect	
 ﾠwith	
 ﾠheterologous	
 ﾠtoxin	
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expression	
 ﾠ
SNARE  proteins  are  indispensable  mediators  of  regulated  exocytosis  and  targeting  the 
respective  isoforms  in  a  platelet-specific  manner  seemed  an  obvious  approach  in  our 
attempt  to  generate  mouse  lines  with  a  secretion  defect  in  platelets.  Clostridium  toxins 
represent natural tools to target specific SNARE proteins and make them unavailable for 
fusion events by cleavage at specific sites. It is well established that botulinum toxins and 
tetanus toxin can be efficiently applied to interfere with granule secretion in vitro (Schiavo, 
Matteoli et al. 2000) and it has been shown that expression of tetanus toxin in Sertoli cells 
leads  to  severe  impairment  of  spermatogenesis  (Eisel,  Reynolds  et  al.  1993)  or  to 
suppression of glutamatergic signaling in cerebellar granule cells (Yamamoto, Wada et al. 
2003) in vivo. The level of cleavage of the respective SNARE family member had to be 
substantial, especially when other proteins may be able to compensate the loss of one 
isoform. In our transgenic constructs, compensatory action was conceivable after BoNT-C 
cleavage of syntaxin-2 in mouse platelets, which could be replaced by syntaxin-4 in fusion 
events or TeNT cleavage of VAMP-3, where VAMP-8 could compensate, although these 
two VAMP isoforms present in mouse platelets seem to have a more specialized function 
(Ren, Ye et al. 2008). The PF4 promotor seemed to be a suitable driver of toxin expression 
in platelets since it is a platelet-specific protein and is highly abundant in platelet alpha 
granules (Brandt, Petersen et al. 2000; Blair and Flaumenhaft 2009). Still, it is conceivable 
that  important  regulatory  domains  lying  further  upstream  or  downstream  than  the  area 	
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covered  by  the  PF4  gene-carrying  BAC  used  in  this  study  (approximately  100,000  bp 
upstream and downstream of the PF4 gene) were missing in our constructs. There are 
occasional reports of regulatory elements lying more than 100,000 bp apart from the gene 
they  control  (Yuasa,  Takeda  et  al.  2012).  Another  critical  parameter  for  efficient 
transcription into mRNA is organism-specific codon usage (Gustafsson, Govindarajan et al. 
2004). We had the Clostridial sequences of BoNT-C and -E optimized for Mus musculus 
codon usage, potential splice sites removed and synthetized by experts (Entelechon). It 
was thus unexpected that even after repeated injection of the thoroughly verified constructs 
into  mouse  oocytes,  the  best  reduction  of  the  respective  SNARE  protein  in  transgenic 
founder animals of the PF4-BoNT-C line was approximately 40% of wild-type syntaxin-2 
levels; in the PF4-BoNT-E line, it was approximately 60% of wild-type SNAP-23 levels and 
cleavage of VAMP-3 by PF4-TeNT constructs was uncertain. These results from Western 
blot analysis of isolated platelets were not promising with regard to functional defects in 
platelet granule release. The mouse line with the best potential for functional impact on 
platelet release was the PF4-BoNT-E line with a maximum of 40% of SNAP-23 cleaved 
since SNAP-23 is the only SNAP isoform described in platelets (Flaumenhaft, Croce et al. 
1999).  However,  none  of  the  founder  mice  and  their  offspring,  even  after  breeding 
homozygous  mice  and  double-transgene-positives  for  PF4-BoNT-C  and  PF4-BoNT-E, 
showed impaired platelet function as determined by aggregometry, P-selectin exposure in 
flow  cytometry  and  flow  chamber  assays.  One  group  (Foran,  Mohammed  et  al.  2003) 
observed that BoNT-A caused a complete abrogation of neuromuscular transmission but 
only cleaved 6% of SNAP-25 in nerve endings. They hypothesized that the toxin specifically 
cleaves  a  subpopulation  of  SNAP-25  in  the  active  zone  directly  involved  in  transmitter 
release. Another report (Meunier, Lisk et al. 2003) found only 11.7% cleavage of SNAP-25 
by BoNT-E and 6.5% cleavage by BoNT-A in completely paralyzed muscles mediating the 
toe spread reflex after minimal dose hind leg injection of the toxins in mice. In contrast to 
our mouse lines which only expressed the light chain capable of SNARE cleavage but not 
of entering a cell, these authors used the full-length toxin. Maybe the full-length toxin is 
capable  not  only  to  bind  to  membrane  receptors  and  mediate  its  own  uptake  into  the 
endocyctotic pathway (Schiavo, Matteoli et al. 2000) but also to relocate to the active zone 
and recognize a subset of its target SNARE protein which is activated and ready to mediate 
granule fusion. This ability may be lost when the heavy chain is not present or secondary 
structure is affected when only the light chain is translated.  
6.2  Establishing	
 ﾠa	
 ﾠmouse	
 ﾠline	
 ﾠwith	
 ﾠspecific	
 ﾠplatelet	
 ﾠ
granule	
 ﾠsecretion	
 ﾠdefect	
 ﾠwith	
 ﾠexpression	
 ﾠof	
 ﾠ
dominant-ﾭ‐negative	
 ﾠSNAP-ﾭ‐23	
 ﾠmutants	
 ﾠ
With the two dominant-negative constructs, one lacking the last eight amino acids of SNAP-
23  and  one  with  three  alanine  mutations  at  important  positions  for  interaction  with  the 
exocytotic SNARE complex, we sought to overcome the problems encountered with the 	
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toxin constructs. We amplified SNAP-23 cDNA from freshly isolated primary mouse RNA 
and  optimized  expression  with  the  insertion  of  two  short  introns  known  to  increase 
expression (Lacy-Hulbert, Thomas et al. 2001) in vivo. We added a triple myc tag to be able 
to trace expression of the construct. However, as experienced with the toxin constructs 
discussed earlier, our results suggest that the level of expression of the dominant-negative 
constructs  was  too  low  to  cause  functional  defects  in  exocytosis.  The  constructs  were 
carefully checked for integrity and correct sequence and expression of the construct in vivo 
could  be  confirmed  at  least  for  the  PF4-SNAP-23  Ala  construct,  albeit  at  low  levels 
compared to endogenous SNAP-23 protein levels. A possible explanation for the failure of 
the three toxin and the two SNAP-23 constructs could be the backbone sequence they 
have  in  common:  the  PF4  BAC  RP24-98A4.  This  BAC  seemed  to  be  the  best  choice 
available since it is the only commercially available BAC that covers large areas upstream 
and downstream of the PF4 gene, but again, as mentioned in section 4.1, it  is  always 
possible that important regulatory sequences were missing. 
6.3  Analysis	
 ﾠof	
 ﾠthe	
 ﾠJinx	
 ﾠmouse	
 ﾠline,	
 ﾠa	
 ﾠgenetically	
 ﾠ
modified	
 ﾠnull-ﾭ‐mutant	
 ﾠof	
 ﾠthe	
 ﾠMunc13-ﾭ‐4	
 ﾠgene	
 ﾠ
6.3.1  Basal	
 ﾠanalysis	
 ﾠ	
 ﾠ
Our Western blot analysis of Munc13-4 levels in platelets isolated from Unc13d
Jinx mice 
showed no detectable Munc13-4 protein, which corresponds well with the in silico prediction 
that the premature stop codon caused by the Jinx mutation leads to an unstable mRNA 
product and subsequent decay (Crozat, Hoebe et al. 2007). Loss of the Munc13 isoforms 
has been shown to cause severe defects in vesicle release in many secretory cell types. 
Lack  of  Munc13-1  causes  abrogation  of  vesicle  release  in  glutamatergic  hippocampal 
neurons (Augustin, Rosenmund et al. 1999), mice deficient for the mainly cerebellar isoform 
Munc13-3  are  unable  to  learn  complex  motor    tasks  due  to  impairment  in  signaling  in 
parallel fiber-Purkinje cell synapses (Augustin, Korte et al. 2001). Insulin secretion from 
mouse pancreatic beta cells deficient in Munc13-1 is reduced, causing glucose intolerance 
(Kwan, Xie et al. 2007). Mutations in the Munc13-4 gene in humans are associated with 
type  3  Familial  hemophagocytic  lymphohisiocytosis  (FHL3)  which  is  caused  by  severe 
defects  in  exocytosis  of  lytic  granules  of  lymphocytes.  Crozat  et  al.  show  that  the  Jinx 
mutation leads to severe impairment of NK cells to lyse target cells (Crozat, Hoebe et al. 
2007). We found Munc13-4 to be the only Munc13 isoform expressed in platelets and thus 
hypothezised that loss of Munc13-4 would interfere with granule secretion without affecting 
other platelet functions or morphology. Accordingly, we detected normal platelet numbers 
and normal levels of the platelet surface receptors GPIb, GPV, GPVI, GPIX, integrin α2, 
integrin β1, integrin αIIbβ3. CD9 levels were approximately 15% lower in Munc13-4 KO 
platelets  compared  to  wild-type  platelets  and  surface  CLEC-2  was  reduced  by 
approximately 35%. Activation of integrin αIIbβ3 is termed the “final common pathway” of 	
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platelet activation (Nieswandt, Varga-Szabo et al. 2009). Agonist stimulation results in PLC 
activation and formation of IP3 and DAG, which leads to a rise in intracellular calcium levels 
and in the end, triggers the switch of a “low-affinity state” of integrin αIIbβ3 to a “high-affinity 
state”. Therefore, the level of integrin αIIbβ3 in active conformation of agonist-stimulated 
platelets  is  a  cumulative  measure  of  several  signaling  cascades  in  platelets  including 
activation by agonists, efficient intracellular signal transduction and efficient modification of 
integrin αIIbβ3 itself. It also predicts the efficiency of integrin αIIbβ3 to bind to its ligand 
fibrinogen,  which  influences  platelet  aggregation  and  further  “outside-in”  signaling  of 
integrin αIIbβ3 to stabilize aggregates. We saw a roughly 20% reduction in active integrin 
αIIbβ3  in  Munc13-4-deficient  platelets  with  all  agonists  tested  (thrombin,  ADP,  U46619, 
CRP  and  rhodocytin)  but  only  with  the  snake  venom  rhodocytin,  this  difference  was 
statistically  significant.  This  slight  reduction  may  be  secondary  to  the  dense  granule 
secretion defect found in these platelets since the lack of ADP as a secondary mediator of 
autocrine and paracrine positive feedback loops certainly influences overall activation of 
platelets, even if they are diluted 1:100 in flow cytometry compared to aggregation assays. 
The fact that in high concentrations of the strong platelet agonist thrombin, the difference in 
integrin  αIIbβ3  activation  in  Munc13-4  KO  platelets  and  wild-type  platelets  no  longer 
observed, also supports this notion.  
We chose the two functionally important alpha granule proteins PF4 and vWF as 
representative markers of alpha granule release. The platelet-specific chemokine PF4 and 
the  adhesive  molecule  vWF  are  synthetized  in  megakaryocytes  during  thrombopoiesis 
(Harrison and Cramer 1993) and contribute to hemostatic as well as pathophysiological 
functions of platelets (Terraube, Marx et al. 2007; Kasper and Petersen 2011; Nieswandt, 
Pleines et al. 2011). There was no difference in PF4 or vWF secretion between Munc13-4 
KO  platelets  and  wild-type  platelets  in  response  to  low,  intermediate  and  high 
concentrations of thrombin. The small, but not significant decrease in PF4 release after 
stimulation  with  low-dose  thrombin  could  be  reversed  by  the  addition  of  a  selective 
antagonist against P2Y12 receptor (data not shown), indicating that this difference is caused 
by a lack of ADP secretion from dense granules in Munc13-4-deficient platelets. U46619 
and collagen only evoked minor release of PF4 under the conditions assessed here and 
there was no difference between Munc13-4 KO and wild-type platelets (data not shown). 
Another common marker of platelet granule release is exposure of P-selectin on the surface 
of activated platelets. P-selectin is absent from the outer membranes of resting platelets 
and  can  be  found  associated  with  membranes  of  alpha  and  dense  granules  (Israels, 
Gerrard et al. 1992; Youssefian, Masse et al. 1997). Upon granule fusion, P-selectin is 
integrated into the outer membrane and mediates interaction with leukocytes in hemostasis 
but is also involved in atherogenesis and neointima formation (Smyth, McEver et al. 2009). 
We observed a reduction of 20-40% in P-selectin exposure on the surface of Munc13-4-
deficient  platelets  compared  to  wild-type  platelets  upon  stimulation  with  thrombin,  ADP, 
U46619,  CRP  or  rhodocytin,  not  always  statistically  significant  but  reproducible.  It  is 	
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currently unknown how much of total P-selectin is found associated with dense granule 
membranes and it is technically challenging to obtain reliable results. The total number of 
dense granules per platelet is also hard to determine in electron microscopy (White 2008) 
but is estimated to be approximately 10 times lower than the number of alpha granules per 
platelet  (Holmsen  and  Weiss  1979).  On  the  other  hand,  upon  maximal  stimulation  with 
thrombin, up to 90% of platelet dense granules are released but only about 60% of alpha 
granules  (Ren,  Barber  et  al.  2007).  The  observed  reduction  of  surface  P-selectin  in 
Munc13-4 KO platelets could thus be caused by the portion of P-selectin associated with 
dense granules that are not released in Munc13-4 KO platelets or by a subpopulation of 
alpha granules containing P-selectin, but not PF4 or vWF, which is released in a Munc13-4-
dependent manner. 
In contrast to alpha granule secretion, we found no detectable ATP secretion from 
dense  granules  of  isolated  Munc13-4-deficient  platelets  upon  stimulation  with  thrombin, 
U46619 or collagen, suggesting that platelet dense granule release in these platelets is 
completely abrogated. To our knowledge, this is the first genetically modified mouse line 
with  a  specific  dense  granule  secretion  defect  without  affecting  granule  formation  or 
contents.  
The ability of washed Munc13-4 KO platelets to adhere to collagen, which mainly 
requires binding of platelet GPVI receptor (Nieswandt, Pleines et al. 2011), is unaltered, 
whereas in the more complex setting of the flow chamber assay, Munc13-4 platelets can 
form smaller aggregates but fail to produce stable, large, three-dimensional structures as 
observed for wild-type platelets. Under high shear stress as in the flow chamber (1000
-s), 
initial contact with collagen is mainly mediated by interaction of the GPIb-V-IX complex with 
collagen-bound  vWF,  subsequent  binding  of  GPVI  together  with  its  non-covalently 
associated  co-receptor  FcR  γ-chain  activates  platelets,  leads  to  secretion  of  secondary 
mediators like ADP, recruitment of more platelets and leukocytes into the thrombus. Binding 
of integrins to vWF and fibrinogen and less well-defined mediators like CLEC-2, Gas6 and 
CD40L support bridging between platelets (Nieswandt, Pleines et al. 2011). The lack of 
large, three-dimensional aggregates in Munc13-4 KO platelets in flow chamber assays is 
probably  due  to  reduced  numbers  of  platelets  recruited  through  local  ADP  secretion  to 
already activated and collagen-bound platelets. Blood flow is very fast at a shear rate of 
1000
-s and platelets only have the length of a coverslip to get in contact with collagen or 
secondary mediators, decelerate and attach to collagen or other platelets. This may require 
very efficient signal amplification and a loss of ADP as autocrine and paracrine messenger 
cannot  be  compensated.  This  notion  is  supported  by  reports  showing  that  blocking  the 
platelet  ADP  receptors  leads  to  impaired  aggregation  in  vitro  (Hechler,  Cattaneo  et  al. 
2005). Serotonin (Nishihira, Yamashita et al. 2006), polyphosphates (Ruiz, Lea et al. 2004; 
Smith, Mutch et al. 2006) and calcium (Rendu, Brohard-Bohn 2001) released from platelet 
dense granules may play supportive roles in aggregate and thrombus stabilization. 	
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Secondary  mediators,  mainly  ADP  and  thromboxane  A2,  influence  platelet 
aggregation in response to weak agonists. Aggregometry is used routinely as a diagnostic 
tool for human platelet disorders. Storage pool disorders of dense granules are rare but 
patients with Hermansky Pudlak syndrome or Chediak Higashi syndrome mostly have intact 
alpha granule content and function but reduced amounts of dense granules and reduced 
nucleotide  levels.  Aggregation  responses  of  platelet-rich  plasma  of  patients  with  these 
syndromes in response to collagen are usually decreased (Kottke-Marchant and Corcoran 
2002), and in response to thromboxane analogues show reduced maximum aggregation 
levels (Weiss and Lages 1988). We found delayed and decreased plateau levels of platelet 
aggregation in platelets isolated from Munc13-4 KO mice compared to wild-type platelets in 
response to collagen and reduced maximal aggregation in these platelets upon stimulation 
with U46619. These findings maybe show a more pronounced defect in Munc13-4-deficient 
platelets but in general correspond well to the clinical data on patients with dense granule 
storage pool diseases and defects in dense granule secretion. In the storage pool diseases 
described so far, ADP secretion from dense granules is only strongly decreased (Kottke-
Marchant and Corcoran 2002), so the consequences of a complete shutdown of dense 
granule secretion as observed for Munc13-4 KO mice are expected to be more severe. 
The lack of stable, large aggregates found in flow chamber assay and the impaired 
aggregation responses of Munc13-4 KO platelets have dramatic correlates in these mice in 
tail bleeding and ferric chloride thrombosis models in vivo. Tail bleeding in Munc13-4 KO 
has to be stopped by outside intervention to prevent critical loss of blood in Munc13-4 KO 
animals. Some small, mural thrombi are formed in Munc13-4 KO mice when mesenteric 
arteries are denuded with ferric chloride, but no larger aggregates build up and eventually 
occlude the vessel as seen after approximately 10 min in wild-type animals. These results 
correlate well with the observation that mice lacking Hermansky-Pudlak syndrome 3 (HPS3) 
gene,  which  have  impaired  platelet  dense-granule  secretion  due  to  defects  in  dense 
granule  biogenesis  (Novak,  Sweet  et  al.  1988;  Suzuki,  Li  et  al.  2001),  have  negligible 
reduction of arterial blood flow after treatment with ferric chloride (King, McNamee et al. 
2009). In another mouse model of Hermansky Pudlak syndrome, ruby eye mice, animals 
were shown to have strongly diminished amounts of aggregate formation after laser injury 
of  cremaster  arterioles  (Graham,  Ren  et  al.  2009),  a  model  which  depends  more  on 
formation of thrombin than exposure of ECM (Sachs and Nieswandt 2007). Blocking P2Y 
receptors  is  sufficient  to  inhibit  thrombus  formation  in  vivo  (Oury,  Toth-Zsamboki  et  al. 
2006)  and  in  clinical  applications  (Secco,  G.  G.,  R.  Parisi,  et  al.  2012),  lack  of  ADP 
secretion  in  Munc13-4-deficient  animals  is  thus  probably  the  major  factor  causing  the 
protection from thrombosis in these mice. As in aggregate formation under flow, addiotional 
lack of serotonin, polyphosphates and calcium may further contribute to the inhibition of 
thrombus formation in Munc13-4 KO mice. 
In  summary,  our  basal  analysis  of  Munc13-4-deficient  platelet  function  reveals  a 
selective abrogation of dense granule secretion, while morphology, platelet count, granule 	
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constituents  and  basal  surface  glycoprotein  receptor  levels  as  well  as  alpha  granule 
secretion are intact. The lack of dense granule secretion leads to severe phenotypes in tail 
bleeding and thrombosis models, emphasizing the contribution of dense granule contents, 
mainly secondary activation of platelets via ADP, to these pathophysiological conditions. 
Our results are largely confirmed by a report from Ren et al. describing platelet responses 
of the same mouse line (Unc13d
Jinx) with regard to morphology, platelet count, activation, 
level of granule contents, and, importantly, complete lack of dense granule secretion (Ren, 
Wimmer et al. 2010).  
6.3.2  Applying	
 ﾠMunc13-ﾭ‐4	
 ﾠKO	
 ﾠmice	
 ﾠto	
 ﾠstudy	
 ﾠthe	
 ﾠimpact	
 ﾠof	
 ﾠdense	
 ﾠ
granule	
 ﾠsecretion	
 ﾠon	
 ﾠthe	
 ﾠprogression	
 ﾠof	
 ﾠatherosclerosis	
 ﾠin	
 ﾠa	
 ﾠ
mouse	
 ﾠmodel	
 ﾠ
A previous report showing reduced atherosclerotic plaque formation in mice with a strong 
reduction  in  dense  granule  formation  during  thrombopoiesis  (Graham,  Ren  et  al.  2009) 
could not be confirmed in this study in two independent experiments with LDL receptor 
knockout mice transplanted with Munc13-4-deficient or wild-type bone marrow. LDLR KO 
mice are prone to develop atherosclerotic lesions after being exposed to high blood levels 
of  fat  and  cholesterol  and  are  one  of  two  well-established  murine  models  for 
atherosclerosis. There was no difference in aortic plaque formation after 16 weeks of high 
fat, high cholesterol diet in LDLR KO mice reconstituted with Munc13-4-deficient or wild-
type bone marrow.  
Several molecules released from platelet dense granules have been implicated in 
inflammation and atherogenesis. Dense-granule-derived polyphosphates have been shown 
to  upregulate  bradykinin  production,  which  in  turn  stimulates  the  generation  of  the  pro-
inflammatory cytokines IL1β and TNFα (Muller, Mutch et al. 2009). The protein 14-3-3ζ was 
identified in dense granules from human platelets with a proteomics approach and shown to 
be present in atherosclerotic plaques from patients’ samples with aneurysms (Hernandez-
Ruiz, Valverde et al. 2007). Serotonin has mitogenic effects on endothelial cells (Pakala, 
Willerson et al. 1994) and smooth muscle cells (Hodivala-Dilke, McHugh et al. 1999) in vitro 
and could contribute to the proliferation of these cell types characteristic for atherosclerotic 
plaque  formation  in  vivo.  In  summary,  there  is  some  indirect  evidence  that  molecules 
released from dense granules could be involved in atherogenesis but the contributions of 
alpha granule proteins like PF4, RANTES, CD40L are much more well-established. It is 
thus not surprising that we do not see a reduction of plaque formation in LDLR KO mice 
lacking platelet dense granule secretion but with largely normal alpha granule secretion. 
6.3.3  Studying	
 ﾠthe	
 ﾠrole	
 ﾠof	
 ﾠplatelet	
 ﾠdense	
 ﾠgranule	
 ﾠsecretion	
 ﾠin	
 ﾠ
tumor	
 ﾠmetastasis	
 ﾠwith	
 ﾠMunc13-ﾭ‐4-ﾭ‐deficient	
 ﾠmice	
 ﾠ
Platelets have been shown to be associated with tumor cells early after vascular arrest 
(Crissman, Hatfield et al. 1988; Im, Fu et al. 2004) and to be able to closely interact with 	
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tumor cells (Nieswandt, Hafner et al. 1999; Borsig, Wong et al. 2001). Together with the 
observation that chemical or genetic depletion of platelets strongly suppresses metastasis 
in  mouse  models  (Pearlstein,  Ambrogio  et  al.  1984;  Camerer,  Qazi  et  al.  2004),  we 
hypothesized that platelets could influence the important step after vascular arrest of tumor 
cells in the metastatic cascade, leaving the circulation through extravasation to reach the 
organ  parenchyma.  The  first  barrier  for  tumor  cells  to  overcome  in  extravasation  is  the 
endothelial layer. Transmigration assays represent a simplified and well-controlled in vitro 
model for this step, so we investigated the impact of platelets on the ability of tumor cells to 
transmigrate  through  an  endothelial  layer.  We  found  a  2-4-fold  increase  in  tumor  cell 
transmigration upon the addition of platelets, depending on the tumor cell line used. These 
results are consistent with studies describing a supporting role of platelets in diapedesis of 
neutrophils (Lam, Burns et al. 2011; Badrnya, Butler et al. 2012) and monocytes (da Costa 
Martins, van Gils et al. 2006; van Gils, Zwaginga et al. 2009)  in vitro and in vivo. It is 
conceivable that platelets facilitate direct contact of tumor cells through their multitude of 
surface receptors known to interact with endothelial cells and many other cell types (Stokes 
and  Granger  2012)  and  also  tumor  cells  (Jain,  Harris  et  al.  2010;  Gay  and  Felding-
Habermann 2011), or that secondary to their ability to connect directly with tumor cells, they 
become activated and release mediators that influence tumor cells or endothelial cells. We 
found that the enhancement of tumor cells transmigration was strictly dependent on the 
presence of endothelial cells. Since tumor cells are very heterogeneous in many of their 
properties, this may be different in other cell lines, but none of the two mouse or the two 
human tumor cell lines tested here showed an increase in basal tumor cell transmigration in 
the presence of platelets or supernatants from resting platelets. We could show that tumor 
cell-stimulated  supernatants  of  platelets  were  sufficient  to  induce  the  platelet-mediated 
fraction of tumor cell transendothelial migration and that apyrase, an enzyme, which quickly 
dephosphorylates ATP and ADP, was able to block this effect completely, suggesting that 
nucleotides  secreted  from  activated  platelets  enable  tumor  cells  to  transmigrate  more 
efficiently.  This  was  confirmed  by  applying  Munc13-4-deficient  platelets,  which  lack 
nucleotide secretion, to the transmigration assay, as here again, the enhancing effects of 
wild-type  platelets  on  tumor  cell  transmigration  through  an  endothelial  layer  were 
completely  inhibited.  Wild-type  platelets  showed  a  strong,  tumor  cell-induced  ATP 
secretion, an effect, which also abrogated in Munc13-4 KO platelets. At the same time, we 
could show that the ability of Munc13-4 KO platelets to attach to tumor cells or the ability of 
tumor cells to elicit alpha granule secretion in these platelets was normal. These unique 
properties make Munc13-4-deficient mice an ideal tool to investigate whether nucleotide 
secretion from platelets plays a role in metastatic events in vivo. Indeed, we saw a strong 
reduction in formation of metastases in the lungs of Munc13-4 KO animals compared to 
wild-type mice in the two homotypic tumor models available for C57/Bl6 background, B16 
melanoma and LLC1 lung carcinoma. The reduction in metastasis was also observed upon 
i.v.  injection  of  B16  and  LLC1  cells  and  the  size  distribution  of  metastases  showed 	
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reduction in metastases of all sizes in Munc13-4-deficient animals, implying that this effect 
is independent of a primary tumor and growth of metastases is not affected. This notion, at 
least for larger, structured metastases, is supported by the fact that analysis of primary 
tumors showed no signs of leakage or gross differences in tumor structure in H/E staining 
(data not shown) or abnormal angiogenesis in Munc13-4 KO animals. These data indicate 
that  release  of  nucleotides  from  platelets  promotes  tumor  cell  metastasis  in  vivo  and 
provide a possible mechanism for observations that the metastatic potential of tumor cells 
correlates with their ability to activate platelets (Pearlstein, Salk et al. 1980; Camerer, Qazi 
et al. 2004). To elucidate the down-stream signaling pathways mediating this effect, we 
studied the impact of tumor cells in combination with platelets on endothelial morphology 
and  permeability  and  saw  a  nucleotide-dependent  disruption  of  endothelial  barriers  and 
parallel  increase  in  endothelial  permeability,  confirming  that  nucleotides  released  from 
tumor cell-stimulated platelets act on endothelial receptors, facilitating tumor cell passage. 
Of the seven known metabotropic and seven ionotropic nucleotide receptors in mice, we 
found predominant expression of the UTP/ATP receptor P2Y2 and the ion-channel P2X4 in 
mouse endothelial cells. This corresponds to the fact that addition of exogenous ATP alone 
was sufficient to increase tumor cell transmigration through an endothelial layer, since P2Y2 
is the P2Y-type receptor with the highest affinity to ATP (Lazarowski, Watt et al. 1995; Kim, 
Ravi  et  al.  2002).  Blockade  and  knockdown  of  P2X4  in  endothelial  cells  prior  to 
transmigration  did  not  influence  platelet-facilitated  transmigration  of  tumor  cells,  but 
knockdown of P2Y2, for which no selective antagonist is available, prevented this effect in 
transmigration of both B16 and LLC1 cells. These data indicate that ATP secreted from 
platelets  in  large  amounts  upon  stimulation  by  tumor  cells  binds  to  endothelial  P2Y2 
receptors to facilitate tumor cell transmigration and is in line with a report demonstrating 
that  endothelial  P2Y2  receptor  mediates  neutrophil  transendothelial  migration  (Kukulski, 
Ben Yebdri et al. 2010). The downstream effects of P2Y2 activation are rise of intracellular 
calcium  through  coupling  to  G-proteins  Gq/G11  (Abbracchio,  Burnstock  et  al.  2006)  and 
activation of protein kinase C, which has been shown to destabilize the endothelial barrier 
(Gavard  and  Gutkind  2008;  Knezevic,  Tauseef  et  al.  2009;  Korhonen,  Fisslthaler  et  al. 
2009),  specifically  by  disassembling  VE-cadherin  adherens  junction,  which  leads  to  an 
increase  endothelial  permeability  (Tiruppathi,  Ahmmed  et  al.  2006;  Vandenbroucke  St 
Amant, Tauseef et al. 2012). Our finding that P2Y2 is the major ATP receptor in this context 
is supported by a study showing that selective agonists and antagonists of P2X receptors 
could not reproduce or block the intracellular effects of ATP on HUVECs but the selective 
P2Y2 agonist UTP evoked intracellular calcium mobilization with similar EC50 values as ATP 
and knockdown of P2Y2 blunted calcium responses (Raqeeb, Sheng et al. 2011). Another 
pathway  induced  by  endothelial  P2Y2  shown  to  contribute  to  melanoma  metastasis  is 
activation of vascular endothelial growth factor receptor-2 (VEGFR-2/KDR/Flk-1) through 
rapid tyrosine phosphorylation (Seye, Yu et al. 2003; Seye, Yu et al. 2004) and subsequent 	
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upregulation of vascular cell adhesion molecule-1 (VCAM-1) (Vidal-Vanaclocha, Fantuzzi et 
al. 2000; Langley, Carlisle et al. 2001; Seye, Yu et al. 2004).  
In the in vivo situation, we could show that tumor cells injected i.v. increase endothelial 
permeability in the lung at one to approximately three hours after injection and that this 
increase is mediated by platelet nucleotides and P2Y2 receptors, since Munc13-4 KO and 
P2Y2 KO mice showed almost no vascular leakage under these conditions. Less vascular 
leakage  translated  to  lower  numbers  of  extravasating  tumor  cells  in  these  animals 
compared to wild-type controls six hours after tumor cell injection, implying that the strong 
reduction  in  metastases  observed  in  the  lungs  of  Munc13-4  KO  animals  12  days  after 
injection  is  caused  by  a  lower  number  of  tumor  cells  that  pave  their  way  through  the 
endothelial layer to the organ parenchyma. Consequently, P2Y2 KO animals also showed a 
strong decrease in metastases in the lung after i.v. injection of B16 melanoma or LLC1 
carcinoma cells, confirming the concept established in this study.  
In summary, these results suggest that in accordance with the in vitro data, tumor cells 
locally activate platelets, platelets subsequently secrete high amounts of ATP which bind to 
the  endothelial  P2Y2  receptor,  destabilize  endothelial  barriers  and  thus  allow  a  more 
efficient extravasation of tumor cells into the target organ parenchyma. Figure 61 shows a 
model describing this mechanism. 
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Figure 61:  Model of platelet-mediated facilitation of tumor cell transmigration. Tumor 
cells (TC) activate platelets, which in turn secrete ATP from dense granules. ATP 
binds  to  platelet  P2Y  receptors  to  induce  autocrine  and  paracrine  positive 
feedback  loops  and  to  endothelial  ATP  receptor  P2Y2.  This  destabilizes 
endothelial barriers and thus allows tumor cells to transmigrate more efficiently. 
This  mechanism  represents  a  promising  target  for  anti-metastatic  therapies  avoiding 
bleeding  complications  that  arise  from  application  of  classical  anti-platelet  drugs 
(Erpenbeck and Schon 2010; Gay and Felding-Habermann 2011) and proves that platelets 
are major players in the metastatic cascade.  The benefits of low-dose aspirin, which is 
sufficient to inhibit platelet function, in the prevention of metastatic events was pointed out 
in a recent post-hoc analysis of large randomized cardiovascular trials (Rothwell, Wilson et 
al.  2012).  We  hereby  provide  evidence  for  a  new  downstream  mechanism  in  platelet-
mediated tumor metastasis besides evasion of NK cell lysis in the circulation (Nieswandt, 
Hafner  et  al.  1999;  Palumbo,  Talmage  et  al.  2005)  and  release  of  mitogenic  (Labelle, 
Begum  et  al.  2011)  or  angiogenic  factors  (Boucharaba,  Serre  et  al.  2004;  Italiano, 
Richardson et al. 2008). Targeting endothelial P2Y2 receptor to inhibit nucleotide signaling 
from  tumor  cell-activated  platelets  may  be  a  successful  approach  to  prevent  tumor  cell 
metastasis and avoiding side effects of anti-platelet drugs. 
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7  Summary	
 ﾠ
7.1	
 ﾠ Introduction	
 ﾠ
The involvement of platelets in various diseases has been increasingly recognized in the 
recent decades. This contribution is believed to involve platelet secretion and formation of 
reactive microparticles. Platelets contain two functionally important forms of vesicles, alpha 
and  dense  granules,  which  are  secreted  upon  activation  of  platelets.  Alpha  granules 
incorporate  larger  molecules  such  as  adhesive  proteins,  e.g.  P-selectin,  vWF  and 
fibrinogen; chemokines like PF4 and RANTES and growth hormones like VEGF and PDGF 
are  among  the  most  important  proteins  attributed  to  the  involvement  of  platelets  in 
pathological conditions. In contrast, dense granules contain small molecules like ADP, ATP, 
serotonin and histamine, and they are more rapidly and completely secreted than alpha 
granules.  Like  in  all  secreting  cells,  regulated  exocytosis  in  platelets  is  mediated  by 
“zippering” of three different classes of SNARE proteins. The subtypes of these proteins 
found to be involved in platelet secretion are SNAP-23, syntaxin-2 and -4 and VAMP-3 and 
-8. Apart from SNARE proteins, other conserved proteins influencing exocytosis by e.g. 
acting on SNARE proteins have been described, one of the most important ones being 
Munc13.  
Platelets  contribute  to  the  progression  of  atherosclerosis  by  local  deposition  of 
inflammatory mediators like PF4, RANTES and CD40L, which leads to enhanced leukocyte 
recruitment  and  plaque  formation.  In  1865,  Armand  Trousseau  first  described  the 
correlation between cancer and thrombotic events. Since the 1960s, an increasing number 
of  studies  have  found  an  involvement  of  platelets  also  in  the  progression  of  cancer, 
especially in the formation of metastases. Platelets bind to circulating tumor cells and may 
shield  them  from  NK  cell  attacks  and  shear  stress.  Platelets  may  also  facilitate  the 
interaction of tumor cells with other cell types and the vessel wall. Lastly, they may secrete 
molecules that influence the tumor cell phenotype and invasiveness. 
7.2	
 ﾠ Aims	
 ﾠof	
 ﾠthis	
 ﾠstudy	
 ﾠ
We  sought  to  generate  and  describe  genetically  modified  mouse  lines  with  defective 
platelet secretion and to employ these mouse lines in murine models of atherosclerosis and 
tumor  progression  to  study  the  role  of  platelet  secretion  under  pathological  in  vivo 
conditions. 
7.3	
 ﾠ Results	
 ﾠ	
 ﾠ
Clostridial toxins cleave members of the SNARE protein family and can thus completely 
block exocytosis of neuronal and other cells. We generated three transgenic mouse lines 
expressing tetanus, botulinum-E or -C light chains and two transgenic mouse lines with 
dominant-negative  mutations  of  SNAP-23  under  the  control  of  the  platelet-specific  PF4 
promotor. None of these constructs was able to interfere with platelet secretion despite 
expression of the transgene. 	
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A functional null mutant of the only Munc13 isoform expressed in platelets, Munc13-
4,  showed  complete  lack  of  dense  granule  secretion,  measured  by  ATP  release,  while 
alpha  granule  release  as  determined  by  PF4  and  vWF  secretion,  was  unaltered. 
Morphology, composition and adhesion of these platelets were also normal. Aggregation in 
response  to  U46619  and  collagen  and  formation  of  large  aggregates  in  flow  chamber 
assays was attenuated. Munc13-4-deficient mice showed a severe defect in bleeding time 
and no formation of stable aggregates in FeCl3 thrombosis model. 
In response to B16 melanoma and LLC1 carcinoma cells, Munc13-4 KO platelets 
also  showed  complete  abrogation  of  dense  granule  secretion,  whereas  alpha  granule 
secretion and binding of platelets to tumor cells was unchanged. Interestingly, wild-type 
platelets, but not Munc13-4 KO platelets, enhanced transmigration of B16 and LLC1 cells 
through an endothelial cell layer. Exogenous ATP was able to mimic the effect of wild-type 
platelets  and  the  ATP-degrading  enzyme  apyrase  blocked  platelet-mediated  tumor  cell 
transmigration. Platelets incubated with tumor cells secreted large amounts of ATP. Murine 
endothelial cells showed perturbed adherens junctions identified by irregular VE-cadherin 
staining  and  gap  formation  when  incubated  with  supernatants  from  tumor  cell-activated 
platelets as well as increased permeability under the same conditions. Addition of apyrase 
preserved normal endothelial morphology and function. In vivo, primary tumor growth and 
weight  was  comparable  in  wild-type  and  Munc13-4  KO  mice  upon  B16  or  LLC1  flank 
injection but formation of lung metastases was strongly reduced. Number, but not size of 
metastases was also reduced upon i.v. injection of B16 and LLC1 cells. We found P2Y2 and 
P2X4  receptors  to  be  the  most  abundantly  expressed  endothelial  metabotropic  and 
ionotropic  ATP  receptors,  respectively.  Neither  knock-down  nor  inhibition  of  P2X4  in 
endothelial cells influenced platelet-mediated transendothelial migration of B16 cells, but 
knock-down of P2Y2, for which no specific antagonist is available, strongly reduced platelet-
dependent tumor cell transmigration. When B16 melanoma cells were injected i.v. shortly 
after FITC-dextran (70 kDa) into wild-type mice, prominent leakage of FITC-dextran was 
observed three hours post-injection at extraluminal sites in the lung. In contrast, leakage 
into the lung parenchyma was at basal levels in Munc13-4 KO and P2Y2 KO mice after B16 
cell  injection.  Marginal  vascular  leakage  in  Munc13-4  KO  mice  lacking  platelet  ATP 
secretion and in P2Y2 KO mice lacking the main endothelial ATP receptor correlated with 
strongly reduced extravasation of CFSE-labeled B16 melanoma cells 6 hours post-injection 
in  these  mice.  Consistently,  P2Y2  KO  mice  showed  strongly  reduced  formation  of 
metastases in the lung after i.v. injection of B16 or LLC1 tumor cells. 
Bone marrow-transplanted LDLR KO mice reconstituted with Munc13-4-deficient or wild-
type  bone  marrow  and  subjected  to  16  weeks  of  high  fat  diet  showed  no  significant 
difference in atherosclerotic plaque formation in the aorta. 
7.4	
 ﾠ Discussion	
 ﾠ
We hereby provide a thorough analysis of a mouse line with an exclusive defect in platelet 
dense granule secretion, thus representing a unique genetic tool to study the role of dense 	
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granule secretion in various contexts without interfering with other platelet functions. We 
also provide evidence how extravasation of circulating tumor cells is facilitated by tumor 
cell-induced ATP release from platelets. This ATP release destabilizes endothelial barriers 
and facilitates tumor cell extravasation and formation of metastases in the target organ. 
Since metastasis is the leading cause of cancer death, pharmacological interference with 
endothelial P2Y2 receptor function may represent a promising therapeutic strategy. 
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9  Appendices	
 ﾠ
9.1  Zusammenfassung	
 ﾠ
9.1.1  Einleitung	
 ﾠ
In den letzten Jahrzehnten wurde in zahlreichen Publikationen gezeigt, dass Thrombozyten 
über  ihre  Funktion  in  der  Hämostase  hinaus  an  vielen  weiteren  Prozessen,  vor  allem 
pathologischen  Veränderungen  mit  immunologischer  Komponente,  beteiligt  sind. 
Ermöglicht  wird  dies  durch  die  Sekretion  einer  breiten  Palette  proinflammatorischer 
Proteine  sowie  durch  die  Bildung  reaktiver  Mikropartikel  nach  Aktivierung  der 
Thrombozyten. Thrombozyten besitzen zwei funktionell wichtige Arten von Vesikeln, alpha 
und dense granules. Alpha granules enthalten größere Moleküle wie die Adhesion-Proteine 
P-Selektin und vWF, Chemokine wie PF4, RANTES oder IL-1β sowie Wachstumsfaktoren 
wie VEGF und PDGF. In dense granules sind hingegen kleine Moleküle, vor allem ATP und 
ADP, aber auch Calcium, Serotonin und Histamin gespeichert.  
Wie in allen sekretorischen Zellen wird die regulierte Exozytose in Thrombozyten 
von  drei  verschiedenen  Klassen  von  SNARE-Proteinen,  SNAP,  Syntaxin  und  VAMP, 
vermittelt. SNARE-Proteine sind zu einem Teil an die Plasmamembran, zum anderen an 
die Vesikel-Membran gebunden, richten im Verlauf des Exozytose-Vorgangs cytosolische 
Alpha-Helices aneinander aus und lagern sich schließlich zusammen. Die so frei werdende 
Bindungsenergie  reicht  aus,  um  die  Abstoßungskräfte  der  beiden  Membranen  zu 
überwinden  und  zur  Fusion  zu  führen.  Mehrere  Isoformen  o.g.  Proteine  sind  in 
Thrombozyten nachweislich an sekretorischen Vorgängen beteiligt: SNAP-23, Syntaxin-2 
und -4 und VAMP-3 und -8 (Chen, Lemons et al. 2000; Flaumenhaft, Rozenvayn et al. 
2007). Andere, ebenfalls sehr konservierte Protein-Familien sind fast ausschließlich in der 
Nähe der Plasmamembran zu finden, der sogenannten “active zone” und beeinflussen die 
Sekretion,  indem  sie  mit  SNARE-Proteinen  interagieren.  Eines  der  wichtigsten  Proteine 
dieser Art ist Munc13. Der Wirkungsmechanismus ist noch nicht vollständig geklärt, aber 
Verlust  der  zellspezifischen  Isoform(en)  führt  oft  zu  starken  Einschränkungen  oder 
komplettem  Verlust  der  Sekretion  einzelner  oder  aller  Vesikel-Arten  dieser  Zelle 
(Rosenmund, Sigler et al., 2002; Feldmann, Callebaut et al. 2003). 
Thrombozyten  verstärken  das  Fortschreiten  atherosklerotischer  Veränderungen, 
indem sie inflammatorische Stimuli wie PF4, RANTES und CD40L an Gefäßpartien, die ein 
dysfunktionales  Endothel  aufweisen,  deponieren.  Dies  führt  zu  einer  vermehrten 
Rekrutierung  von  Leukozyten,  “foam-cell”-Bildung  und  atherosklerotischer  Plaque-
Formation (Gleissner, Shaked et al. 2010; Lievens, Zernecke et al. 2010).  
Eine Beziehung zwischen Thrombozyten und Tumorerkrankungen wurde erstmals 
1865  von  dem  französischen  Arzt  Armand  Trousseau  (Armand  Trousseau,  Phlegmasia 
alba  dolens,  in:  Clinique  Medicale  de  l’Hotel-Dieu  de  Paris,  Vol  3,  2
nd  Edition,  Ballière, 
Paris, 1865, pp 654-712) beschrieben. Er beobachtete, dass Krebs-Patienten eine erhöhte 	
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Neigung zu thrombotischen Komplikationen haben und umgekehrt, dass bei Patienten mit 
akuter Thrombose das Risiko der Manifestation einer Krebserkrankung erhöht ist. Etwa seit 
den 1960er Jahren wird aber auch eine stetig steigende Anzahl an Studien veröffentlicht, 
die zeigen, dass Thrombozyten darüber hinaus direkt auf primäre Tumoren und besonders 
Tumor-Metastasierung  einwirken  können.  Thrombozyten  könnten  in  der  direkten 
Umgebung  von  Primär-Tumoren  dazu  veranlasst  werden,  gezielt  pro-angiogenetische 
Faktoren wie VEGF und PDGF freizusetzen. Dies erscheint durchaus plausibel, da in den 
letzten  fünf  Jahren  immer  mehr  Belege  veröffentlicht  wurden,  die  zeigen,  dass  alpha 
granules heterogene Subpopulationen bilden, die kontextspezifisch und stimulusabhängig 
sezerniert  werden  können  (Ma,  Perini  et  al.  2005;  Italiano,  Richardson  et  al.  2008). 
Allerdings  war  es  bisher  nicht  möglich,  den  Beitrag  von  Thrombozyten  zu  Tumor-
Angiogenese von dem anderer Immunzellen zu differenzieren, die die gleichen Moleküle 
freisetzen können. Pharmakologische und genetische Depletion von Thrombozyten führt zu 
einem  starken  Rückgang  der  Metastasen-Bildung  in  verschiedenen  Mausmodellen.  Die 
diesem Phänomen zugrundeliegenden Mechanismen sind aber bisher unklar geblieben. Es 
ist bekannt, dass Thrombozyten an zirkulierende Tumorzellen binden und diese vor Lyse 
durch  NK-Zellen,  der  effektivsten  anti-metastatischen  Immunabwehr  des  Körpers,  sowie 
gegen  Scherkräfte  schützen.  Thrombozyten  lassen  sich  auch  nach  Andocken  der 
Tumorzellen an der Gefäßwand in der Mikrozirkulation an deren Oberfläche nachweisen.  
Sie  könnten  durch  verschiedene  Oberflächen-Rezeptoren  die  indirekte  Interaktion  von 
Tumorzellen  mit  Leukozyten  oder  Endothelzellen  erleichtern.  Von  Tumorzellen  aktivierte 
Thrombozyten  könnten  aber  auch  Mediatoren  freisetzen,  die  die  Eigenschaften  der 
Tumorzelle, insbesondere deren Aggressivität, beeinflussen (Labelle, Begum et al. 2011). 
9.1.2  Ziele	
 ﾠdieser	
 ﾠArbeit	
 ﾠ
Die Ziele dieser Arbeit waren 
(I)  die Generierung und 
(II)  Analyse  genetisch  modifizierter  Mauslinien  mit  Sekretionsdefekten  in 
Thrombozyten und 
(III)  deren  Nutzung  zur  Untersuchung  der  Rolle  von  Thrombozyten-Sekretion  in 
Atherosklerose- und Tumor-Mausmodellen. 
9.1.3  Ergebnisse	
 ﾠ
Der  Wirkungsmechanismus  der  Toxine  von  Clostridium  beruht  auf  der  enzymatischen 
Spaltung  verschiedener  SNARE-Proteine  durch  die  leichte  Kette  des  Toxins.  Um  eine 
selektive Störung thrombozytärer Sekretion zu erzielen, ersetzten wir in einem bakteriellen 
artifizielle  Chromosom  die  für  das  Thrombozyten-spezifische  PF4-Protein  kodierende 
Sequenz durch die cDNA der leichten Ketten von Tetanus-Toxin bzw. Botulinum-Toxin E 
und C. Diese Konstrukte wurden in den Pronukleus fertilisierter Maus-Oozyten injiziert, und 
die resultierenden founder-Tiere wurden in Bezug auf Toxin-Expression und Thrombozyten-	
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Sekretion  untersucht.  Auch  nach  zum  Teil  mehrmaliger  Injektion  war  die  beste 
Spaltungsrate  in  einem  founder-Tier  der  Botulinum-E-exprimierenden  Linie  40%  des 
thrombozytären  SNAP-23  und  60%  der  thrombozytären  Menge  von  Syntaxin-2  in  der 
Botulinum-C-exprimierenden  Linie.  Die  Spaltung  von  VAMP-3  durch  Tetanus-Toxin  in 
Thrombozyten  konnte  nicht  eindeutig  nachgewiesen  werden.  Keine  dieser  Mauslinien 
zeigte eine gestörte Sekretion in isolierten Thrombozyten.  
SNAP-23 ist die einzige SNAP-Isoform in Thrombozyten, während für die Syntaxin- 
und  VAMP-Familie  jeweils  mindestens  zwei  Isoformen  nachweislich  an  der  Sekretion 
beteiligt sind. Durch die bekannte Promiskuität der SNARE-Proteine könnte also der Verlust 
einer Isoform eventuell kompensiert werden. Deshalb konstruierten wir zwei von anderen 
Publikationen  hergeleitete  dominant-negative  Mutanten  von  SNAP-23  und  exprimierten 
diese ebenfalls unter der Kontrolle des PF4-Promotors. Die eine Mutante wurde nicht in 
nachweisbarer Menge exprimiert, das andere Konstrukt wurde zwar exprimiert, führte aber 
auch  in  dem  founder-Tier  mit  der  höchsten  Expression  zu  keiner  funktionellen 
Einschränkung der Thrombozyten-Sekretion.  
Munc13-4 ist die einzige Isoform des SNARE-assoziierten Proteins Munc13, die in 
Thrombozyten exprimiert wird. Deshalb erschien es vielversprechend, eine im Labor von 
Bruce  Beutler  hergestellte  funktionelle  Null-Mutante  (Munc13-4
Jinx)  auf  Defekte  in 
Thrombozyten-Sekretion zu untersuchen. In der Tat war bei dieser Mauslinie die Sekretion 
von  dense  granules,  bestimmt  durch  ATP-Ausschüttung,  vollständig  unterdrückt  nach 
Stimulation  mit  Thrombin,  dem  Thromboxan  A2-Analog  U46619  oder  Kollagen. 
Demgegenüber war Sekretion von alpha granules, gemessen durch Freisetzung von PF4 
oder vWF, unverändert in isolierten Munc13-4-defizienten Thrombozyten im Vergleich zu 
Wildtyp-Thrombozyten.  Ebenfalls  normal  waren  Morphologie,  Thrombozytenanzahl, 
Gesamtmenge  des  alpha-granule-Proteins  PF4  sowie  die  Anzahl  repräsentativer 
Thrombozyten-Oberflächenrezeptoren.  Die  Aggregation  der  Munc13-4-defizienten 
Thrombozyten  war  nach  Stimulation  mit  Kollagen  oder  U46619  deutlich  gehemmt.  Die 
Bildung großflächiger Aggregate in der Flusskammer, die Scherkräfte und Exposition von 
Kollagen in kleinen Gefäßen simuliert und mit heparinisiertem Blut durchströmt wird, war in 
Munc13-4-defizienten  Thrombozyten  im  Vergleich  zu  Wildtyp-Thrombozyten  vermindert. 
Munc13-4-defiziente Tiere zeigten eine stark verlängerte Blutungszeit nach Entfernung von 
2 mm der Schwanzspitze. Auch im FeCl3-Thrombosemodell war innerhalb der Versuchszeit 
von 60 min keine Bildung von stabilen Aggregaten in mesenterialen Arterien Munc13-4-
defizienter Tiere zu beobachten, während die Arterien gleichaltriger Wildtyp-Mäuse nach 
etwa  10  min  vollständig  verschlossen  waren.  Diese  Befunde  zeigen,  dass  Verlust  von 
Munc13-4 in Thrombozyten zu einer selektiven Unterdrückung der dense-granule-Sekretion 
führt, wodurch es zur Störung der Thrombozytenaggregation in vitro und in vivo kommt. 
Um  die  Rolle  von  dense-granule-Sekretion  im  Rahmen  chronischer 
Gefäßerkrankungen wie Atherosklerose zu untersuchen, bedienten wir uns eines Maus-
Modells,  bei  dem  der  LDL-Rezeptor  genetisch  inaktiviert  wurde.  LDLR-KO  Mäuse 	
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entwickeln  nach  mehreren  Wochen  fett-  und  cholesterinreicher  Diät  atherosklerotische 
Veränderungen, die denen in humanen Gefäßen sehr nahe kommen. Wir transplantierten 
Knochenmark von Wildtyp- und Munc13-4-defizienten Donoren in LDLR-KO-Mäuse. Nach 
16 Wochen fett-  und cholesterinreicher Diät war kein Unterschied in atherosklerotischer 
Plaque-Bildung zwischen den Aorten beider Versuchsgruppen zu erkennen.  
Da Depletion von Thrombozyten zu starker Verminderung der Metastasen-Bildung in Maus-
Tumormodellen  führt  und  Thrombozyten  direkt  an  Tumorzellen  binden,  wollten  wir 
überprüfen,  ob  Thrombozyten  die  Extravasation  von  Tumorzellen  beeinflussen.  Dazu 
wählten  wir  zunächst  ein  in-vitro-Testsystem,  in  dem  die  Transmigration  zweier  Maus-
Tumorzelllinien  (B16  Melanom  und  LLC1-Lungenkarzinom)  durch  eine  murine 
Endothelzellschicht (MS1-Zellen) bestimmt wird. Zugabe von Wildtyp-Thrombozyten zu den 
Tumorzellen in den oberen Teil der transwell-Kammer führte bei beiden Tumorzelllinien zu 
einer  zwei-  bis  dreifachen  Erhöhung  der  Transmigrationsrate,  während  die  Zugabe  von 
Munc13-4-defizienten Thrombozyten die basale Transmigrationsrate nicht beeinflusste. Um 
zu überprüfen, ob die Unterdrückung eines Sekretionsproduktes in Munc13-4-defizienten 
Thrombozyten  diesen  Effekt  verursachte,  gaben  wir  nur  den  Überstand  zuvor  mit  den 
entsprechenden  Tumorzellen  inkubierter  Wildtyp-Thrombozyten  in  den  Transmigrations-
Versuch und erhielten die gleiche Erhöhung der Tumorzell-Transmigration. Das ATP/ADP-
degradierende Enzym Apyrase verhinderte die Thrombozyten-abhängige Transmigration, 
während  alleine  die  Zugabe  von  exogenem  ATP  eine  vergleichbar  erhöhte 
Transmigrationsrate zur Folge hatte. Inkubation von Thrombozyten mit Tumorzellen führte 
zu einer starken Ausschüttung von ATP in Wildtyp-,  aber  nicht  in  Munc13-4-defizienten 
Thrombozyten. Die Sekretion der alpha granules war jedoch auch nach Stimulation durch 
Tumorzellen  in  beiden  Genotypen  vergleichbar.  Da  die  Erhöhung  der  Tumorzell-
Transmigration  durch  Thrombozyten  Endothel-abhängig  war,  untersuchten  wir,  welche 
Wirkung  Überstände  Tumorzell-stimulierter  Thrombozyten  auf  die  Morphologie  und 
Permeabilität  einer  Endothelzellschicht  haben.  Die  Adhäsionsverbindungen  der 
Endothelzellen waren unter diesen Bedingungen gestört und lösten sich zum Teil ganz. 
Auch  die  Permeabilität  der  Endothelzellschicht  für  FITC-Dextran  (70  kDa)  war  deutlich 
erhöht.  Bei  zusätzlicher  Anwesenheit  von  Apyrase  während  der  Inkubation  von 
Thrombozyten  und  Tumorzellen  waren  Morphologie und Permeabilität hingegen  normal. 
Um die Relevanz dieser Befunde in vivo zu untersuchen, injizierten wir B16- oder LLC1-
Zellen  in  die  Flanken  von  Wildtyp-  und  Munc13-4-defizienten  Mäusen.  Hierbei  zeigten 
Munc13-4-defiziente  Mäuse  und  Wildtyp-Mäuse  vergleichbares  Wachstum,  Gewicht  und 
Tumor-Angiogenese  in  B16-  und  LLC1-Tumoren.  Die  Metastasierung  in  der  Lunge  war 
jedoch unabhängig von der Größe der Metastasen um etwa 70% reduziert in Munc13-4-
defizienten  Tieren  im  Vergleich  zu  Wildtyp-Mäusen.  Diese  starke  Verminderung  in  der 
Metastasierung stellte sich auch nach i.v.-Injektion von B16- oder LLC1-Zellen ähnlich dar. 
Um  den  Mechanismus  unter  Zellkultur-Bedingungen  detaillierter  zu  charakterisieren, 
untersuchten  wir  die  Expression  von  ionotropen  und  metabotropen  ATP-Rezeptoren  in 	
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murinen  Endothelzellen  und  fanden  P2X4  und  P2Y2  jeweils  am  höchsten  exprimiert. 
Inhibierung  oder  knockdown  von  P2X4  beeinflusste  die  Thrombozyten-vermittelte 
Tumorzell-Transmigration nicht, aber knockdown des P2Y2-Rezeptors, für den es keinen 
spezifischen  Antagonisten  gibt,  reduzierte  diesen  Effekt  erheblich.  Ob  ein  ähnlicher 
Mechanismus für die reduzierte Metastasen-Bildung in Munc13-4-defizienten Tieren in vivo 
verantwortlich ist, testeten wir, indem wir FITC-Dextran und kurz darauf B16-Tumorzellen 
i.v. injizierten. Nach drei Stunden war in den Lungen von Wildtyp-Mäusen eine deutliche 
extraluminale  Akkumulation  von  FITC-Dextran  zu  beobachten,  während  Munc13-4-
defiziente  und  P2Y2-KO-Mäuse  sowie  Wildtyp-Mäuse  ohne  Injektion  von  Tumorzellen 
(Kontrollgruppe)  eine  ähnlich  niedrige  extraluminale  FITC-Dextran-Präsenz  zeigten.  Die 
erhöhte Durchlässigkeit der Gefäße für FITC-Dextran korrelierte mit einer viel stärkeren 
Extravasation von CFSE-gefärbten B16-Zellen sechs Stunden nach Injektion in Wildtyp-
Mäusen  gegenüber  Munc13-4-defizienten  und  P2Y2-KO-Mäusen.  Übereinstimmend  mit 
einer  Rolle  endotheler  P2Y2-Rezeptoren  in  Thrombozyten-vermittelter  Extravasation  von 
Tumorzellen in vivo war die Metastasierung in den Lungen von P2Y2-KO-Mäusen nach i.v.-
Injektion von B16- oder LLC1-Zellen ähnlich stark reduziert wie in Munc13-4-defizienten 
Mäusen. 
9.1.4  Diskussion	
 ﾠ
Von den im ersten Projektteil generierten fünf BAC-transgenen Mauslinien zeigte keine eine 
signifikante  Störung  der  thrombozytären  Sekretion.  Fehlende  Promotor-Elemente  oder 
mangelhafter Transport zur “active zone” könnte die nicht ausreichende Expression und 
Wirkung  der  Toxin-Konstrukte  und  SNAP-23-Mutanten  unter  der  Kontrolle  des  PF4-
Promotors  erklären.  Mit  der  Munc13-4
Jinx-Mutante  konnten  wir  jedoch  eine  Mauslinie 
identifizieren, die einen isolierten, vollständigen Defekt in der Sekretion von dense granules 
in Thrombozyten aufweisen bei gleichzeitiger Erhaltung der alpha-granule-Sekretion und 
aller anderen wichtigen Thrombozyten-Merkmale. Damit stellt diese Mauslinie ein bisher 
einzigartiges Werkzeug dar, um die Rolle der dense-granule-Sekretion in verschiedensten 
Kontexten zu untersuchen. 
Dass der Verlust von dense-granule-Sekretion die atherosklerotische Progression 
nicht beeinflusst, ist nicht unerwartet, da außer Polyphosphaten (Muller, Mutch et al. 2009) 
bisher keine potentiell inflammtorischen Mediatoren in dense granules beschrieben wurden. 
Die  vorliegende  Arbeit  liefert  viele  Belege  für  einen  Mechanismus,  der  es 
Tumorzellen  ermöglicht,  Thrombozyten  lokal  in  der  Mikrozirkulation  des  Ziel-Organs  zu 
nutzen, um durch eine hohe Ausschüttung von ATP und P2Y2-vermittelte Destabilisierung 
der Endothel-Barriere diese leichter zu überwinden und Metastasen zu bilden. Auch eine 
andere  Studie  fand,  dass  P2Y2-Rezeptoren  die  transendotheliale  Migration  von 
zirkulierenden Zellen vermitteln, in diesem Fall von Neutrophilen (Kukulski, Ben Yebdri et 
al.  2010).  Desweiteren  deckt  sich  mit  unseren  Ergebnissen,  dass  Aktivierung  von 
endothelen P2Y2-Rezeptoren über Koppelung an die G-Proteine Gq/G11 zum Anstieg von 	
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intrazellulärem Calcium (Abbracchio, Burnstock et al. 2006) und Aktivierung von Protein 
Kinase C führt, was die Destabilisierung der Endothel-Barrieren zur Folge hat (Gavard and 
Gutkind 2008; Knezevic, Tauseef et al. 2009; Korhonen, Fisslthaler et al. 2009). Eine in 
diesem Jahr erschienene Meta-Analyse kardiovaskulärer Verlaufsstudien (Rothwell, Wilson 
et  al.  2012)  kommt  zu  dem  Schluss,  dass  tägliche  Einnahme  niedrig-dosierten  Aspirins 
nach fünf Jahren zu einer Reduktion der krebsbedingten Todesfälle um ca. 15% führt, was 
ausschließlich auf die anti-metastatische Wirkung dieser Thrombozyten-hemmenden Dosis 
zurückzuführen sei. Unsere Ergebnisse legen einen Mechanismus nahe, der eine mögliche 
Erklärung für die vielfach beobachtete Beteiligung von Thrombozyten bei der Metastasen-
Bildung liefert und gleichzeitig einen neuen Therapieansatz eröffnet, der die Gefahr von 
Einblutungen bei Gabe klassischer Thrombozyten-Inhibitoren umgeht. Wir konnten zeigen, 
dass die Metastasierung im murinen Modell durch Sekretion aus dense granules Tumorzell-
aktivierter Thrombozyten stark beeinflusst wird. Wir fanden, dass ATP aus dense granules 
über endothele P2Y2-Rezeptoren die Endothel-Barriere destabilisiert und den Tumorzellen 
so den Zugang zum Parenchym des Zielorgans erleichtert. P2Y2-Rezeptoren könnten somit 
ein  vielversprechendes  Ziel  pharmakologischer  Intervention  in  der  Tumortherapie 
darstellen.   	
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